var title_f40_45_41680="Morcellation of uterus";
var content_f40_45_41680=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66674&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Morcellation of uterus during laparoscopic hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Lyons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41680=[""].join("\n");
var outline_f40_45_41680=null;
var title_f40_45_41681="RANKL and ROS-activated signals";
var content_f40_45_41681=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61626&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    RANKL and ROS-activated signals affecting the genesis and lifespan of osteoclasts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 450px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In osteoclast precursors, RANKL-induced activation of RANK stimulates NFATc1 activation via cFOS/AP-1 and CREB. In addition, mitochondria biogenesis coupled with activation of the transferrin receptor by the iron-tranferrin complex stimulates mitochondria respiration and reactive oxygen species (ROS) production, which are also essential for osteoclast activation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from: Macmillan Publishers Ltd: Ishii KA, Fumoto T, Iwai K, et al. Coordination of PGC-1beta and iron uptake in mitochondrial biogenesis and osteoclast activation. Nat Med 2009; 15:259. Copyright &copy; 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41681=[""].join("\n");
var outline_f40_45_41681=null;
var title_f40_45_41682="Cap polyposis Endosc IV";
var content_f40_45_41682=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57358&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Cap polyposis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jerome D Waye, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41682=[""].join("\n");
var outline_f40_45_41682=null;
var title_f40_45_41683="Fracture of the tibia-fibula with heterotopic ossification";
var content_f40_45_41683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F65133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F65133&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Fracture of the tibia-fibula with heterotopic ossification",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fracture of the tibia-fibula with heterotopic ossification (bright white areas) as seen on plain extremity radiography (left) and computed tomography (right).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Joe Hsu, San Antonio Military Medical Center Department of Orthopedic Surgery and Rehabilitation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41683=[""].join("\n");
var outline_f40_45_41683=null;
var title_f40_45_41684="Tafluprost: Patient drug information";
var content_f40_45_41684=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tafluprost: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/51/5939?source=see_link\">",
"     see \"Tafluprost: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13913593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zioptan&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13854602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat glaucoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high eye pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13854601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tafluprost or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13854606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698504",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your eye pressure checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13854607\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye color may change with use. This drug may raise the brown pigment. Dark eyelashes and skin around the eye may also happen. These changes may be long-lasting.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13854608\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13854604\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2893439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Open right before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13854605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13854609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668645",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store unopened foil pouch in the refrigerator.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3668646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Once foil pouch is open, keep drug in the foil pouch at room temperature for up to 28 days.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13854610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83370 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-08F90C6EF9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41684=[""].join("\n");
var outline_f40_45_41684=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13913593\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854602\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854601\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854606\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854607\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854608\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854604\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854605\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854609\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13854610\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?5/51/5939?source=related_link\">",
"      Tafluprost: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_international\" href=\"mobipreview.htm?42/28/43457?source=related_link\">",
"      Tafluprost: International drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_45_41685="Porcelain gallbladder Light";
var content_f40_45_41685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Porcelain gallbladder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cross section of a porcelain gallbladder wall shows replacement of the mucosal and muscularis layers by dense fibrosis and calcification.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Salam F Zakko, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41685=[""].join("\n");
var outline_f40_45_41685=null;
var title_f40_45_41686="Dexamethasone (systemic): Patient drug information";
var content_f40_45_41686=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Dexamethasone (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14042?source=see_link\">",
"     see \"Dexamethasone (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/18/6442?source=see_link\">",
"     see \"Dexamethasone (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13452560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Baycadron&trade;;",
"     </li>",
"     <li>",
"      Decadron&reg; [DSC];",
"     </li>",
"     <li>",
"      Dexamethasone Intensol&trade;;",
"     </li>",
"     <li>",
"      DexPak&reg; 10 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 13 Day TaperPak&reg;;",
"     </li>",
"     <li>",
"      DexPak&reg; 6 Day TaperPak&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8015649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Dexamethasone&reg;;",
"     </li>",
"     <li>",
"      Dexasone&reg;;",
"     </li>",
"     <li>",
"      Dom-Dexamethasone;",
"     </li>",
"     <li>",
"      PHL-Dexamethasone;",
"     </li>",
"     <li>",
"      PMS-Dexamethasone;",
"     </li>",
"     <li>",
"      PRO-Dexamethasone;",
"     </li>",
"     <li>",
"      ratio-Dexamethasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10030963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691277",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to add adrenal hormone to the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Addison's disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat arthritis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691735",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat asthma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691762",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat brain swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691790",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat COPD (chronic obstructive pulmonary disease).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling from autoimmune diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691910",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat swelling in parts of the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat leukemia.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691947",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lymphoma.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691999",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat organ transplant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sarcoidosis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692097",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat spinal cord injuries.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat ulcerative colitis.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat upset stomach and throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546347",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat mountain sickness.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to dexamethasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Malaria infection in the brain or bad yeast infection.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696653",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid being near anyone with chickenpox or measles.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697204",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. This drug may raise blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697224",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma or cataracts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are being treated for any infection, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have soft, brittle bones (osteoporosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697342",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have stomach ulcers, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697345",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have TB (tuberculosis), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698138",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood sugar may cause diabetes while on this drug. This most often goes back to normal when this drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697937",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in body fat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698390",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698341",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin changes (pimples, stretch marks, slow healing, hair growth).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697932",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cataracts or glaucoma with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698688",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been exposed to chickenpox and have not had chickenpox or had a chickenpox vaccine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695878",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take in the morning if taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694218",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take calcium and vitamin D as you were told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11651 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41686=[""].join("\n");
var outline_f40_45_41686=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13452560\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8015649\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030963\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030965\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030964\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030969\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030970\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030972\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030967\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030968\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030973\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030974\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/997?source=related_link\">",
"      Dexamethasone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/49/17172?source=related_link\">",
"      Dexamethasone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/45/14042?source=related_link\">",
"      Dexamethasone (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_45_41687="Hereditary coproporphyria";
var content_f40_45_41687=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary coproporphyria",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Ashwani K Singal, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Karl E Anderson, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41687/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/45/41687/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H9950261\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary coproporphyria (HCP; OMIM #121300) is one of the acute hepatic porphyrias resulting in neurovisceral symptoms that are identical to those seen in acute intermittent porphyria (AIP) and variegate porphyria (VP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. In contrast to AIP, blistering skin lesions, similar to those seen in VP and porphyria cutanea tarda (PCT), may also occur.",
"   </p>",
"   <p>",
"    HCP is due to deficient activity of the mitochondrial enzyme coproporphyrinogen oxidase (CPOX), the sixth enzyme in the heme biosynthetic pathway (",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"mobipreview.htm?0/9/155\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"mobipreview.htm?34/50/35617\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Affected individuals are heterozygous for mutations of the gene for that enzyme.",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of HCP will be discussed here. A general review of the porphyrias is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link\">",
"     \"Porphyrias: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other acute porphyrias are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40198?source=see_link\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute intermittent porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/51/825?source=see_link\">",
"     \"Variegate porphyria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5656?source=see_link\">",
"     \"ALA dehydratase porphyria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950268\">",
"    <span class=\"h1\">",
"     PREVALENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCP is the third most common acute porphyria after AIP and VP. The disease is mostly reported from Europe and North America, but is expected to occur in all ethnic groups. A prevalence of two per million was estimated in Denmark [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/6\">",
"     6",
"    </a>",
"    ]. HCP typically manifests after puberty in heterozygotes, and more commonly in women. Homozygous cases of HCP and a genetic variant form termed harderoporphyria have been described, with disease onset in childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/7-10\">",
"     7-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950275\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to AIP and VP, HCP is characterized by variable penetrance, with symptoms developing in not more than 10 to 20 percent of heterozygotes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/2\">",
"     2",
"    </a>",
"    ]. Although acute attacks are generally milder than those seen in AIP, they can be severe and even fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Acute attacks are reversible if treated promptly, although motor weakness, if present, may take months and even several years to resolve.",
"   </p>",
"   <p>",
"    As in AIP and VP, the risk of hepatocellular carcinoma is increased in HCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17548582\">",
"    <span class=\"h2\">",
"     Neurovisceral manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neurovisceral manifestations in HCP are not distinguishable from those in AIP and VP (",
"    <a class=\"graphic graphic_table graphicRef56856 \" href=\"mobipreview.htm?26/3/26683\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal pain is present in approximately 80 percent of symptomatic cases; nausea, vomiting, hypertension, tachycardia, constipation, and neuropsychiatric manifestations are present in 20 to 35 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/2,12\">",
"       2,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As in AIP and VP, motor neuropathy may develop in severe attacks and may progress to respiratory failure and death. Severe motor neuropathy in the absence of abdominal pain is rare [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) can occur during acute attacks. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=see_link\">",
"       \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=see_link\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Seizures may be caused by hyponatremia or be a neurological manifestations of acute porphyria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17548589\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with HCP have cutaneous manifestations similar to those seen in porphyria cutanea tarda (PCT) and variegate porphyria (VP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/2\">",
"     2",
"    </a>",
"    ]. However, cutaneous manifestations are relatively uncommon in HCP, especially when compared with their incidence in VP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=see_link&amp;anchor=H4530124#H4530124\">",
"     \"Porphyria cutanea tarda and hepatoerythropoietic porphyria\", section on 'Skin findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/51/825?source=see_link&amp;anchor=H660113#H660113\">",
"     \"Variegate porphyria\", section on 'Cutaneous symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051818\">",
"    <span class=\"h2\">",
"     Precipitating factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that can precipitate attacks in HCP are the same as those that precipitate attacks in AIP and VP, and include certain drugs (",
"    <a class=\"graphic graphic_table graphicRef57422 \" href=\"mobipreview.htm?42/6/43116\">",
"     table 3",
"    </a>",
"    ), fasting, endogenous steroid hormones (especially progesterone), and metabolic stress due to other illnesses or infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40198?source=see_link&amp;anchor=H6#H6\">",
"     \"Etiology and pathogenesis of acute intermittent porphyria\", section on 'Exacerbating factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pregnancy is usually well tolerated, but is sometimes associated with attacks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/16\">",
"     16",
"    </a>",
"    ]. Concurrent liver disease may increase porphyrin levels and lead to photosensitivity.",
"   </p>",
"   <p>",
"    Most drugs and other factors that precipitate neurovisceral attacks in HCP increase the demand for hepatic heme synthesis and induce the ubiquitous form of ALA synthase (ALAS1) in the liver. Following ALAS1 induction, which is rate limiting for heme synthesis in the liver, the partially-deficient coproporphyrinogen oxidase activity in HCP can become rate limiting for heme synthesis, leading to the accumulation of the heme pathway intermediate coproporphyrinogen III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=see_link&amp;anchor=H4#H4\">",
"     \"Porphyrias: An overview\", section on 'Regulation of heme synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950282\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950291\">",
"    <span class=\"h2\">",
"     Enzymatic defect in HCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;HCP is due to the deficient activity of the sixth enzyme in the heme biosynthetic pathway, coproporphyrinogen oxidase (CPOX) (",
"    <a class=\"graphic graphic_table graphicRef54358 \" href=\"mobipreview.htm?0/9/155\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef57890 \" href=\"mobipreview.htm?34/50/35617\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/4\">",
"     4",
"    </a>",
"    ]. The enzyme is localized to the mitochondrial intermembrane space, and it catalyzes the oxidative decarboxylation of coproporphyrinogen III to protoporphyrinogen IX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. This reaction, which does not require a metal or other cofactor, leads to removal of the carboxyl substituents and a hydrogen atom from two proprionic acid groups to form the two vinyl groups of protoporphyrinogen IX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deficient activity of hepatic CPOX and increased activity of ALAS1 may lead to accumulation of the substrate coproporphyrinogen III in hepatocytes, followed by its auto-oxidation to coproporphyrin III and excretion in both urine and bile. Elevation of delta",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"     aminolevulinic acid",
"    </a>",
"    (ALA) and porphobilinogen (PBG) during acute attacks may be explained by the inhibition of PBG deaminase by coproporphyrinogen III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The half-normal enzyme activity in those heterozygous for severe CPOX mutations is due to production of the enzyme from the normal CPOX allele. In rare homozygous cases, the enzyme activity is &lt;10 percent of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/8\">",
"     8",
"    </a>",
"    ], as measured in mitochondria-containing cells, such as lymphocytes or cultured fibroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/21\">",
"     21",
"    </a>",
"    ]. Mature erythrocytes are not suitable for assessing CPOX activity, as these cells do not contain mitochondria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950298\">",
"    <span class=\"h2\">",
"     Porphyrin accumulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased excretion of coproporphyrin III in the urine and feces, derived from oxidation of accumulated coproporphyrinogen III, is the diagnostic feature of HCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/2,3,9\">",
"     2,3,9",
"    </a>",
"    ]. Patients with harderoporphyria have associated increased excretion of the tricarboxyl porphyrin harderoporphyrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950305\">",
"    <span class=\"h2\">",
"     CPOX mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CPOX gene has been localized to chromosome 3 and consists of seven exons and six introns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/22\">",
"     22",
"    </a>",
"    ]. The enzyme protein consists of 354 amino acids and has a molecular weight of 74,000 daltons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/19\">",
"     19",
"    </a>",
"    ]. A mutation of the CPOX gene (arginine to tryptophan substitution at position 691) was first identified in 1994 in a patient with homozygous HCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/7\">",
"     7",
"    </a>",
"    ]. Since then, a variety of CPOX mutations have been described, showing the disease to be heterogeneous at the molecular level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/10,23-27\">",
"     10,23-27",
"    </a>",
"    ]. Genotype-phenotype correlation is not evident in heterozygotes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051833\">",
"    <span class=\"h3\">",
"     Homozygous HCP and harderoporphyria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rare cases of homozygous HCP present with photosensitivity and neurological manifestations in childhood; affected individuals are homozygous or compound heterozygous for CPOX mutations. At least one mutation must express some enzyme activity.",
"   </p>",
"   <p>",
"    Harderoporphyria is in many respects a distinct phenotype from other homozygous cases of HCP. Harderoporphyria is caused by specific CPOX mutations (eg, lysine to glutamic acid substitution at position 304) that result in the accumulation and increased excretion of harderoporphyrin III and coproporphyrin III [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Harderoporphyrinogen III (a tricarboxylate porphyrin) is the intermediate in the two-step decarboxylation of coproporphyrinogen III (a tetracarboxylate porphyrin) to protoporphyrinogen IX (a porphyrin with two carboxyl groups). It was first isolated in its oxidized form (harderoporphyrin) from the rodent Harderian gland, hence its name [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9,28\">",
"     9,28",
"    </a>",
"    ]. Hemolytic anemia, neonatal jaundice, hepatosplenomegaly, and cutaneous photosensitivity are prominent features of harderoporphyria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9,29,30\">",
"     9,29,30",
"    </a>",
"    ]. Iron overload may occur, although the cause of this complication is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950312\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL FINDINGS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute or chronic symptoms of HCP have substantial elevations of urinary and fecal coproporphyrin III. Urinary ALA and PBG are elevated during acute attacks, but elevations of these porphyrin precursors are less than those seen during attacks of AIP and decrease to normal more quickly. Elevation of urinary uroporphyrin accompanies the elevation of porphyrin precursors, as in AIP and VP. Uroporphyrin can form non-enzymatically from PBG in urine prior to voiding. It is also possible in this and other acute porphyrias that excess ALA transported to tissues other than the liver may re-enter the pathway to form excess porphyrinogens enzymatically.",
"   </p>",
"   <p>",
"    In contrast to VP, plasma porphyrins are generally normal or only modestly increased in HCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/31\">",
"     31",
"    </a>",
"    ], but are expected to be more elevated in the few patients who have cutaneous manifestations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The excess coproporphyrin in urine and feces in HCP, with a marked predominance of isomer III, is distinctive. In harderoporphyria, elevations in both coproporphyrin III and harderoporphyrin III are evident in feces [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9\">",
"       9",
"      </a>",
"      ]. Elevation of coproporphyrin in the urine without its elevation in the feces is not sufficient to diagnose HCP. (See",
"      <a class=\"local\" href=\"#H3052018\">",
"       'Deciding which of the acute porphyrias is present'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Marked fecal porphyrin elevations are also seen in VP, but in that condition both coproporphyrin III and protoporphyrin IX are elevated, whereas the fecal porphyrins in HCP are almost entirely coproporphyrin III. Fecal and plasma porphyrins are normal or only slightly elevated in AIP. Therefore, plasma and fecal porphyrin analyses can readily differentiate HCP, VP, and AIP as the cause of elevated PBG.",
"     </li>",
"     <li>",
"      A high ratio of coproporphyrin III to I in feces is sensitive for detecting asymptomatic adult relatives of patients with HCP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measurement of CPOX activity in mitochondria-containing cells, such as lymphocytes, can help confirm a diagnosis of HCP, but such assays are not widely available. DNA studies are important for confirming the diagnosis, and enable detection of relatives who have inherited the same mutation and may or may not have symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Erythrocyte zinc protoporphyrin is normal or modestly increased in heterozygotes, but substantially elevated in homozygous cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3051939\">",
"    <span class=\"h2\">",
"     Initial diagnostic testing for HCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial elevation in porphobilinogen (PBG) on a spot urine sample is a highly specific finding, and documents that a patient has AIP, VP, or HCP. Therefore, testing for elevation of urinary PBG is the primary initial diagnostic test for patients presenting with acute neurovisceral symptoms in whom acute porphyria is part of the differential diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"mobipreview.htm?26/12/26831\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A commercially available kit is recommended for rapid documentation of PBG elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/34\">",
"     34",
"    </a>",
"    ]. Previous tests for elevated PBG, such as the Watson-Schwartz and Hoesch tests, are obsolete. PBG can be measured in serum in patients with advanced renal disease.",
"   </p>",
"   <p>",
"    Acute attacks of the acute porphyrias (ie, AIP, VP, HCP) are treated in the same manner, and in a patient with a substantial PBG elevation, treatment can be initiated",
"    <strong>",
"     before",
"    </strong>",
"    it is known which of these conditions the patient has, but",
"    <strong>",
"     after",
"    </strong>",
"    samples are collected to differentiate them. (See",
"    <a class=\"local\" href=\"#H9950319\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The samples needed to make the diagnosis of HCP include the initial urine specimen, plus a plasma sample and a random stool sample. Measurement of erythrocyte PBG deaminase activity is also useful, since it is decreased in most patients with AIP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9\">",
"     9",
"    </a>",
"    ].The urine sample used to screen rapidly for elevation in PBG should be saved for routine measurement of PBG (to confirm the result using the kit), as well as for determination of ALA and total porphyrins. The rare acute porphyria ALA dehydratase porphyria (ADP), which is also associated with acute neurovisceral attacks, is diagnosed in part by demonstrating increased levels of ALA in the urine along with normal levels of PBG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5656?source=see_link&amp;anchor=H11#H11\">",
"     \"ALA dehydratase porphyria\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3052018\">",
"    <span class=\"h2\">",
"     Deciding which of the acute porphyrias is present",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with neurovisceral complaints and found to have a substantial elevation in urinary PBG, the differential diagnosis among the porphyric conditions includes AIP, HCP, and VP. In contrast, in ADP, ALA is markedly increased and PBG is normal or only slightly increased. For patients presenting with PBG elevation and blistering cutaneous complaints, the differential diagnosis includes only VP and HCP. These conditions can be separated from one another as follows (",
"    <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"mobipreview.htm?26/12/26831\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80601 \" href=\"mobipreview.htm?31/63/32765\">",
"     table 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Urinary ALA and PBG are increased during acute attacks in AIP, VP, and HCP. Urinary PBG is normal or only slightly increased in ALA dehydratase porphyria (ADP).",
"     </li>",
"     <li>",
"      Marked fecal porphyrin elevations are seen in both HCP and VP. In VP both coproporphyrin III and protoporphyrin IX are elevated, whereas the fecal porphyrins in HCP are almost entirely coproporphyrin III. Fecal and plasma porphyrins are normal or only slightly elevated in AIP.",
"     </li>",
"     <li>",
"      For patients presenting with blistering skin lesions on sun exposed areas, porphyrins are measured initially in plasma or urine. Normal results exclude all porphyrias that cause blistering photosensitivity. HCP is differentiated from PCT, VP, CEP, and HEP by porphyrin patterns in urine, plasma, and feces, and particularly the finding in feces of a marked and generally isolated elevation in coproporphyrin III (",
"      <a class=\"graphic graphic_table graphicRef60572 \" href=\"mobipreview.htm?4/23/4477\">",
"       table 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Urinary ALA and PBG may become normal more rapidly in HCP and VP than in AIP, but urinary porphyrin elevation is more prolonged. Therefore, normal urine porphyrins help to exclude HCP and VP.",
"   </p>",
"   <p>",
"    However, elevations in urinary porphyrins (especially coproporphyrin) are seen in many medical conditions other than porphyria, including hepatobiliary and bone marrow disorders. Therefore, an elevation in urinary coproporphyrin does not support a diagnosis of HCP unless there is also a marked elevation in fecal coproporphyrin III. Not uncommonly, HCP is misdiagnosed in patients based solely on nonspecific urinary coproporphyrin elevations.",
"   </p>",
"   <p>",
"    Rarely, mutations affecting two separate enzymes in the heme pathway are found in the same patient, and a CPOX mutation was one of the dual mutations documented at the molecular level in one such case [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950319\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950328\">",
"    <span class=\"h2\">",
"     Acute attacks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of an acute attack in a patient newly diagnosed as having one of the acute porphyrias, based on a substantial increase in urinary PBG, can begin before the cause of the PBG elevation is determined to be AIP, HCP, or VP. If a patient with an established diagnosis of HCP and a history of prior attacks presents with recurrent symptoms, the diagnosis of an acute attack is based on clinical evaluation to determine whether the current presentation is similar to previous attacks, and to exclude other causes of the symptoms (eg, appendicitis, pancreatitis, etc.).",
"   </p>",
"   <p>",
"    Prior laboratory documentation of HCP, including both biochemical and molecular confirmation, should be available to the treating physician from the medical records or from records provided by the patient. In such patients, it is advisable to obtain a spot urine for PBG, but in many instances treatment can be started before the result is available. In the absence of such prior documentation, an elevation in urinary PBG should be documented using the screening kit before initiating treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    As in AIP, the preferred treatment for acute attacks is intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"     hemin",
"    </a>",
"    , although attacks that are mild (without pain requiring narcotics, hyponatremia, seizures or motor weakness) are sometimes treated with carbohydrate loading [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/11\">",
"     11",
"    </a>",
"    ]. Further details of specific treatment with hemin or glucose, and symptomatic treatment and supportive management are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As in AIP, harmful drugs, such as barbiturates, sulfonamide antibiotics,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/61/6102?source=see_link\">",
"     griseofulvin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , anticonvulsants (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ), ergot alkaloids, and progestins should be identified and discontinued if at all possible. Other precipitating factors, such as inadequate intake of calories and carbohydrates, alcohol use, metabolic stress due to another illness, or luteal phase increases in endogenous progesterone should be recognized and addressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/15,36\">",
"     15,36",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9950342\">",
"     'Long term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950335\">",
"    <span class=\"h2\">",
"     Blistering skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in VP, blistering skin lesions are prevented by advising patients to avoid sunlight exposure as much as possible.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"     Beta-carotene",
"    </a>",
"    and charcoal or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    , which act by binding porphyrins in the intestine and preventing their reabsorption, have sometimes been helpful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     Hydroxychloroquine",
"    </a>",
"    and phlebotomy, which are effective in the treatment of PCT, are not useful for the treatment of HCP or VP. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15834?source=see_link&amp;anchor=H3912303#H3912303\">",
"     \"Erythropoietic protoporphyria\", section on 'Beta-carotene for photoprotection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950342\">",
"    <span class=\"h2\">",
"     Long term management",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of long-term management issues are present in HCP and other acute porphyrias. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some patients with HCP, VP, or AIP may develop chronic pain, depression, or other psychiatric problems. Because there may be risk for suicide, these manifestations must be recognized and managed appropriately [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although recurrent attacks are less common in HCP than in AIP, factors that have contributed to past acute attacks or might precipitate future attacks should be identified and addressed. Harmful drugs should be avoided whenever possible. Information on safe and harmful drugs is available at the websites of the",
"      <a class=\"external\" href=\"file://www.porphyriafoundation.com/\">",
"       American Porphyria Foundation",
"      </a>",
"      and the",
"      <a class=\"external\" href=\"file://www.porphyria-europe.org/\">",
"       European Porphyria Network",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Anesthesia for major surgery should avoid barbiturates and include safe agents such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"       propofol",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Frequent attacks during the luteal phase of the menstrual cycle are rare, but can be prevented with a gonadotropin releasing hormone analogue, which is started during the first few days of a cycle [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Unexplained, frequent noncyclic attacks are rare, and can sometimes be prevented by prophylactic weekly infusions of a single dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      As in AIP and VP, the risk of hepatocellular carcinoma is increased in HCP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41687/abstract/11\">",
"       11",
"      </a>",
"      ]. It is generally recommended that patients with acute porphyrias and persistent increases in porphyrin precursors and porphyrins be screened for hepatocellular carcinoma by imaging at 6 to 12 month intervals after age 50. Monitoring serum alpha-fetoprotein levels and liver function test is not useful for surveillance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9950349\">",
"    <span class=\"h2\">",
"     Genetic counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a CPOX mutation has been detected in an affected patient, confirming the diagnosis of HCP, this facilitates reliably identifying family members with latent HCP. These individuals can then be counseled to avoid certain drugs and other factors that may precipitate acute attacks of the disease. The diagnosis of HCP can be made in utero by amniocentesis, but this is seldom indicated because the prognosis in most heterozygotes is favorable and therefore pregnancy interruption is not often considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17548853\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary coproporphyria (HCP) is one of the acute hepatic porphyrias resulting in neurovisceral symptoms that are identical to those seen in acute intermittent porphyria (AIP) and variegate porphyria (VP) (",
"      <a class=\"graphic graphic_table graphicRef56856 \" href=\"mobipreview.htm?26/3/26683\">",
"       table 2",
"      </a>",
"      ). Blistering skin lesions, similar to those seen in VP and porphyria cutanea tarda, may also occur, but are uncommon. (See",
"      <a class=\"local\" href=\"#H9950275\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of one of the acute porphyrias is established in a patient with acute neurovisceral symptoms who demonstrates increased concentrations of porphobilinogen (PBG) in a random urine sample (",
"      <a class=\"graphic graphic_algorithm graphicRef61709 \" href=\"mobipreview.htm?26/12/26831\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3051939\">",
"       'Initial diagnostic testing for HCP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The specific diagnosis of HCP is confirmed by demonstrating, along with increased urinary concentrations of delta",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/22/3428?source=see_link\">",
"       aminolevulinic acid",
"      </a>",
"      (ALA) and PBG, which is most likely to occur at the time of an acute attack, a markedly increased concentration of coproporphyrin III in urine and feces with little increase in fecal protoporphyrin (",
"      <a class=\"graphic graphic_table graphicRef80601 \" href=\"mobipreview.htm?31/63/32765\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60572 \" href=\"mobipreview.htm?4/23/4477\">",
"       table 5",
"      </a>",
"      ). Identifying the CPOX mutation also confirms the diagnosis even in the absence of symptoms, and facilitates screening of other family members for latent HCP. (See",
"      <a class=\"local\" href=\"#H9950312\">",
"       'Biochemical findings and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As in AIP, where this has been shown to be effective, we recommend that patients with acute neurovisceral attacks due to HCP receive treatment with intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/39/21107?source=see_link\">",
"       hemin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We suggest that patients with milder attacks (ie, without pain requiring narcotics, hyponatremia, seizures, or motor weakness) may receive initial treatment with carbohydrate loading (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=see_link&amp;anchor=H2#H2\">",
"       \"Management of acute intermittent porphyria\", section on 'Treatment of the acute attack'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As in AIP, harmful drugs should be identified, discontinued, and avoided in the future, if at all possible (",
"      <a class=\"graphic graphic_table graphicRef57422 \" href=\"mobipreview.htm?42/6/43116\">",
"       table 3",
"      </a>",
"      ). Information on safe and harmful drugs is available at the websites of the",
"      <a class=\"external\" href=\"file://www.porphyriafoundation.com/\">",
"       American Porphyria Foundation",
"      </a>",
"      and the",
"      <a class=\"external\" href=\"file://www.porphyria-europe.org/\">",
"       European Porphyria Network",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Other precipitating factors, such as inadequate intake of calories and carbohydrates, metabolic stress due to another illness, or luteal phase increases in endogenous progesterone should be recognized and addressed. (See",
"      <a class=\"local\" href=\"#H9950328\">",
"       'Acute attacks'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9950342\">",
"       'Long term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/1\">",
"      BERGER H, GOLDBERG A. Hereditary coproporphyria. Br Med J 1955; 2:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/2\">",
"      Brodie MJ, Thompson GG, Moore MR, et al. Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood. Q J Med 1977; 46:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/3\">",
"      Mart&aacute;sek P. Hereditary coproporphyria. Semin Liver Dis 1998; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/4\">",
"      Elder GH, Evans JO, Thomas N. The primary enzyme defect in hereditary coproporphyria. Lancet 1976; 2:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/5\">",
"      Martasek P, Camadro JM, Delfau-Larue MH, et al. Molecular cloning, sequencing, and functional expression of a cDNA encoding human coproporphyrinogen oxidase. Proc Natl Acad Sci U S A 1994; 91:3024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/6\">",
"      With TK. Hereditary coproporphyria and variegate porphyria in Denmark. Dan Med Bull 1983; 30:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/7\">",
"      Martasek P, Nordmann Y, Grandchamp B. Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. Hum Mol Genet 1994; 3:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/8\">",
"      Grandchamp B, Phung N, Nordmann Y. Homozygous case of hereditary coproporphyria. Lancet 1977; 2:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/9\">",
"      Nordmann Y, Grandchamp B, de Verneuil H, et al. Harderoporphyria: a variant hereditary coproporphyria. J Clin Invest 1983; 72:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/10\">",
"      Lamoril J, Martasek P, Deybach JC, et al. A molecular defect in coproporphyrinogen oxidase gene causing harderoporphyria, a variant form of hereditary coproporphyria. Hum Mol Genet 1995; 4:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/11\">",
"      Andant C, Puy H, Deybach JC, et al. Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria. Am J Gastroenterol 1997; 92:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/12\">",
"      K&uuml;hnel A, Gross U, Doss MO. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem 2000; 33:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/13\">",
"      Barohn RJ, Sanchez JA, Anderson KE. Acute peripheral neuropathy due to hereditary coproporphyria. Muscle Nerve 1994; 17:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/14\">",
"      Seshabhattar P, Morrow JS. Syndrome of inappropriate antidiuretic hormone secretion associated with coproporphyria: case report and review of literature. Endocr Pract 2007; 13:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/15\">",
"      Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 2005; 142:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/16\">",
"      Brodie MJ, Moore MR, Thompson GG, et al. Pregnancy and the acute porphyrias. Br J Obstet Gynaecol 1977; 84:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/17\">",
"      Elder GH, Evans JO. Evidence that the coproporphyrinogen oxidase activity of rat liver is situated in the intermembrane space of mitochondria. Biochem J 1978; 172:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/18\">",
"      Grandchamp B, Phung N, Nordmann Y. The mitochondrial localization of coproporphyrinogen III oxidase. Biochem J 1978; 176:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/19\">",
"      Yoshinaga T, Sano S. Coproporphyrinogen oxidase. I. Purification, properties, and activation by phospholipids. J Biol Chem 1980; 255:4722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/20\">",
"      Meissner P, Adams P, Kirsch R. Allosteric inhibition of human lymphoblast and purified porphobilinogen deaminase by protoporphyrinogen and coproporphyrinogen. A possible mechanism for the acute attack of variegate porphyria. J Clin Invest 1993; 91:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/21\">",
"      Elder GH, Smith SG, Smyth SJ. Laboratory investigation of the porphyrias. Ann Clin Biochem 1990; 27 ( Pt 5):395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/22\">",
"      Cacheux V, Martasek P, Fougerousse F, et al. Localization of the human coproporphyrinogen oxidase gene to chromosome band 3q12. Hum Genet 1994; 94:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/23\">",
"      Fujita H, Kondo M, Taketani S, et al. Characterization and expression of cDNA encoding coproporphyrinogen oxidase from a patient with hereditary coproporphyria. Hum Mol Genet 1994; 3:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/24\">",
"      Lamoril J, Puy H, Whatley SD, et al. Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. Am J Hum Genet 2001; 68:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/25\">",
"      Gross U, Puy H, Meissauer U, et al. A molecular, enzymatic and clinical study in a family with hereditary coproporphyria. J Inherit Metab Dis 2002; 25:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/26\">",
"      To-Figueras J, Badenas C, Enr&iacute;quez MT, et al. Biochemical and genetic characterization of four cases of hereditary coproporphyria in Spain. Mol Genet Metab 2005; 85:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/27\">",
"      Sassa S, Kondo M, Taketani S, et al. Molecular defects of the coproporphyrinogen oxidase gene in hereditary coproporphyria. Cell Mol Biol (Noisy-le-grand) 1997; 43:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/28\">",
"      Jackson AH, Jones DM, Philip G, et al. Synthetic and biosynthetic studies of porphyrins, Part IV. Further studies of the conversion of corporporhyrinogen-III to protoporphyrin-IX: mass spectrometric investigations of the incubation of specifically deuteriated coproporhyringen-III with chicken red cell haemolysates. Int J Biochem 1980; 12:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/29\">",
"      Lamoril J, Puy H, Gouya L, et al. Neonatal hemolytic anemia due to inherited harderoporphyria: clinical characteristics and molecular basis. Blood 1998; 91:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/30\">",
"      Hasanoglu A, Balwani M, Kasapkara CS, et al. Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R. J Inherit Metab Dis 2011; 34:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/31\">",
"      Allen KR, Whatley SD, Degg TJ, Barth JH. Hereditary coproporphyria: comparison of molecular and biochemical investigations in a large family. J Inherit Metab Dis 2005; 28:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/32\">",
"      Blake D, McManus J, Cronin V, Ratnaike S. Fecal coproporphyrin isomers in hereditary coproporphyria. Clin Chem 1992; 38:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/33\">",
"      Sassa S. Modern diagnosis and management of the porphyrias. Br J Haematol 2006; 135:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/34\">",
"      Deacon AC, Peters TJ. Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem 1998; 35 ( Pt 6):726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/35\">",
"      Akagi R, Inoue R, Muranaka S, et al. Dual gene defects involving delta-aminolaevulinate dehydratase and coproporphyrinogen oxidase in a porphyria patient. Br J Haematol 2006; 132:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/36\">",
"      Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythropoietic protoporphyria. Curr Treat Options Gastroenterol 2007; 10:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/37\">",
"      Hunter JA, Khan SA, Hope E, et al. Hereditary coproporphyria. Photosensitivity, jaundice and neuropsychiatric manifestations associated with pregnancy. Br J Dermatol 1971; 84:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/38\">",
"      Meissner PN, Harrison GG, Hift RJ. Propofol as an i.v. anaesthetic induction agent in variegate porphyria. Br J Anaesth 1991; 66:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41687/abstract/39\">",
"      Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med 1984; 311:643.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7100 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-83.177.194.223-8B216F4EAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41687=[""].join("\n");
var outline_f40_45_41687=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17548853\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950261\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950268\">",
"      PREVALENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950275\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17548582\">",
"      Neurovisceral manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17548589\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3051818\">",
"      Precipitating factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950282\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950291\">",
"      Enzymatic defect in HCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950298\">",
"      Porphyrin accumulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950305\">",
"      CPOX mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3051833\">",
"      - Homozygous HCP and harderoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950312\">",
"      BIOCHEMICAL FINDINGS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3051939\">",
"      Initial diagnostic testing for HCP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3052018\">",
"      Deciding which of the acute porphyrias is present",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9950319\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950328\">",
"      Acute attacks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950335\">",
"      Blistering skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950342\">",
"      Long term management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9950349\">",
"      Genetic counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17548853\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7100|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?26/12/26831\" title=\"algorithm 1\">",
"      Diagnosis acute porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7100|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?34/50/35617\" title=\"figure 1\">",
"      Heme biosynthetic pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7100|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/9/155\" title=\"table 1\">",
"      Heme pathway enzymes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/3/26683\" title=\"table 2\">",
"      Symptoms and signs in AIP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/6/43116\" title=\"table 3\">",
"      Acute porphyrias drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/63/32765\" title=\"table 4\">",
"      Classification porphyrias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/23/4477\" title=\"table 5\">",
"      Excretion patterns",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5656?source=related_link\">",
"      ALA dehydratase porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/12/10439?source=related_link\">",
"      Clinical manifestations and diagnosis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/29/15834?source=related_link\">",
"      Erythropoietic protoporphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/16/40198?source=related_link\">",
"      Etiology and pathogenesis of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/20/3398?source=related_link\">",
"      Management of acute intermittent porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/50/28458?source=related_link\">",
"      Porphyria cutanea tarda and hepatoerythropoietic porphyria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/19/28984?source=related_link\">",
"      Porphyrias: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/51/825?source=related_link\">",
"      Variegate porphyria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_45_41688="Overview of neuromuscular junction toxins";
var content_f40_45_41688=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of neuromuscular junction toxins",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Tracy Weimer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Laurie Gutmann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41688/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/45/41688/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signal transduction at the neuromuscular junction is a multistep, complex process required for many of the functions that sustain life. Neuromuscular toxins act in various ways to inhibit this process. These toxins are naturally occurring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/1\">",
"     1",
"    </a>",
"    ], and some have been developed as biochemical weapons.",
"   </p>",
"   <p>",
"    This topic will briefly discuss the neuromuscular transmission disorders due to botulism, tick paralysis, snake venom, organophosphates and carbamates, and hypermagnesemia or hypocalcemia.",
"   </p>",
"   <p>",
"    Acquired myasthenia gravis, congenital and neonatal myasthenia gravis, and Lambert-Eaton myasthenic syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=see_link\">",
"     \"Pathogenesis of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=see_link\">",
"     \"Clinical manifestations of myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link\">",
"     \"Neuromuscular junction disorders in newborns and infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=see_link\">",
"     \"Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE NEUROMUSCULAR JUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuromuscular junction consists of a presynaptic axon terminal and a postsynaptic muscle end plate (",
"    <a class=\"graphic graphic_figure graphicRef62694 \" href=\"mobipreview.htm?18/25/18838\">",
"     figure 1",
"    </a>",
"    ). Within the presynaptic terminal are vesicles containing acetylcholine, adenosine triphosphate (ATP), magnesium, and calcium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Most of these vesicles are bound to the actin cytoskeleton by proteins called synapsins. When an action potential induces opening of calcium channels, increased intracellular calcium levels promote phosphorylation of synapsins. This phosphorylation results in release of the vesicles from their cytoskeletal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After release from the cytoskeleton, vesicles become bound at the presynaptic membrane terminal in areas called active zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. This \"docking\" allows rapid exocytosis of the vesicles. Docking is mediated by proteins termed SNARES (soluble N-ethylmaleimide-sensitive-fusion-attachment protein receptors). SNARES attached to the terminal membrane (t-SNARES) form complexes with proteins located on the vesicle (v-SNARES) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteins involved in SNARE complexes include VAMP (vesicle-associated membrane protein), which is found on the vesicle surface, along with SNAP-25 (synaptosomal-associated protein of 25 kD) and syntaxin, proteins found at the terminal membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. VAMP, syntaxin, and SNAP-25 are targets of the protease activity of botulinum toxin.",
"   </p>",
"   <p>",
"    Phosphorylation of docking proteins occurs in response to increased calcium levels. This induces SNARE complex formation, followed by exocytosis of the vesicle contents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. The vesicle membrane becomes added to the terminal membrane. Vesicles are recycled when pits form in the terminal membrane and become coated with a protein called clathrin. These clathrin-coated pits then pinch off to form vesicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/9\">",
"     9",
"    </a>",
"    ]. Acetylcholine is then synthesized and repackaged into these vesicles.",
"   </p>",
"   <p>",
"    The postsynaptic membrane is heavily folded and invaginated. Acetylcholine receptors are found at the crests of the junctional folds, and voltage-sensitive Na+ channels are concentrated within the folds. The acetylcholine receptors have an ideal binding constant to allow reversible binding of acetylcholine. When bound, ion channels within the receptor are opened with an influx of Na+, and there is a transient depolarization of the end-plate region. If this end-plate potential is large enough, a muscle fiber action potential is generated, which leads to muscle contraction. Acetylcholine remaining in the synapse is rapidly degraded by the enzyme acetylcholinesterase, and the muscle is allowed to repolarize [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BOTULISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulism is an uncommon and life-threatening disease caused by bacteria in the Clostridium family. The botulinum neurotoxin is considered the most potent lethal substance known. In high enough doses, it causes rapid and severe paralysis of skeletal muscles.",
"   </p>",
"   <p>",
"    Botulism is briefly reviewed here and is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link\">",
"     \"Botulism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organisms of the Clostridium genus are commonly found in soil and include C. botulinum, C baratii, and C butyricum. They are all gram-positive, anaerobic, spore-forming rods, which have evolved to produce a potent neurotoxin.",
"   </p>",
"   <p>",
"    Eight distinct C. botulinum toxin types have been described: A, B, C1, C2, D, E, F, and G. Of these eight, types A, B, E, and rarely F and G cause human disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H3#H3\">",
"     \"Botulism\", section on 'Pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modern syndrome of botulism occurs in five forms, differentiated by the mode of acquisition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Food borne botulism occurs after ingestion of food contaminated by preformed botulinum toxin",
"     </li>",
"     <li>",
"      Infant botulism occurs after the ingestion of clostridial spores that then colonize the host's gastrointestinal (GI) tract and release toxin produced in vivo",
"     </li>",
"     <li>",
"      Wound botulism occurs after infection of a wound by Clostridium botulinum with subsequent in vivo production of neurotoxin",
"     </li>",
"     <li>",
"      Adult enteric infectious botulism or adult infectious botulism of unknown source is similar to infant botulism in that toxin is produced in vivo in the GI tract of an infected adult host",
"     </li>",
"     <li>",
"      Inhalational botulism is the form that would occur if aerosolized toxin was released in an act of bioterrorism",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An average of 110 cases of botulism is reported each year in the United States. Approximately 72 percent of these cases are infant botulism, 25 percent are food borne botulism, and the remaining 3 percent are wound botulism. The incidence of wound botulism has increased due to the use of heroin. Adult infectious botulism is only occasionally reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H4#H4\">",
"     \"Botulism\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms range from minor cranial nerve palsies associated with symmetric descending weakness to rapid respiratory arrest. Key features of the botulism syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Absence of fever",
"     </li>",
"     <li>",
"      Symmetric neurologic deficits",
"     </li>",
"     <li>",
"      Preserved responsiveness",
"     </li>",
"     <li>",
"      Normal or slow heart rate and normal blood pressure",
"     </li>",
"     <li>",
"      No sensory deficits with the exception of blurred vision",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fever may be seen with wound botulism, but it probably results from concurrent bacterial infection of the wound by non-clostridial species. Food borne botulism produces gastrointestinal (GI) symptoms such as nausea, vomiting, or diarrhea. These may precede neurologic symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H10#H10\">",
"     \"Botulism\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disease presentation and severity are quite variable in infant botulism, most likely as a result of size of the bacterial inoculum and host susceptibility. A detailed discussion of infant botulism is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Routine lab tests in botulism are generally nonspecific, and specific laboratory confirmation may take up to days. Therefore, the diagnosis is usually clinical. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H16#H16\">",
"     \"Botulism\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Neurophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies (nerve conduction studies and electromyography) are frequently helpful in diagnosis of botulism. Sensory action potentials and nerve conduction velocities are typically normal. However, compound motor action potential (CMAP) amplitudes are decreased if the presynaptic block is severe enough. Repetitive nerve stimulation (RNS) at frequencies of 2 to 5 Hz depletes readily available stores of acetylcholine from the neuromuscular junction and decreases CMAP amplitudes even further, a finding termed the decremental response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A decrement of greater than 10 percent is considered abnormal. In more severe cases, the baseline CMAP may be too low to see decremental response.",
"   </p>",
"   <p>",
"    In contrast, increased rates of stimulation (20 to 50 Hz) or exercise cause accumulation of calcium in the presynaptic terminal and increase release of acetylcholine, a finding termed the incremental response, or postactivation facilitation (",
"    <a class=\"graphic graphic_figure graphicRef63756 \" href=\"mobipreview.htm?5/15/5361\">",
"     figure 2",
"    </a>",
"    ). This can be seen in approximately 60 percent of cases of adult botulism poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/12\">",
"     12",
"    </a>",
"    ]. The amount of facilitation seen with botulism (40 to 100 percent) is usually less than that seen in Lambert-Eaton myasthenic syndrome (200 percent or more) (",
"    <a class=\"graphic graphic_figure graphicRef66509 \" href=\"mobipreview.htm?39/8/40079\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/11\">",
"     11",
"    </a>",
"    ]. No increment or only very mild increment will be seen if the block produced by botulism is too severe. The post-tetanic facilitation may also be extraordinarily prolonged with botulism, occasionally up to four minutes. Postactivation exhaustion, a decrease in CMAP amplitude occurring two to four minutes after maximal muscle contraction, is not present in cases of botulism poisoning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, EMG diagnosis of botulism should be based on the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduced baseline CMAP amplitude",
"     </li>",
"     <li>",
"      Postactivation facilitation (between 40 and 200 percent)",
"     </li>",
"     <li>",
"      Absence of postactivation exhaustion",
"     </li>",
"     <li>",
"      Postactivation facilitation which persists longer than two minutes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sensitivity of repetitive nerve stimulation is much greater in cases of infantile botulism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=see_link&amp;anchor=H14#H14\">",
"     \"Neuromuscular junction disorders in newborns and infants\", section on 'Infant botulism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botulinum antitoxin should be given as soon as botulism is suspected. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H21#H21\">",
"     \"Botulism\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TICK PARALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several tick species produce a toxin that inhibits transduction at the neuromuscular junction by blocking influx of sodium ions. This prevents presynaptic terminal axon depolarization and inhibits release of acetylcholine at the nerve terminal. The toxin has not been fully identified.",
"   </p>",
"   <p>",
"    The ticks primarily responsible include the Rocky Mountain wood tick (Dermacentor andersoni), the American dog tick (D. variabilis), the Lone Star tick (Amblyomma americanum), the black-legged tick (Ixodes scapularis), the western black-legged tick (I. pacificus), the Gulf coast tick (A. maculatum), and the Australian Ixodes holocyclus.",
"   </p>",
"   <p>",
"    Tick paralysis is briefly reviewed here; a detailed discussion is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link\">",
"     \"Tick paralysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms include anorexia, lethargy, muscle weakness, nystagmus, and an ascending flaccid paralysis. Symptom onset occurs three to seven days after attachment of the tick. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link&amp;anchor=H5#H5\">",
"     \"Tick paralysis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Neurophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography shows a reduced amplitude of compound muscle action potentials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/14\">",
"     14",
"    </a>",
"    ]. No abnormalities are seen with repetitive nerve stimulation studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. There may be subtle abnormalities of motor nerve conduction velocity and sensory action potentials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of tick paralysis usually relies on the finding of a tick attached to the patient. Unexposed areas such as the scalp, genitalia, and external meatus should be inspected carefully. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link&amp;anchor=H9#H9\">",
"     \"Tick paralysis\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link&amp;anchor=H10#H10\">",
"     \"Tick paralysis\", section on 'Suggested approach to diagnosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of the tick is the primary treatment of tick paralysis. The tick can be removed with forceps. However, it should be paralyzed with an insecticide prior to removal to ensure removal of mouth parts.",
"   </p>",
"   <p>",
"    Clinical improvement is generally fairly rapid after removal of American ticks. Symptoms may continue and worsen for two to three days after removal of Australian ticks. For severely affected patients, an antivenom derived from dogs is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link&amp;anchor=H10#H10\">",
"     \"Tick paralysis\", section on 'Suggested approach to diagnosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SNAKE VENOM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Four families of snakes produce venom causing neuromuscular transmission disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atractaspididae (African mole viper)",
"     </li>",
"     <li>",
"      Colubridae (boomslang, twig snake)",
"     </li>",
"     <li>",
"      Elapidae, with three major subfamilies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Elapidae (cobras, mambas, coral snakes)",
"     </li>",
"     <li>",
"      Hydrophiinae (sea snakes)",
"     </li>",
"     <li>",
"      Laticaudinae (sea kraits)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Viperidae, with two major subfamilies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Crotalinae, the pit vipers (copperheads, cottonmouth, moccasins, and rattlesnakes)",
"     </li>",
"     <li>",
"      Viperinae, the classic \"Old World\" vipers (carpet viper, common adder, puff adder, horned or desert vipers, Russell's viper)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The toxins produced affect either the presynaptic or postsynaptic junction.",
"   </p>",
"   <p>",
"    Toxins affecting the presynaptic junction include beta-bungarotoxin (krait), notexin (tiger snake), taipoxin (Taipan), and crotoxin (Brazilian rattlesnake). These toxins have phospholipase A2 activity. They catalyze the hydrolysis of one of the fatty ester linkages in diacyl phosphatides, forming lysophosphatides and releasing both saturated and unsaturated fatty acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The exact mechanism of toxicity is undefined, but initial fusion of synaptic vesicles with the presynaptic membrane is induced, followed by inhibited reformation of the vesicles after exocytosis. Further neurotransmitter release is therefore prevented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Poisoned nerve terminals show an absence of vesicles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/23\">",
"     23",
"    </a>",
"    ], which causes delayed degeneration of the motor nerve terminals. Recovery requires nerve terminal regeneration, a process that may take weeks. The presynaptic neurotoxins also possess myotoxic activity, which may lead to degeneration of skeletal muscle and death from acute renal failure.",
"   </p>",
"   <p>",
"    The postsynaptic-acting toxins are present in venom of snakes from the Elapidae family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. They bind irreversibly to the acetylcholine receptor site, and prevent the opening of the associated sodium channel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/24\">",
"     24",
"    </a>",
"    ]. As an example, alpha-bungarotoxin from the krait produces a postjunctional neuromuscular blockade.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Snake venom neurotoxins affect the cranial nerves first, resulting in ptosis, ophthalmoplegia, dysarthria, dysphagia, and drooling. This progresses to weakness of limb muscles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Clotting time is also increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The postsynaptic toxins produce findings on electrodiagnostic studies identical to those seen in myasthenia gravis, since the mechanism of disease is similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/27\">",
"     27",
"    </a>",
"    ]. Repetitive nerve stimulation produces a decremental response. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Electrophysiologic confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Envenomation by the timber rattlesnake causes myokymia (",
"    <a class=\"graphic graphic_waveform graphicRef69008 \" href=\"mobipreview.htm?22/54/23395\">",
"     waveform 1",
"    </a>",
"    ). Spontaneous bursts of motor unit potentials manifest as doublets and multiplets on electromyography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Extensive diagnostic workup is generally unnecessary, since most patients are fully aware of the snake bite.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of snake bites is briefly reviewed here and discussed separately in greater detail (",
"    <a class=\"graphic graphic_algorithm graphicRef61139 \" href=\"mobipreview.htm?16/16/16644\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=see_link\">",
"     \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31431?source=see_link\">",
"     \"Principles of snake bite management worldwide\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Frequently, the species of snake producing the bite is unknown (",
"    <a class=\"graphic graphic_figure graphicRef73865 \" href=\"mobipreview.htm?31/51/32569\">",
"     figure 4",
"    </a>",
"    ), and it is unclear if the bite was actually venomous. However, with any potentially venomous bite or sting, the patient should be observed for several hours before it is decided that the event is benign.",
"   </p>",
"   <p>",
"    Antivenom is available and effective for postsynaptic neurotoxins. It accelerates dissociation of the toxin from the postsynaptic receptor. Presynaptic toxins have no response to antivenom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/25\">",
"     25",
"    </a>",
"    ]. Cutting, biting, sucking, or excising tissue at the site is contraindicated, as these measures do not help remove venom and may introduce infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the neuromuscular blocking agents used during anesthesia, a number of other drugs can affect transmission at the neuromuscular junction, including the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      D-penicillamine",
"     </li>",
"     <li>",
"      Aminoglycoside antibiotics",
"     </li>",
"     <li>",
"      Fluoroquinolone antibiotics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       Phenytoin",
"      </a>",
"      and other anticonvulsants",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       Lithium",
"      </a>",
"     </li>",
"     <li>",
"      Beta blockers",
"     </li>",
"     <li>",
"      Glucocorticoids",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       Magnesium sulfate",
"      </a>",
"      &nbsp;(see",
"      <a class=\"local\" href=\"#H24\">",
"       'Hypermagnesemia/hypocalcemia'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    D-penicillamine, used to treat rheumatoid arthritis and Wilson disease, induces production of antibodies to acetylcholine receptors. This results in a syndrome clinically similar to myasthenia gravis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=see_link&amp;anchor=H9#H9\">",
"     \"Differential diagnosis of myasthenia gravis\", section on 'Penicillamine-induced myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other drugs listed above are generally safe, but may cause reduced transmission at the neuromuscular junction in cases of overdose, or when used in patients who have underlying disease of the neuromuscular junction, such as myasthenia gravis (",
"    <a class=\"graphic graphic_table graphicRef62302 \" href=\"mobipreview.htm?11/61/12254\">",
"     table 1",
"    </a>",
"    ) or Lambert-Eaton myasthenic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=see_link&amp;anchor=H25#H25\">",
"     \"Treatment of myasthenia gravis\", section on 'Drugs that may exacerbate myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Aminoglycoside antibiotics inhibit both pre- and postsynaptic transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     Phenytoin",
"    </a>",
"    causes both pre- and postsynaptic effects and prevents the depolarization required for neurotransmission. There is controversy over the nature of the action of beta blockers on the neuromuscular junction. They may produce a depolarizing or non-depolarizing blockade or have a local anesthetic action [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     Lithium",
"    </a>",
"    , with chronic use, may compete with calcium in the presynaptic region and reduce the release of acetylcholine (ACh) from nerve terminals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Clinical features and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, the offending drug is simply withdrawn, and the diagnosis is made by the resultant clinical improvement. The diagnosis may also be aided by administration of cholinesterase inhibitors.",
"   </p>",
"   <p>",
"    In aminoglycoside poisoning, low rates of repetitive nerve stimulation produce a decremental response, with post-tetanic facilitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/31\">",
"     31",
"    </a>",
"    ]. The facilitation exceeds that seen in myasthenia gravis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/31\">",
"     31",
"    </a>",
"    ]. The decremental response is also larger than occurs in myasthenia.",
"   </p>",
"   <p>",
"    Since D-penicillamine produces a myasthenia syndrome, the findings on electrodiagnostic studies are the same as those in patients with myasthenia (",
"    <a class=\"graphic graphic_waveform graphicRef75502 \" href=\"mobipreview.htm?12/36/12879\">",
"     waveform 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=see_link&amp;anchor=H12#H12\">",
"     \"Diagnosis of myasthenia gravis\", section on 'Electrophysiologic confirmation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical features are usually mild and affect primarily the extraocular muscles. The diagnosis can also be aided by finding elevated serum acetylcholine receptor antibodies. Clinical improvement is usually complete within one year of drug discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=see_link&amp;anchor=H9#H9\">",
"     \"Differential diagnosis of myasthenia gravis\", section on 'Penicillamine-induced myasthenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ORGANOPHOSPHATE AND CARBAMATE TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Organophosphates and carbamates are potent inhibitors of acetylcholinesterase, causing excess acetylcholine concentrations in the synapse. These compounds are formed as the esters of phosphoric or phosphorothioic acid or as the esters of carbamic acid, and are commonly used as pesticides. Each year, over 10,000 cases of organophosphate or carbamate poisoning occur in the United States, and 3,000,000 people are exposed worldwide. Exposure routes include oral ingestion, inhalation, or dermal contact. Organophosphorus \"nerve gases\" (eg, tabun [GA], sarin [GB], soman [GD]) have also been developed.",
"   </p>",
"   <p>",
"    Organophosphate and carbamate toxicity is briefly reviewed here; a detailed discussion is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link\">",
"     \"Organophosphate and carbamate poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the organophosphates and the carbamates have a common mode of action (anticholinesterase activity leading to an overabundance of acetylcholine in the synapse), there are significant differences between their reactions with the enzyme. The bond between an organophosphorus ester and the active site of the acetylcholinesterase enzyme is extremely stable, and these compounds are referred to as irreversible inhibitors. The carbamates interact with acetylcholinesterase in a fashion similar to acetylcholine. They bind non-covalently and the free, active enzyme is regenerated.",
"   </p>",
"   <p>",
"    The spontaneous hydrolysis of organophosphates from acetylcholinesterase is generally very slow. Oximes, specifically",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"     pralidoxime",
"    </a>",
"    , are typically used to induce more rapid dephosphorylation. If the oxime is not administered soon enough after acetylcholinesterase has been inhibited, an alkoxy group may be lost from the phosphorylated enzyme, resulting in a conformational change, known as \"aging\". Aging can occur within minutes for some compounds or may take up to days. Once aging has occurred, oximes can no longer induce dephosphorylation.",
"   </p>",
"   <p>",
"    The excess synaptic acetylcholine produced by organophosphates and carbamates binds muscarinic receptors in the central nervous system (CNS) and the parasympathetic portion of the autonomic nervous system. It also binds nicotinic receptors in the CNS, sympathetic and parasympathetic ganglia, and the neuromuscular junction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H2#H2\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since both sympathetic and parasympathetic systems are involved, symptoms of organophosphate and carbamate poisoning include typical muscarinic signs (lacrimation, bradycardia, bronchospasm) and nicotinic signs (mydriasis, tachycardia, weakness, hypertension). These result from the accumulation of acetylcholine in sympathetic ganglia and at the adrenal medulla (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 2",
"    </a>",
"    ). Increased depolarization at nicotinic neuromuscular synapses results in muscle weakness and flaccid paralysis.",
"   </p>",
"   <p>",
"    The dominant clinical features of acute cholinergic toxicity include bradycardia, miosis, lacrimation, salivation, bronchorrhea, bronchospasm, urination, emesis, and diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H3#H3\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Central nervous system symptoms may be present, with suppression of central medullary centers resulting in anxiety, confusion, seizures, and coma.",
"   </p>",
"   <p>",
"    Ten to 40 percent of patients develop a distinct neurologic disorder 24 to 96 hours after organophosphorus agent poisoning, referred to as the \"intermediate syndrome.\" Characteristic neurologic findings include cranial nerve abnormalities, neck flexion and proximal muscle weakness, respiratory insufficiency, and decreased deep tendon reflexes.",
"   </p>",
"   <p>",
"    A delayed symmetrical motor polyneuropathy, termed organophosphorus agent-induced delayed neuropathy (OPIDN), may occur one to three weeks after exposure to specific organophosphorus agents, including chlorpyrifos.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neurophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrodiagnostic studies in organophosphate poisoning demonstrate repetitive compound muscle action potentials in response to a single stimulus to the nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/37\">",
"     37",
"    </a>",
"    ]. This is caused by excess accumulation of acetylcholine in the synapse and subsequent depolarization of the postsynaptic muscle membrane. The presynaptic receptors are also activated. This combined effect results in repetitive discharges in response to a single stimulus. Repetitive nerve stimulation results in decrement of the compound motor action potential (CMAP) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/37\">",
"     37",
"    </a>",
"    ]. In early stages of organophosphate poisoning, a decrement-increment response may be seen with higher rates of stimulation. This response may recur later, as clinical improvement is seen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds; the clinical features of cholinergic excess should indicate the possibility of organophosphate poisoning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H7#H7\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency management of organophosphate or carbamate poisoning often requires endotracheal intubation and volume resuscitation (",
"    <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"     table 2",
"    </a>",
"    ). All cases require aggressive decontamination with complete removal of the patient's clothes and vigorous irrigation of the affected areas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H10#H10\">",
"     \"Organophosphate and carbamate poisoning\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      is used for symptomatic relief of muscarinic symptoms. It does not reverse the paralysis caused by neuromuscular blockade that results from nicotinic receptor stimulation. Atropine dosing should be titrated to the therapeutic end point of the clearing of respiratory secretions and the cessation of bronchoconstriction. Specific dosing regimens are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H12#H12\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Atropine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"       Pralidoxime",
"      </a>",
"      and other oximes are effective in treating both muscarinic and nicotinic symptoms. Pralidoxime should",
"      <strong>",
"       not",
"      </strong>",
"      be administered without concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , which prevents worsening symptoms due to transient oxime-induced acetylcholinesterase inhibition. Oxime therapy should be given to all patients with evidence of cholinergic toxicity, neuromuscular dysfunction, or exposure to organophosphorus agents known to cause delayed neurotoxicity. Dosing regimens are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H13#H13\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Pralidoxime'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     HYPERMAGNESEMIA/HYPOCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A surplus of magnesium or a deficiency of calcium may cause inhibition of acetylcholine release. The administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    to mothers with eclampsia has resulted in hypermagnesemia in infants with the development of weakness and respiratory depression. Hypermagnesemia is an uncommon problem in the absence of magnesium administration or renal failure. Concentrated sources of magnesium include antacids, enemas, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/40/42628?source=see_link\">",
"     total parenteral nutrition",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13220?source=see_link\">",
"     \"Causes and treatment of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Magnesium has a calcium channel blocking effect that decreases entry of calcium into cells. It also decreases the amount of acetylcholine released and depresses the excitability of the muscle membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/39\">",
"     39",
"    </a>",
"    ]. This produces proximal muscle weakness, which may progress to respiratory insufficiency. Ocular muscles are generally spared. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32914?source=see_link&amp;anchor=H2#H2\">",
"     \"Symptoms of hypermagnesemia\", section on 'Neuromuscular effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fast synaptic transmission is steeply dependent on external calcium concentrations. Hypocalcemia results in an uncoupling of synaptic release of neurotransmitters (glutamate, acetylcholine, GABA) in response to an action potential at the nerve terminal. This is because the proteins involved in synaptic vesicle docking and fusion interact in a calcium-dependent manner [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41688/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrodiagnostic studies show low-amplitude compound muscle action potentials, decremental response to low-frequency stimulation, and post-tetanic facilitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of hypermagnesemia or hypocalcemia is generally made by demonstrating elevated serum magnesium levels or decreased calcium levels and observing clinical improvement as levels normalize.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442037900\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The neuromuscular junction consists of a presynaptic axon terminal and a postsynaptic muscle end plate (",
"      <a class=\"graphic graphic_figure graphicRef62694 \" href=\"mobipreview.htm?18/25/18838\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The neuromuscular junction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botulism is an uncommon and life-threatening disease caused by bacteria in the Clostridium family. The botulinum neurotoxin is considered the most potent lethal substance known. Symptoms range from minor cranial nerve palsies associated with symmetric descending weakness to rapid respiratory arrest. In high enough doses, it causes rapid and severe paralysis of skeletal muscles. Botulinum antitoxin should be given as soon as botulism is suspected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Botulism'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=see_link&amp;anchor=H21#H21\">",
"       \"Botulism\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Several tick species produce a toxin that inhibits transduction at the neuromuscular junction by blocking influx of sodium ions. Symptoms include anorexia, lethargy, muscle weakness, nystagmus, and an ascending flaccid paralysis. Symptom onset occurs three to seven days after attachment of the tick. Removal of the tick is the primary treatment. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Tick paralysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=see_link&amp;anchor=H10#H10\">",
"       \"Tick paralysis\", section on 'Suggested approach to diagnosis and management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Four families of snakes produce venom causing neuromuscular transmission disorders. The toxins produced affect either the presynaptic or postsynaptic junction. Snake venom neurotoxins affect the cranial nerves first, resulting in ptosis, ophthalmoplegia, dysarthria, dysphagia, and drooling. This progresses to weakness of limb muscles. The management of snake bites (",
"      <a class=\"graphic graphic_algorithm graphicRef61139 \" href=\"mobipreview.htm?16/16/16644\">",
"       algorithm 1",
"      </a>",
"      ) is briefly reviewed here and discussed separately in greater detail. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Snake venom'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=see_link\">",
"       \"Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31431?source=see_link\">",
"       \"Principles of snake bite management worldwide\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to the neuromuscular blocking agents used during anesthesia, a number of other drugs can affect transmission at the neuromuscular junction, including D-penicillamine, aminoglycoside antibiotics, fluoroquinolone antibiotics,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      and other anticonvulsants,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , beta blockers, glucocorticoids, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      . D-penicillamine induces production of antibodies to acetylcholine receptors. This results in a syndrome clinically similar to myasthenia gravis. The other drugs listed are generally safe, but may cause reduced transmission at the neuromuscular junction in cases of overdose, or when used in patients who have underlying disease of the neuromuscular junction. Generally, the offending drug is simply withdrawn, and the diagnosis is made by the resultant clinical improvement. The diagnosis may also be aided by administration of cholinesterase inhibitors. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Organophosphates and carbamates are potent inhibitors of acetylcholinesterase, causing excess acetylcholine concentrations in the synapse. These compounds are commonly used as pesticides. Symptoms of organophosphate and carbamate poisoning include typical muscarinic signs (lacrimation, bradycardia, bronchospasm) and nicotinic signs (mydriasis, tachycardia, weakness, hypertension). Central nervous system symptoms may also be present, including anxiety, confusion, seizures, and coma. The diagnosis of organophosphate or carbamate poisoning is made on clinical grounds. Emergency management often requires endotracheal intubation and volume resuscitation (",
"      <a class=\"graphic graphic_table graphicRef63540 \" href=\"mobipreview.htm?18/23/18813\">",
"       table 2",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/23/11640?source=see_link\">",
"       Atropine",
"      </a>",
"      is used for symptomatic relief of muscarinic symptoms but does not reverse the paralysis.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/8/16517?source=see_link\">",
"       Pralidoxime",
"      </a>",
"      is effective in treating both muscarinic and nicotinic symptoms. Pralidoxime should",
"      <strong>",
"       not",
"      </strong>",
"      be administered without concurrent atropine. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Organophosphate and carbamate toxicity'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=see_link&amp;anchor=H10#H10\">",
"       \"Organophosphate and carbamate poisoning\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A surplus of magnesium or a deficiency of calcium may cause inhibition of acetylcholine release. The administration of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      to mothers with eclampsia has resulted in hypermagnesemia in infants with the development of weakness and respiratory depression. Hypermagnesemia is an uncommon problem in the absence of magnesium administration or renal failure. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Hypermagnesemia/hypocalcemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/1\">",
"      Senanayake N, Rom&aacute;n GC. Disorders of neuromuscular transmission due to natural environmental toxins. J Neurol Sci 1992; 107:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/2\">",
"      Whittaker VP. The structure and function of cholinergic synaptic vesicles. The Third Thudichum Lecture. Biochem Soc Trans 1984; 12:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/3\">",
"      Wagner JA, Carlson SS, Kelly RB. Chemical and physical characterization of cholinergic synaptic vesicles. Biochemistry 1978; 17:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/4\">",
"      Benfenati F, Valtorta F, Rubenstein JL, et al. Synaptic vesicle-associated Ca2+/calmodulin-dependent protein kinase II is a binding protein for synapsin I. Nature 1992; 359:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/5\">",
"      Dreyer F, Peper K, Akert K, et al. Ultrastructure of the \"active zone\" in the frog neuromuscular junction. Brain Res 1973; 62:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/6\">",
"      Sheng ZH, Westenbroek RE, Catterall WA. Physical link and functional coupling of presynaptic calcium channels and the synaptic vesicle docking/fusion machinery. J Bioenerg Biomembr 1998; 30:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/7\">",
"      S&ouml;llner T, Whiteheart SW, Brunner M, et al. SNAP receptors implicated in vesicle targeting and fusion. Nature 1993; 362:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/8\">",
"      Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000; 80:717.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz, JH. Chemical messengers: small molecules and peptides. In: Principles of Neural Science, 3rd ed, Kandel, ER, Schwartz, JH, Jessell, TM (Eds), Appleton and Lange, 1991. p.229.",
"    </li>",
"    <li>",
"     Dwyer, T. The electrochemical basis of nerve function. In: Fundamental neuroscience for basic and clinical applications, 3rd ed, Haines, D (Ed), Elsevier, Singapore 2006. p.41.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/11\">",
"      Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil 2005; 84:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/12\">",
"      Cherington M. Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982; 5:S28.",
"     </a>",
"    </li>",
"    <li>",
"     Trontelj, JV, Sanders, DB, Stalber, EV. Electrophysiologic methods for assessing neuromuscular transmission. In: Neuromuscular function and disease, Brown, WF, Bolton, CF, Aminoff, MJ (Eds), WB Saunders Company 2002. p.431.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/14\">",
"      Cherington M, Synder RD. Tick paralysis. Neurophysiologic studies. N Engl J Med 1968; 278:95.",
"     </a>",
"    </li>",
"    <li>",
"     Kimura, J. Myasthenia gravis and other disorders of neuromuscular transmission. In: Electrodiagnosis on diseases of nerve and muscle: principles and practice, 3rd edition, Kimura, J, (Ed), Oxford University Press 2001. p.765.",
"    </li>",
"    <li>",
"     Mebs, D. Venomous and poisonous animals: a handbook for biologists, toxicologists and toxinologists, physicians and pharmacists. Medpharm Scientific Publishers CRC Press, Boca Raton, FL 2002. p.239.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/17\">",
"      Warrell DA. Snake bite. Lancet 2010; 375:77.",
"     </a>",
"    </li>",
"    <li>",
"     Kini, RM. Venom phospholipase A2 enzymes: structure, function, and mechanism, Wiley, Chichester, UK 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/19\">",
"      Lewis RL, Gutmann L. Snake venoms and the neuromuscular junction. Semin Neurol 2004; 24:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/20\">",
"      Karalliedde L. Animal toxins. Br J Anaesth 1995; 74:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/21\">",
"      Dixon RW, Harris JB. Nerve terminal damage by beta-bungarotoxin: its clinical significance. Am J Pathol 1999; 154:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/22\">",
"      Connolly S, Trevett AJ, Nwokolo NC, et al. Neuromuscular effects of Papuan Taipan snake venom. Ann Neurol 1995; 38:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/23\">",
"      Harris JB, Grubb BD, Maltin CA, Dixon R. The neurotoxicity of the venom phospholipases A(2), notexin and taipoxin. Exp Neurol 2000; 161:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/24\">",
"      Hodgson WC, Wickramaratna JC. In vitro neuromuscular activity of snake venoms. Clin Exp Pharmacol Physiol 2002; 29:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/25\">",
"      Harris JB, Goonetilleke A. Animal poisons and the nervous system: what the neurologist needs to know. J Neurol Neurosurg Psychiatry 2004; 75 Suppl 3:iii40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/26\">",
"      White J, Warrell D, Eddleston M, et al. Clinical toxinology--where are we now? J Toxicol Clin Toxicol 2003; 41:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/27\">",
"      Kumar S, Usgaonkar RS. Myasthenia gravis--like picture resulting from snake bite. J Indian Med Assoc 1968; 50:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/28\">",
"      Brick JF, Gutmann L. Rattlesnake venom-induced myokymia. Muscle Nerve 1982; 5:S98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/29\">",
"      Howard JF Jr. Adverse drug effects on neuromuscular transmission. Semin Neurol 1990; 10:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/30\">",
"      Sieb JP. Fluoroquinolone antibiotics block neuromuscular transmission. Neurology 1998; 50:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/31\">",
"      Argov Z, Mastaglia FL. Drug therapy: Disorders of neuromuscular transmission caused by drugs. N Engl J Med 1979; 301:409.",
"     </a>",
"    </li>",
"    <li>",
"     Argov, Z, Wirguin, I. Drugs and the neuromuscular junction pharmacotherapy of transmission disorders and drug-induced myasthenic syndromes. In: Handbook of myasthenia gravis and myasthenic syndromes, Lisak, RP (Eds), Marcel Dekker, New York 1994. p.295.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/33\">",
"      Wislicki L. Excitatory and depressant effects of beta-adrenoceptor blocking agents on skeletal muscle. Arch Int Pharmacodyn Ther 1969; 182:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/34\">",
"      Werman R, Wislicki L. Propranolol, a curariform and cholinomimetic agent at the frog neuromuscular junction. Comp Gen Pharmacol 1971; 2:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/35\">",
"      Vizi ES, Ill&eacute;s P, R&oacute;nai A, Knoll J. Effect of lithium on acetylcholine release and synthesis. Neuropharmacology 1972; 11:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/36\">",
"      Lee P, Tai DY. Clinical features of patients with acute organophosphate poisoning requiring intensive care. Intensive Care Med 2001; 27:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/37\">",
"      Besser R, Gutmann L, Dillmann U, et al. End-plate dysfunction in acute organophosphate intoxication. Neurology 1989; 39:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41688/abstract/38\">",
"      Senanayake N, Karalliedde L. Neurotoxic effects of organophosphorus insecticides. An intermediate syndrome. N Engl J Med 1987; 316:761.",
"     </a>",
"    </li>",
"    <li>",
"     Shnider, SM, Levinson, G. Anesthesia for obstetrics. In: Anesthesia, 4th ed, Miller, RD (Ed), Churchill Livingstone, New York 1994. p.2031.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5139 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41688=[""].join("\n");
var outline_f40_45_41688=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H442037900\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE NEUROMUSCULAR JUNCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BOTULISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TICK PARALYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SNAKE VENOM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ORGANOPHOSPHATE AND CARBAMATE TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      HYPERMAGNESEMIA/HYPOCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442037900\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5139\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5139|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?16/16/16644\" title=\"algorithm 1\">",
"      Snake bite management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5139|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/25/18838\" title=\"figure 1\">",
"      Normal neuromuscular junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/15/5361\" title=\"figure 2\">",
"      RNS incremental response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/8/40079\" title=\"figure 3\">",
"      CMAP postexercise facilitat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/51/32569\" title=\"figure 4\">",
"      Venomous vs nonvenomous",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5139|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/61/12254\" title=\"table 1\">",
"      Drugs that may worsen MG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/23/18813\" title=\"table 2\">",
"      Organophosphate and carbamate poisoning - Rapid overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5139|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?22/54/23395\" title=\"waveform 1\">",
"      EMG myokymia envenomation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"mobipreview.htm?12/36/12879\" title=\"waveform 2\">",
"      RNS study MG",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/36/37448?source=related_link\">",
"      Botulism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/58/13220?source=related_link\">",
"      Causes and treatment of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/9/35992?source=related_link\">",
"      Clinical features and diagnosis of Lambert-Eaton myasthenic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/51/17206?source=related_link\">",
"      Clinical manifestations of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32968?source=related_link\">",
"      Diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15654?source=related_link\">",
"      Differential diagnosis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/52/5962?source=related_link\">",
"      Management of Crotalinae (rattlesnake, water moccasin [cottonmouth], or copperhead) bites in the United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/166?source=related_link\">",
"      Neuromuscular junction disorders in newborns and infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31287?source=related_link\">",
"      Pathogenesis of myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31431?source=related_link\">",
"      Principles of snake bite management worldwide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/26/3494?source=related_link\">",
"      Tick paralysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/57/7066?source=related_link\">",
"      Treatment of myasthenia gravis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_45_41689="Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx";
var content_f40_45_41689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The larynx and hypopharynx",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Kerstin M Stenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     David J Sher, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Marshall R Posner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/45/41689/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/45/41689/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide, there are approximately 130,000 new laryngeal cancer cases and 70,000 deaths annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, laryngeal cancer accounts for about 25 percent of the 53,000 cases of head and neck cancer diagnosed annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/2\">",
"     2",
"    </a>",
"    ]. Glottic, supraglottic, and subglottic cancers represent approximately two-thirds, one-third, and two percent of laryngeal cancers, respectively. Hypopharyngeal cancer is less common than laryngeal cancer, with approximately one fourth as many cases.",
"   </p>",
"   <p>",
"    Tumors of the glottic larynx commonly present with hoarseness and are diagnosed at an early stage. However, patients with supraglottic and subglottic laryngeal cancers, as well as hypopharyngeal cancers, usually present with advanced disease due to a paucity of symptoms, propensity for local extension (subglottis), and rich lymphatics resulting in a high incidence of lymph node metastases (supraglottis).",
"   </p>",
"   <p>",
"    The management of locoregionally advanced laryngeal and hypopharyngeal cancer is presented here. The treatment of early stage laryngeal and hypopharyngeal cancers is discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The larynx\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853305\">",
"    <span class=\"h1\">",
"     ANATOMY AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The larynx is divided into three anatomic regions (",
"    <a class=\"graphic graphic_figure graphicRef58555 graphicRef72411 \" href=\"mobipreview.htm?22/62/23530\">",
"     figure 1A-B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraglottis &mdash; suprahyoid epiglottis, infrahyoid epiglottis, aryepiglottic folds (laryngeal aspect), arytenoids, and ventricular bands (false cords)",
"     </li>",
"     <li>",
"      Glottis &mdash; true vocal cords, including anterior and posterior commissures",
"     </li>",
"     <li>",
"      Subglottis &mdash; subglottis, extending from lower boundary of the glottis to the lower margin of the cricoid cartilage",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The hypopharynx lies beside and behind the larynx and extends to the esophageal inlet. It contains the paired pyriform sinuses, the posterior pharyngeal wall, and the postcricoid area (",
"    <a class=\"graphic graphic_figure graphicRef75396 \" href=\"mobipreview.htm?26/56/27525\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The tumor node metastases (TNM) staging system of the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used to classify cancers of the larynx (",
"    <a class=\"graphic graphic_table graphicRef66619 \" href=\"mobipreview.htm?22/14/22766\">",
"     table 1",
"    </a>",
"    ) and hypopharynx (",
"    <a class=\"graphic graphic_table graphicRef55865 \" href=\"mobipreview.htm?36/42/37549\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/3\">",
"     3",
"    </a>",
"    ]. For laryngeal cancers, staging of the primary tumor (T) is defined separately for supraglottic, glottic, and subglottic tumors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830501\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with advanced (stage III and IV) cancer of the larynx or hypopharynx should be seen prior to treatment by a multidisciplinary team with experience in the treatment of head and neck cancer. Selection of a treatment approach depends upon tumor extent and location, patient-specific factors (eg, age, performance status, comorbidity, psychosocial support), physician expertise, and the availability of rehabilitation services. Treatment-related toxicity associated with chemoradiotherapy and rehabilitation issues related to surgery must also be considered.",
"   </p>",
"   <p>",
"    Functional organ preservation is widely recommended and generally utilizes a combination of chemotherapy plus radiation therapy (RT). However, advances in surgical techniques, such as laryngeal preservation surgery and minimally invasive surgery, offer alternative options for larynx preservation in carefully selected patients. These surgical approaches have not been directly compared to chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H291853346\">",
"     'Larynx preservation surgery'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although functional organ sparing approaches permit larynx preservation in patients with locoregionally advanced cancer of the larynx and hypopharynx, they do not provide a survival advantage over total laryngectomy. When feasible, most patients should be offered the option of organ preservation because of the importance of the larynx to speech and swallowing (",
"    <a class=\"graphic graphic_table graphicRef72929 \" href=\"mobipreview.htm?8/49/8990\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preservation of the larynx is not the exclusive determinant of quality of life. An international consensus panel has recommended that a new endpoint of laryngoesophageal dysfunction-free survival is a more useful objective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Events included in this endpoint include death, local relapse, total or partial laryngectomy, tracheotomy at two or more years, and the presence of a feeding tube at two or more years.",
"   </p>",
"   <p>",
"    In addition, patients should be counseled about smoking cessation; ongoing tobacco use during radiotherapy has been associated with reduced survival in patients with locally advanced head and neck cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830523\">",
"    <span class=\"h1\">",
"     COMBINED MODALITY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy was given as a neoadjuvant prior to definitive RT in the initial clinical trials. Subsequent trials have used chemotherapy given at the same time as RT (concurrent chemoradiotherapy), and induction chemotherapy has been combined with concurrent chemoradiotherapy in sequential therapy regimens.",
"   </p>",
"   <p>",
"    Chemoradiotherapy and induction chemotherapy have replaced total laryngectomy plus postoperative RT as functional organ preserving alternatives in the treatment of potentially operable, locally advanced cancer of the larynx and hypopharynx for most good performance status patients. Chemoradiotherapy and induction chemotherapy approaches require that the patient be able to withstand the prolonged course of treatment and associated toxicities and participate in rehabilitation from the radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chemoradiotherapy and induction chemotherapy are also used to provide definitive treatment for patients who are inoperable because of extensive locoregional disease.",
"   </p>",
"   <p>",
"    While chemoradiotherapy and induction chemotherapy usually maintain laryngeal function in patients with resectable disease, they are associated with considerable toxicity that in rare cases may compromise the patient&rsquo;s ability to protect the airway and thus may not achieve the goal of functional larynx preservation. Thus, organ function-preserving approaches are not appropriate for all patients with locoregionally advanced cancer of the larynx and hypopharynx:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Elderly patients and those with a poor performance status may not be suitable candidates for this treatment because of the toxicity associated with chemotherapy and chemoradiotherapy. Definitive radiation therapy alone or total laryngectomy followed by postoperative RT may be preferable in this setting. (See",
"      <a class=\"local\" href=\"#H291853368\">",
"       'Elderly and poor performance status patients'",
"      </a>",
"      below.)",
"      <br/>",
"     </li>",
"     <li>",
"      Patients with destruction of both vocal cords may not recover vocal or airway protective function with larynx-preservation approaches and may function better after total laryngectomy, when feasible, rather than induction chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H349830938\">",
"       'Total laryngectomy'",
"      </a>",
"      below.)",
"      <br/>",
"     </li>",
"     <li>",
"      The optimal treatment for tumors with limited cartilage invasion (stage T4a) is controversial (",
"      <a class=\"graphic graphic_table graphicRef66619 \" href=\"mobipreview.htm?22/14/22766\">",
"       table 1",
"      </a>",
"      ). Significant cartilage destruction prior to treatment may be an indication for initial laryngectomy, because cartilage destruction limits the probability of adequate response and functional recovery with larynx-preserving approaches and increases the probability of radiation-induced necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, the presence of cartilage invasion alone does not necessarily preclude an organ sparing approach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. When the findings are unclear, an attempt at functional larynx preservation may be undertaken with surgery as salvage if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830549\">",
"    <span class=\"h2\">",
"     Feasibility of functional organ preservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The feasibility of functional organ preservation using induction chemotherapy prior to definitive RT was established by the Department of Veterans Affairs (VA) Laryngeal Cancer Study Group larynx trial. Similar results were seen in a European cooperative group trial (EORTC 24891) that included patients with cancers of the hypopharynx as well as the larynx.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the VA trial, 332 patients with stage III or IV laryngeal cancer were randomly assigned to either three cycles of induction chemotherapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (PF) followed by definitive RT or primary surgery (typically total laryngectomy) followed by postoperative RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients without at least a partial response and those with any evidence of disease progression during or after induction chemotherapy were treated with surgery and postoperative radiation therapy (RT).",
"      <br/>",
"      <br/>",
"      At a median follow-up of 33 months, the two-year survival rate was equal in both treatment groups (68 percent), and the larynx was successfully preserved in 64 percent of patients treated with induction chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/11\">",
"       11",
"      </a>",
"      ]. A subsequent reported that the three-year survival rates were 53 and 56 percent for chemotherapy plus RT and surgery plus RT, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the European trial, 194 patients with stage II through IV squamous cell carcinoma of the pyriform sinus or aryepiglottic fold were randomly assigned to receive induction chemotherapy with PF followed by definitive RT or surgery (total laryngectomy with partial pharyngectomy) followed by postoperative RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Patients who failed to achieve a complete response to induction chemotherapy underwent salvage surgery and postoperative RT. At a median follow-up of 10.5 years, there were no significant differences in survival or patterns-of-failure outcomes. The 10-year progression-free survival probabilities for the chemotherapy plus definitive RT and for the surgery arms were 11 and 9 percent, respectively. Overall survival probabilities at 10 years were 13 and 14 percent, respectively. The 5- and 10-year probabilities of being alive with a functional larynx were 21.9 and 8.7 percent, respectively; however, for those patients alive at 5 and 10 years, 59.5 percent",
"      <span class=\"nowrap\">",
"       (22/37)",
"      </span>",
"      and 62.5 percent",
"      <span class=\"nowrap\">",
"       (5/8)",
"      </span>",
"      maintained a normal larynx, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Following the demonstration of benefit with induction chemotherapy followed by RT, various subsequent trials evaluated the concurrent administration of chemotherapy with radiation therapy (concurrent chemoradiotherapy), induction chemotherapy, and induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177767476\">",
"    <span class=\"h2\">",
"     Concurrent chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent chemoradiotherapy administers systemic chemotherapy at the same time as definitive RT to improve the likelihood of disease control and laryngeal preservation. This approach is more effective in achieving locoregional control of disease. However, concurrent chemoradiotherapy is less effective in preventing the development of distant metastases compared with induction chemotherapy followed by definitive RT and is associated with more unexplained deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/19\">",
"     19",
"    </a>",
"    ].(See",
"    <a class=\"local\" href=\"#H432436853\">",
"     'Comparison of organ-preserving approaches'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data supporting the role of concurrent chemotherapy come from the 2011 update of the Meta-Analysis of Chemotherapy on Head and Neck Cancer (MACH-NC) Collaborative Group, which conducted a comprehensive analysis by tumor site [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/20\">",
"     20",
"    </a>",
"    ]. This analysis was based upon individual patient data for 3216 patients with laryngeal cancer. There was an overall benefit for the addition of chemotherapy to locoregional therapy (hazard ratio [HR] for death 0.87, 95% CI 0.80-0.96). Furthermore, this benefit with concomitant chemoradiotherapy (HR 0.80, 95% CI 0.71-0.90) was significantly better than with neoadjuvant chemotherapy or adjuvant chemotherapy, although this analysis did not examine PF or TPF induction specifically as has been the case for the analyses of 2009 and 2010. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281027161#H281027161\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Concurrent chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For the 2767 patients with hypopharyngeal cancer, a similar benefit in survival with chemotherapy was observed (HR 0.88, 95% CI 0.80-0.96). However, there was no statistically significant difference between those given concomitant chemoradiotherapy (HR 0.85) and those given neoadjuvant chemotherapy (HR 0.88), although the authors cautioned that the study may not have adequate power to detect a difference in this disease site.",
"   </p>",
"   <p>",
"    Based upon these results, concurrent chemoradiotherapy is widely recommended for good performance status patients with resectable locally advanced (stage III and carefully selected stage IV) laryngeal and hypopharyngeal cancer, with a platinum-based chemotherapy regimen, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (100",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830665\">",
"    <span class=\"h2\">",
"     Induction chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy followed by definitive RT is an alternative for the functional organ preservation treatment of locally advanced cancer of the larynx and hypopharynx. Although this approach may not be as effective as concurrent chemoradiotherapy in initial control of locoregional disease without salvage laryngectomy, induction therapy may decrease the incidence of distant metastases compared with concurrent chemoradiotherapy alone and had a better, although not statistically significant, survival outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In earlier reports of the MACH-NC meta-analysis, there was no statistically significant survival benefit for induction chemotherapy in general versus definitive locoregional therapy alone, although there was a benefit for induction chemotherapy in the subset of trials using induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (hazard ratio (HR) 0.88, 95% CI 0.79-0.97) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Furthermore, the subsequent TAX 323 trial found that a three-drug combination that added a taxane to cisplatin plus 5-fluorouracil regimen significantly improved overall survival compared with cisplatin plus 5-fluorouracil alone, when both were followed by definitive RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281026593#H281026593\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The responsiveness of the tumor to induction therapy provides predictive and prognostic information that may be useful in deciding whether functional organ preservation is feasible or whether surgical resection is indicated or whether more intensive chemoradiotherapy might be given. Three or four cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (TPF) chemotherapy are typically used for induction therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830807\">",
"    <span class=\"h2\">",
"     Sequential chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sequential therapy incorporates induction chemotherapy followed by concurrent chemoradiotherapy. In theory, sequential therapy combines the reduction in distant metastases afforded by induction chemotherapy with improvements in locoregional control achieved with concurrent chemoradiotherapy.",
"   </p>",
"   <p>",
"    The most extensive data on sequential chemoradiotherapy in squamous head and neck cancer come from the TAX 324 trial, which demonstrated improved effectiveness of induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , plus 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (TPF) rather than cisplatin plus 5-fluorouracil alone, with both regimens followed by concurrent chemoradiotherapy using weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/23\">",
"     23",
"    </a>",
"    ]. The trial was conducted in a broad spectrum of patients with squamous cell carcinoma of the head and neck. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281026593#H281026593\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequential therapy was studied specifically in patients with laryngeal and hypopharyngeal cancers in the randomized phase II TREMPLIN study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/24\">",
"     24",
"    </a>",
"    ]. In that trial, 153 enrolled patients were treated with induction chemotherapy (three cycles of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , and 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ). Overall, 126 patients (82 percent) responded, and 116 were randomly assigned to RT plus cisplatin or RT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . Local control was superior in the cisplatin arm, but laryngeal preservation, laryngeal function, and overall survival were similar for the two treatment groups (95 versus 93 percent, 87 versus 82 percent, and 92 versus 89 percent), for the cisplatin and cetuximab arms, respectively.",
"   </p>",
"   <p>",
"    Although the results with both regimens were highly favorable in patients who successfully completed induction therapy, the likelihood of success with a sequential strategy is more limited when patients who failed the induction regimen were considered. Using a composite endpoint of laryngoesophageal dysfunction-free survival (which included death, local relapse, laryngectomy, tracheotomy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    feeding tube at two years) in the initial treatment cohort of 153 patients, the overall likelihood of a successful outcome was approximately 57 percent. There was no statistically significant difference between concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Patients who might benefit the most from sequential therapy are those with large primary tumors (bulky T3 and select T4)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    advanced nodal presentations (large N2a, N2b, N2c, and N3) who are at high-risk for distant metastases although randomized trials have yet to confirm a survival benefit for these indications. When a sequential therapy approach is chosen, we generally use TPF induction chemotherapy, followed by concurrent therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , as used in the TAX 324 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281026593#H281026593\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Induction chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H432436853\">",
"    <span class=\"h2\">",
"     Comparison of organ-preserving approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most extensive data directly comparing concurrent chemoradiotherapy versus induction therapy versus RT alone for organ preservation in patients with stage III or IV laryngeal cancer come from the intergroup Radiation Therapy Oncology Group (RTOG) 91-11 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In this trial, 547 patients (520 ultimately evaluable) were randomly assigned to one of three groups:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induction chemotherapy, using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 1) plus 5-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"       fluorouracil",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"       /day",
"      </span>",
"      by continuous intravenous infusion for five days), for three cycles followed by definitive RT (the control group)",
"      <br/>",
"     </li>",
"     <li>",
"      Concurrent chemoradiotherapy, with definitive RT and concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on days 1, 22, and 43)",
"      <br/>",
"     </li>",
"     <li>",
"      Definitive RT alone",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Definitive RT in all three groups was given using conventional techniques to a total dose of 70 Gy in 35 fractions. However, intensity modulated RT (IMRT) was not used in this trial.",
"   </p>",
"   <p>",
"    The primary composite endpoint of the trial was laryngectomy free survival (LFS). Although induction chemotherapy followed by RT and concurrent chemoradiotherapy significantly improved LFS compared to RT alone, the patterns of disease control differed. Key results with a follow-up of almost 11 years included the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Laryngectomy free survival (LFS) was significantly improved with both combined modality approaches compared with RT alone. (Concurrent versus RT alone, five-year LFS 47 versus 34 percent, HR for failure 0.78, 95% CI 0.61-0.98; induction versus RT alone, five-year LFS 44 versus 34 percent, HR for failure 0.75, 95% CI 0.59-0.95).",
"     </li>",
"     <li>",
"      Locoregional disease control was significantly improved with concurrent chemoradiotherapy compared with induction chemotherapy or RT alone. (Concurrent versus induction, five-year control rate 68 versus 55 percent, HR for failure 0.66, 95% CI 0.48-0.92; concurrent versus RT alone, five-year control rate 68 versus 51 percent, HR for failure 0.59, 95% CI 0.43-0.82).",
"     </li>",
"     <li>",
"      Distant control was improved for both concurrent chemoradiotherapy and induction chemotherapy plus RT compared with RT alone. (Induction versus RT alone five-year control 85 versus 78 percent, HR for failure 0.63, 95% CI 0.39-1.01; concurrent versus RT alone 86 versus 78 percent, HR for failure 0.69, 95% CI 0.43-1.11)",
"     </li>",
"     <li>",
"      The difference in overall survival was not statistically significant among the three approaches, although there was a trend for concurrent chemoradiotherapy to have a poorer survival than induction chemotherapy with longer follow-up (five-year overall survival rates 55, 58, and 54 percent, respectively, and 10-year survival rates 28, 39, and 32 percent, respectively, for concurrent, induction and RT alone; HR for death for concurrent versus RT alone 1.08, 95% CI 0.85-1.39; HR for death for induction versus RT alone 0.87, 95% CI 0.68-1.12; HR for death for concurrent versus induction 1.25, 95% CI 0.98-1.61, p = 0.08). This trend for a survival decrement with concurrent chemoradiotherapy was in the context of its continued superiority in locoregional control, suggesting that non-cancer causes of death were increased in this arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sequential therapy has not been compared with concurrent chemoradiotherapy alone in adequately powered randomized trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H374890817\">",
"    <span class=\"h2\">",
"     Experimental chemotherapy approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two series, carefully selected patients with locally advanced laryngeal cancer (predominantly glottis cancers) were managed with observation only following a complete response to induction chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach resulted in long-term disease control in about 30 percent. This is lower than would be expected with an initial combined modality approach and may compromise the opportunity for cure.",
"   </p>",
"   <p>",
"    Chemotherapy followed by observation is investigational and should be considered only in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830915\">",
"    <span class=\"h1\">",
"     SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although chemoradiotherapy is now widely used in patients with locoregionally advanced disease, surgery retains a role in carefully selected patients as an alternative approach to functional organ preservation. Surgery is also important for the management of patients who are not candidates for chemoradiotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853346\">",
"    <span class=\"h2\">",
"     Larynx preservation surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical approaches that preserve the larynx, used in combination with postoperative RT or chemoradiotherapy, may provide an alternative treatment option for patients with advanced disease due to neck node burden but with small T-stage primary lesions. In carefully selected cases, such approaches may provide effective local control while maintaining laryngeal function and avoiding a permanent tracheal stoma. Following detailed preoperative evaluation, minimally invasive surgery may be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853353\">",
"    <span class=\"h3\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detailed preoperative assessment is critical for patient selection for larynx preservation surgery:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preoperative laryngeal examination (typically flexible fiber optic examination",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      videostroboscopy), with careful attention to the mobility of the vocal cord and arytenoid cartilages, is critical. Fixation of the vocal cord is an important negative prognostic finding.",
"      <br/>",
"     </li>",
"     <li>",
"      Imaging using CT or MRI can help assess the degree of invasion; however, these techniques are limited by low sensitivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/29-32\">",
"       29-32",
"      </a>",
"      ]. Dynamic imaging, such as a modified",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      swallow, is also important in evaluating laryngeal function.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Patient selection should consider the patient's ability to actively participate in speech and swallowing rehabilitation. Other treatment options should be considered in patients with significant impairments to rehabilitative potential and in those who will require postoperative radiation therapy (RT), since functional outcomes after laryngeal conservation surgery and postoperative RT might be significantly worse than after concurrent chemoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pulmonary reserve, assessed with pulmonary function tests and assessment of exercise tolerance, is an important indicator of how a patient will tolerate postoperative aspiration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/30\">",
"       30",
"      </a>",
"      ].",
"      <br/>",
"     </li>",
"     <li>",
"      Intraoperative assessment, with visualization through a rigid endoscopic examination and palpation of the larynx, aids surgical planning by determining tumor extent and evaluating the uninvolved larynx.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830923\">",
"    <span class=\"h3\">",
"     Partial laryngectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Open partial laryngectomy (partial horizontal supracricoid laryngectomy with cricohyoidopexy) in the past offered a functional alternative to concurrent chemoradiotherapy and total laryngectomy as primary treatment for advanced tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. Partial laryngectomy has also been used in carefully selected cases as salvage treatment for locally recurrent disease following RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830930\">",
"    <span class=\"h3\">",
"     Minimally invasive surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive surgery, including transoral laser surgery (TLS, also transoral laser microsurgery [TLM]) with or without postoperative RT, is another effective laryngeal-preservation strategy, more commonly reserved for small, T1 and T2, tumors rather than for T3 or T4 lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Oncologic results are consistent with open procedures, and morbidity (hospital stay, swallow recovery, and non-routine tracheotomy) is significantly less [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/10,41\">",
"     10,41",
"    </a>",
"    ]. Postoperative hemorrhage is the most common complication (6 percent), and tracheostomy and gastrostomy dependence is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. TLS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=see_link\">",
"     \"Treatment of early (stage I and II) head and neck cancer: The larynx\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low local recurrence rates and good larynx function have been reported for carefully selected, locally advanced cancers (stage III and IV) of the larynx (glottic and supraglottic) and hypopharynx, with five-year locoregional control rates of 69 to 76 percent, recurrence-free survival rates of 60 to 69 percent, and overall survival rates of 47 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/38-40,44\">",
"     38-40,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853361\">",
"    <span class=\"h3\">",
"     Postoperative radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following larynx preservation surgery, postoperative RT with or without concurrent chemotherapy is indicated for all T3 and T4 tumors after surgical excision as well as for patients who have positive resection margins, lymphovascular or perineural invasion, or positive lymph nodes.",
"   </p>",
"   <p>",
"    The concurrent administration of chemotherapy with postoperative RT is generally preferable to RT alone for high-risk patients, such as those with positive margins or lymph nodes with extracapsular extension. Postoperative RT or chemoradiotherapy should be initiated within six weeks of surgery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349830938\">",
"    <span class=\"h2\">",
"     Total laryngectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Total laryngectomy may be more appropriate than chemoradiotherapy for some patients with advanced laryngeal and hypopharyngeal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/10,45-47\">",
"     10,45-47",
"    </a>",
"    ]. In addition, total laryngectomy is frequently needed to treat recurrent disease following chemoradiotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The elderly and frail patient, as well as patients with poor compliance or functional status and those with poor psychosocial support, may have less difficulty with acceptance and care of a tracheal stoma than the rigors of prolonged treatment with induction chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      concurrent chemoradiotherapy and the associated toxicities. The lack of psychosocial support, however, may make postlaryngectomy communication a significant issue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      barrier to appropriate care.",
"     </li>",
"     <li>",
"      Patients with resectable tumors with destruction of both vocal cords may not recover vocal or airway protective function with larynx-preservation approaches and may function better after total laryngectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Total laryngectomy confers protection from aspiration, often results in functionally easier swallowing, and provides the ability to create voice through the patient's mouth (via a tracheoesophageal prosthetic). The main stigma for patients is the presence of the tracheostomy. Postoperative radiation or chemoradiotherapy, however, is still required for most of these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177767560\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF THE NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of the neck is complex. The risk of occult lymph node metastases or residual disease following treatment must be balanced against the potential complications of neck dissection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    irradiation. Factors that should be considered include the site of the primary tumor, as well as the extent of disease, treatment modality used to treat the primary tumor, and response to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Small glottic tumors infrequently have lymph node metastases, since the glottis has minimal lymphatic drainage. The risk of lymph node involvement increases when glottic tumors extend into supraglottic and subglottic structures, which have more extensive lymphatics.",
"      <br/>",
"     </li>",
"     <li>",
"      Supraglottic and subglottic tumors, regardless of tumor size, have high risk of lymph node involvement.",
"      <br/>",
"     </li>",
"     <li>",
"      The hypopharynx also has a rich bilateral lymphatic plexus, and thus is prone to early occult metastatic disease. Moreover, hypopharyngeal malignancies are more likely to spread to the retropharyngeal and level V lymph nodes (",
"      <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The larynx\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=see_link\">",
"       \"Treatment of early (stage I and II) head and neck cancer: The hypopharynx\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177767574\">",
"    <span class=\"h2\">",
"     Patients treated with chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observation is recommended for patients with N0 or N1 disease who attain a complete clinical response in the neck. Neck dissections are indicated for all patients with clinically residual nodal disease.",
"   </p>",
"   <p>",
"    In patients with N2-3 disease, management of the neck following complete clinical response with induction chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concurrent chemoradiotherapy is controversial, with some experts feeling that patients can be safely observed while others believe that a neck dissection is indicated for all of these patients.",
"   </p>",
"   <p>",
"    The key criteria for selecting such patients for observation include the absence of any clinical or imaging evidence of residual disease, and the assessment that the patient will be reliable for careful follow-up. Many centers now are use the results of a combined computed",
"    <span class=\"nowrap\">",
"     tomography/positron",
"    </span>",
"    emission tomography",
"    <span class=\"nowrap\">",
"     (CT/PET)",
"    </span>",
"    scan 12 weeks following treatment completion to assess response; performance of neck dissection is then based on results of the",
"    <span class=\"nowrap\">",
"     CT/PET",
"    </span>",
"    scan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H281028079#H281028079\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Management of the neck'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the role of selective versus comprehensive neck dissection after chemoradiation therapy is controversial, selective neck dissection, which preserves sternocleidomastoid muscle, jugular vein and accessory nerve has been found to be feasible, safe and oncologically sound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177767907\">",
"    <span class=\"h2\">",
"     Patients managed with primary surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic selective neck dissection, including levels II-IV, is recommended for patients with T3 and T4 tumors with clinically negative cervical nodes (N0) or early nodal disease (N1) (",
"    <a class=\"graphic graphic_figure graphicRef54099 \" href=\"mobipreview.htm?8/3/8244\">",
"     figure 3",
"    </a>",
"    ). Bilateral treatment is recommended for midline or bulky glottic lesions and for supraglottic, subglottic, and hypopharyngeal cancers. RT is an alternative treatment for patients with N0 or N1 lymph nodes, particularly if the primary site requires adjuvant RT.",
"   </p>",
"   <p>",
"    When primary surgery is used to treat laryngeal or hypopharyngeal cancers with N2 or N3 disease, we suggest a modified or radical neck dissection if the nodes are invading the jugular vein, accessory nerve, or sternocleidomastoid muscle. If the nodes are mobile and tissue planes preserved, many head and neck surgeons will perform selective neck dissections, if feasible, in order to preserve contour and function.",
"   </p>",
"   <p>",
"    All patients with pathologically confirmed lymph node involvement should undergo postoperative RT, with the addition of concurrent chemotherapy if adverse pathologic factors are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=see_link\">",
"     \"Postoperative radiation therapy in the management of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853368\">",
"    <span class=\"h1\">",
"     ELDERLY AND POOR PERFORMANCE STATUS PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Induction chemotherapy and concurrent chemotherapy are often avoided in the elderly and those with poor performance status since the use of chemotherapy may delay or prevent the delivery of a course of definitive RT. In this setting, definitive RT alone remains a treatment option for elderly patients and those with a poor performance status. This decreases the opportunity for functional organ preservation. However, it may not compromise survival, especially in laryngeal cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=see_link&amp;anchor=H1049946406#H1049946406\">",
"     \"Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Total laryngectomy may also be an option. (See",
"    <a class=\"local\" href=\"#H349830938\">",
"     'Total laryngectomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853375\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications from treatment for advanced laryngeal and hypopharyngeal head and neck cancer include vocal, swallowing, and airway problems, loss of taste and smell, fistula, cranial nerve and spinal accessory nerve injuries, vascular injury and events, fibrosis, and hypothyroidism. These complications and their management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853382\">",
"    <span class=\"h1\">",
"     POSTTREATMENT EVALUATION AND SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients treated with concurrent chemoradiation or sequential chemoradiotherapy, assessment to insure the absence of residual disease is critical. The clinical examination is critical in this evaluation. Imaging studies, particularly computed tomography (CT) and positron emission tomography (PET), augment this evaluation but can be difficult to interpret if they are performed too soon (prior to 12 weeks) after the completion of concurrent chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/45/41689/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regular posttreatment follow-up is an essential part of the care of patients after potentially curative treatment of head and neck cancer, both to detect recurrent disease and to diagnosis second malignancies that may develop. Patients should be educated about possible signs and symptoms of tumor recurrence, including hoarseness, pain, dysphagia, bleeding, and enlarged lymph nodes.",
"   </p>",
"   <p>",
"    In general, the intensity of follow-up is greatest in the first two to four years, since approximately 80 to 90 percent of all recurrences after curative intent treatment will occur within this timeframe. Continued follow-up beyond five years is generally recommended because of the risk of late recurrence, second malignancy, and late complications. Posttreatment surveillance of head and neck cancer, including screening for treatment-related complications, is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"     \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rehabilitation of voice and swallowing function following treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=see_link\">",
"     \"Alaryngeal speech rehabilitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=see_link\">",
"     \"Speech and swallowing rehabilitation of the patient with head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/38/6755?source=see_link\">",
"       \"Patient information: Laryngeal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H291853389\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to treatment, all patients with advanced (stage III and IV) cancer of the larynx or hypopharynx should be seen by a multidisciplinary team with experience in the treatment of head and neck cancer. Selection of a treatment approach depends upon tumor extent and location, patient-specific factors (eg, age, performance status, comorbidity, psychosocial support), physician expertise, and the availability of rehabilitation services. (See",
"      <a class=\"local\" href=\"#H349830501\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most good performance status patients with locally advanced (stage III or IV) laryngeal or hypopharyngeal cancer, we recommend a functional organ preservation strategy rather than surgical resection (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Organ-sparing approaches may permit larynx preservation but do not provide a survival advantage compared with total laryngectomy. (See",
"      <a class=\"local\" href=\"#H349830501\">",
"       'Overview of management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Concurrent chemoradiotherapy, induction chemotherapy followed by radiotherapy alone, and sequential therapy are all used as functional organ preservation techniques. Concurrent chemoradiotherapy may be preferable for patients with N0, N1, and N2a presentations, while induction therapy may offer advantages for patients with a relatively high risk of distant metastases. Sequential therapy may be particularly useful in patients with large primary tumors (bulky T3 and select T4)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      advanced nodal presentations (large N2a, N2b, N2c, and N3) who are at high-risk for distant metastases. (See",
"      <a class=\"local\" href=\"#H349830523\">",
"       'Combined modality therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Partial laryngectomy and minimally invasive surgery may be options for carefully selected patients, especially those with relatively small primary tumors combined with more extensive neck disease. Postoperative RT is generally required in these cases. (See",
"      <a class=\"local\" href=\"#H349830915\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H291853361\">",
"       'Postoperative radiation therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who may not be candidates for an organ preservation approach include patients with resectable tumors that have destroyed both vocal cords, elderly patients for whom the toxicity associated with chemoradiotherapy or full dose radiotherapy alone is problematic, and those with extensive cartilage destruction from the primary tumor. (See",
"      <a class=\"local\" href=\"#H349830501\">",
"       'Overview of management'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H349830938\">",
"       'Total laryngectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H291853368\">",
"       'Elderly and poor performance status patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management of the neck is complex and depends upon disease extent, treatment modality used to treat the primary tumor, and response to therapy. (See",
"      <a class=\"local\" href=\"#H177767560\">",
"       'Management of the neck'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      For patients who are not candidates for a functional organ preserving approach, total laryngectomy is a potential alternative. Definitive RT alone may be used as a functional organ preserving approach for laryngeal cancer patients who are not felt to be candidates for chemotherapy, although there is a higher risk of recurrence and thus a need for salvage laryngectomy. (See",
"      <a class=\"local\" href=\"#H349830938\">",
"       'Total laryngectomy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H291853368\">",
"       'Elderly and poor performance status patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adequate posttreatment surveillance and long-term follow-up are crucial to ensure adequate voice and swallowing rehabilitation and to monitor for disease recurrence or a second primary malignancy. Lifelong follow-up is also necessary to ensure that late complications of treatment are addressed to mitigate the risk of non-cancer causes of mortality. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=see_link\">",
"       \"Posttreatment surveillance of squamous carcinoma of the head and neck\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     file://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/4\">",
"      Gourin CG, Conger BT, Sheils WC, et al. The effect of treatment on survival in patients with advanced laryngeal carcinoma. Laryngoscope 2009; 119:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/5\">",
"      American Society of Clinical Oncology, Pfister DG, Laurie SA, et al. American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancer. J Clin Oncol 2006; 24:3693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/6\">",
"      Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations--a consensus panel summary. Head Neck 2009; 31:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/7\">",
"      Lefebvre JL, Ang KK, Larynx Preservation Consensus Panel. Larynx preservation clinical trial design: key issues and recommendations-a consensus panel summary. Int J Radiat Oncol Biol Phys 2009; 73:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/8\">",
"      Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 1993; 328:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/9\">",
"      Browman GP, Mohide EA, Willan A, et al. Association between smoking during radiotherapy and prognosis in head and neck cancer: a follow-up study. Head Neck 2002; 24:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/10\">",
"      Silver CE, Beitler JJ, Shaha AR, et al. Current trends in initial management of laryngeal cancer: the declining use of open surgery. Eur Arch Otorhinolaryngol 2009; 266:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/11\">",
"      Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 1991; 324:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/12\">",
"      Becker M. Neoplastic invasion of laryngeal cartilage: radiologic diagnosis and therapeutic implications. Eur J Radiol 2000; 33:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/13\">",
"      Rodriguez CP, Adelstein DJ, Rybicki LA, et al. Clinical predictors of larynx preservation after multiagent concurrent chemoradiotherapy. Head Neck 2008; 30:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/14\">",
"      Knab BR, Salama JK, Solanki A, et al. Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol 2008; 19:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/15\">",
"      Stenson KM, Maccracken E, Kunnavakkam R, et al. Chemoradiation for patients with large-volume laryngeal cancers. Head Neck 2012; 34:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/16\">",
"      Hong WK, Lippman SM, Wolf GT. Recent advances in head and neck cancer--larynx preservation and cancer chemoprevention: the Seventeenth Annual Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1993; 53:5113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/17\">",
"      Lefebvre JL, Chevalier D, Luboinski B, et al. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996; 88:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/18\">",
"      Lefebvre JL, Andry G, Chevalier D, et al. Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 2012; 23:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/19\">",
"      Vokes EE. Competing roads to larynx preservation. J Clin Oncol 2013; 31:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/20\">",
"      Blanchard P, Baujat B, Holostenco V, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011; 100:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/21\">",
"      Pignon JP, Bourhis J, Domenge C, Design&eacute; L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/22\">",
"      Vermorken JB, Remenar E, van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/23\">",
"      Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/24\">",
"      Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study. J Clin Oncol 2013; 31:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/25\">",
"      Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/26\">",
"      Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013; 31:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/27\">",
"      Holsinger FC, Kies MS, Diaz EM Jr, et al. Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol 2009; 27:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/28\">",
"      Holsinger FC, Lin HY, Bassot V, Laccourreye O. Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer 2009; 115:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/29\">",
"      Holsinger FC, Nussenbaum B, Nakayama M, et al. Current concepts and new horizons in conservation laryngeal surgery: an important part of multidisciplinary care. Head Neck 2010; 32:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/30\">",
"      Chu EA, Kim YJ. Laryngeal cancer: diagnosis and preoperative work-up. Otolaryngol Clin North Am 2008; 41:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/31\">",
"      Barbera L, Groome PA, Mackillop WJ, et al. The role of computed tomography in the T classification of laryngeal carcinoma. Cancer 2001; 91:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/32\">",
"      Beitler JJ, Muller S, Grist WJ, et al. Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy. J Clin Oncol 2010; 28:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/33\">",
"      Laccourreye H, Laccourreye O, Weinstein G, et al. Supracricoid laryngectomy with cricohyoidopexy: a partial laryngeal procedure for selected supraglottic and transglottic carcinomas. Laryngoscope 1990; 100:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/34\">",
"      Laccourreye H, Laccourreye O, Weinstein G, et al. Supracricoid laryngectomy with cricohyoidoepiglottopexy: a partial laryngeal procedure for glottic carcinoma. Ann Otol Rhinol Laryngol 1990; 99:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/35\">",
"      Akbas Y, Demireller A. Oncologic and functional results of supracricoid partial laryngectomy with cricohyoidopexy. Otolaryngol Head Neck Surg 2005; 132:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/36\">",
"      Paleri V, Thomas L, Basavaiah N, et al. Oncologic outcomes of open conservation laryngectomy for radiorecurrent laryngeal carcinoma: a systematic review and meta-analysis of English-language literature. Cancer 2011; 117:2668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/37\">",
"      Agrawal A, Moon J, Davis RK, et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709. Arch Otolaryngol Head Neck Surg 2007; 133:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/38\">",
"      Olthoff A, Ewen A, Wolff HA, et al. Organ function and quality of life after transoral laser microsurgery and adjuvant radiotherapy for locally advanced laryngeal cancer. Strahlenther Onkol 2009; 185:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/39\">",
"      Steiner W, Ambrosch P, Hess CF, Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg 2001; 124:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/40\">",
"      Vilaseca I, Blanch JL, Bernal-Sprekelsen M, Moragas M. CO2 laser surgery: a larynx preservation alternative for selected hypopharyngeal carcinomas. Head Neck 2004; 26:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/41\">",
"      Lucioni M, Marioni G, Bertolin A, et al. Glottic laser surgery: outcomes according to 2007 ELS classification. Eur Arch Otorhinolaryngol 2011; 268:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/42\">",
"      Ellies M, Steiner W. Peri- and postoperative complications after laser surgery of tumors of the upper aerodigestive tract. Am J Otolaryngol 2007; 28:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/43\">",
"      Hinni ML, Salassa JR, Grant DG, et al. Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/44\">",
"      Remacle M, Lawson G, Hantzakos A, Jamart J. Endoscopic partial supraglottic laryngectomies: techniques and results. Otolaryngol Head Neck Surg 2009; 141:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/45\">",
"      Lango MN. Multimodal treatment for head and neck cancer. Surg Clin North Am 2009; 89:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/46\">",
"      Agrawal N, Goldenberg D. Primary and salvage total laryngectomy. Otolaryngol Clin North Am 2008; 41:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/47\">",
"      Chen AY, Halpern M. Factors predictive of survival in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/48\">",
"      Layland MK, Sessions DG, Lenox J. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, oropharynx, larynx, and hypopharynx: N0 versus N+. Laryngoscope 2005; 115:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/49\">",
"      Langerman A, Comstock R, Konda S, et al. Neck dissection planning based on postchemoradiation computed tomography in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/45/41689/abstract/50\">",
"      Ljumanovic R, Langendijk JA, Hoekstra OS, et al. Pre- and post-radiotherapy MRI results as a predictive model for response in laryngeal carcinoma. Eur Radiol 2008; 18:2231.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3402 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-F7325097AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41689=[""].join("\n");
var outline_f40_45_41689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H291853389\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291853305\">",
"      ANATOMY AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349830501\">",
"      OVERVIEW OF MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349830523\">",
"      COMBINED MODALITY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349830549\">",
"      Feasibility of functional organ preservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177767476\">",
"      Concurrent chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349830665\">",
"      Induction chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349830807\">",
"      Sequential chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H432436853\">",
"      Comparison of organ-preserving approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H374890817\">",
"      Experimental chemotherapy approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349830915\">",
"      SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H291853346\">",
"      Larynx preservation surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291853353\">",
"      - Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H349830923\">",
"      - Partial laryngectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H349830930\">",
"      - Minimally invasive surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H291853361\">",
"      - Postoperative radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349830938\">",
"      Total laryngectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177767560\">",
"      MANAGEMENT OF THE NECK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177767574\">",
"      Patients treated with chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177767907\">",
"      Patients managed with primary surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291853368\">",
"      ELDERLY AND POOR PERFORMANCE STATUS PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291853375\">",
"      COMPLICATIONS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291853382\">",
"      POSTTREATMENT EVALUATION AND SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H291853389\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3402\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3402|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/27/22967\" title=\"figure 1A\">",
"      Laryngeal anatomy coronal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/61/29654\" title=\"figure 1B\">",
"      Laryngeal anatomy sagittal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/56/27525\" title=\"figure 2\">",
"      Anatomy of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/3/8244\" title=\"figure 3\">",
"      Lymph node levels of the neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3402|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22766\" title=\"table 1\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/42/37549\" title=\"table 2\">",
"      TNM stage hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/49/8990\" title=\"table 3\">",
"      ASCO larynx CA Rx guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/54/16231?source=related_link\">",
"      Alaryngeal speech rehabilitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29946?source=related_link\">",
"      Locally advanced squamous cell carcinoma of the head and neck: Approaches combining chemotherapy and radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?6/38/6755?source=related_link\">",
"      Patient information: Laryngeal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25719?source=related_link\">",
"      Postoperative radiation therapy in the management of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/58/36775?source=related_link\">",
"      Posttreatment surveillance of squamous carcinoma of the head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/51/31545?source=related_link\">",
"      Speech and swallowing rehabilitation of the patient with head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/27/34232?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The hypopharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20552?source=related_link\">",
"      Treatment of early (stage I and II) head and neck cancer: The larynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_45_41690="Pathology of granuloma annulare - palisading granuloma";
var content_f40_45_41690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74645%7EDERM%2F76130%7EDERM%2F54717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74645%7EDERM%2F76130%7EDERM%2F54717&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathology of granuloma annulare - palisading granuloma (H&amp;E 40x)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scanning view showing a broad area necrobiosis. This area is surrounded by a peripheral rim of histiocytes and lymphocytes and a few multinucleated giant cells. The adjacent areas of dermis show normal collagen bundles and fibroblast nuclei (H&amp;E 40x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathology of granuloma annulare (H&amp;E 400x)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 316px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE8AakDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2G/uvLsba8gDiSaIFkLZViR3HQVgRrd39ykcSxRqD1J2qPc07X9YOo3X2e1Cw2yttXkdB/IVSNvZsNr3SuuOgDda4qak9T7LD0XTppz+J/M1PE/8AwiFnpJt9a1iOG5YbEnKkor9ew5FYvgTRNIEF/qOi6pbapcNH5M5hkIVF6jA6g5FZniLw9aa3pElndjKj5o5B/Ce2PSsf4TeE9Q8PeMJPsWoRPDPC0bQvwZT1AHbPv/jW9L2nvJz6dv18zjxNCrGzV5RWr12+Xb8juX0u2lnVdThW4k2syI43HPY57f8A1q85HxPuPDXjKXTr7TIbjTEYRvE6DenoyHp0PTvXqFg8NlezPqZeORmOVlXkfTHaua8TaD4VuNTXV7u28+4i+YmMkCQdg6+1TCUXNe1k7Lov6+ReKjWnFqivedtelvU7S+ig1PTop42KK6h412bWwRnFY8T3Vmm2RfOhP3Sxxj/GuF1X4hXEIuWjRY4UGUJ5+iiuf8JeOtc8Qa/aaf8AYoZRPKFd9pyq55Y49BTgqtWfLGLLdanhoqFaS18m/wAj1M3cs4aMlIYBxsiXDOfc1FcaTaXloWhEnmElDkcYx3NbMtnb2I8qNo5ZYznzGxtPt1rzvxdqni+G4a18OQp9mk++ysDn2IPak+d2UVe/y/FnTKuowc4beS3+W5zUPgDUbfXBNZzLCEl3KQ2GVQecmvffC2pLYaHOYIt14RzLI2Afz9K4Lw7HcvpWNSuLea/GDKY87E9FJ9ffpXSXtlcNbQwy3NtF8uVhgG5jxwSTWk5ykraafj/mc0sPTcbapS1s/wDI5XVfCkviPVZry68TxK0jZMJudm0+2eMV0egaHqugxN9l1F7mzZdpX7UHjI/PiuU8R+Cp9ehEInkVUyWWFs5PvXPx/C7UdMDNBqmpWqkdBGcH9QKuMJyjZOKXo/zQ6vtIy5YRUl6r8E2j2Ia9ps8MVpqN/a2s8R3uxU5UDj5SPvEdMGm6hrHkKH09bC+tIxmSbpgd8j+HivK73QbwJHEssdwwYMzSgRyMe+c8HNeceIZL2y1C9tPtE8EpJGwMRuA5wfUVnKNRLf8Ar8/vJqQjR96Sdu39W/Ox9RRT2uoaPBrOmNtnuF8tlyCrPn5evbP868dX4r3Wg+JXXVNFSFQ5jnCAo688/L0rtvhEG1f4V2doiBJreRtm9tokBJIwfXmk8QeD5fEMEsGqaRI0w+X7Rtw2e3ze1X7NNtSbMYc1Sm+SST7Pt017G/DPa3d7DqNnJ9psLsRlJYfmB3cEMPUd6h1gS6RrEkKNGZ4cumF+Ug9sVw/w+03VfAHiifTtVdpNOlGB5bhwj9jjoD6ivRPFv9n22nNrd5dqAqnO05MgHYen1pSTjpJmtKo+aPOtGrHMeJPE0On6M40+xjiubwoJLhRnkcn3A9adpl39p0O0uLkyrcTRhfLQDZnP3qjg1G18QaQ94YI2RPmeNgBx64rD+InjCC20W3bQIl+eRbVGZcbcLuY+9Jttdbm91R30X3mhrfiODQoo4L13AlyQAMgdOf1rU052uIG8iRP3oLI7cgZGQRXmXjG5bxF4Lsb64Y/brVVMmB1Q8f4flXX/AA5uWPhbT5W5ZIvLJ+hIz+VDg1HmLjVcpuFul0YPiLSbh7KFnjZgdxLjrnP/ANavS7GzWTQVtLiMsuFV/m46cAe9ZHivxXpPhpUhvUFxN5W+JNvBz6nsM074d+L7jxla3qtYqksBCh4+rZ9ffFU6rdkk9DKpVV7GTeeEZoJnfTTG6ygqGmcho89c8c/UV1FvavBa2kMsnmNsCyH1YelXJle2jRXIE2f3gJzyeg/AYpVLR2BmvYsxCfcSD146H8KUqkpblKTWtytBeQxzg7/mhJYxk8vn2/r70zWk8iF4toW5uiGYf88hjnP4muG8K/aNZ8b3muTuEht0+z21sDndzncfYf1ruboeZcyytw5A+8cnFF5RdmXTfv3tb9f+AUWt3jS2RZAxD469T6VPqdu8UUMkoVZo5geDnI7H9KoajPHbQxKGPmb9wHqKPDepR6z4WdwFEttOYpVA+YZPf8aSbN5SacWzu7C8W88MxxSRmWe0kJkjHUoxJ3D8DWFCwh1uKBD8pG0sMdcHH6AVTgupbC9ikQ/NCNrD++p6irGp2ccYuDa/cRsowbnB/wD1mqipao5YUVTlJdJX/H+v6sW5Av8AwjlxM0hcWz48vOSu5vvZqOBnmil2yAjaP3bchj/jUE8Kz6TJDI7mWAxs6ofl+pH0qim+FGMLHkbgPcc0KUki4Qunrrf/ACNW0t3lRYY4mV1bDEHqD/SnyRm3lWSGQMA5QhTgqenSmfb18m0ukfZKXPmFeCAMda3dbjQpatLtUh/PhwcMyEZIP45pczvYwnUlGaUlvczJ2V1MvP7zhto+6elVtUsyLFZR+8RDh2+vc+lWNJBuobplx5pfdgf3fao9K1KOJ2guY5GikyjcZ5Nae0aKTlBvl15SrogtAbiOe7aGGdCrI44B7EfQ054G025SK9XfFkjzYzwR1yDVS5sYhdyW/mY43IWGR9KktpJGi+zyqGgGAqk5Cn2qeZxNmrvmT0f9XLNwSyYyzorfun28keh9araZ5UmoT29z91gSuTgg+1X3tWs2QKyyQSjGR6+hHYiq17FFcWy3Uf3w20t1Ibv+nNU25epMZJqy69SvNbbopvJOWXEi+ox1BqCK83Ku8Mdv3lA/XNS3LSA20pIKsmD9emT9abqNqkUMM8LACQZOWG5D34pc7kbRadlLqWkuCYlPz7DGCHI5K5xVOblmCkgg5X3ptqwjMcjSsFOY3Y/NgH0qzEQImkwdxYAHHFQpPYXwPQZFcXahhIodA3y7jjkVI+Fsd5YGSQks2Oc1etoJYLWUMjTOwLncOhPcH6VcEVva2nkzDzSyneM/Srg2rMxlWSei+4xLCD/RJZWBUKflQnPHGSamlvZRKkJ8tMAbWxtwCO9W2hiFrIY3aNCd2GPpzzVjQI7TXrW4t2gMskXCzDhgPf2qebl6inVSTqSWi/AyziaJkBZlVsl+2al+2zf3/wBKjsJ1jvLiNIvkZDG+7oCOh/Oo/s8v95vyrWEebSXQ05U3aRoSJY6RiztYjd6u4wzqNyRE/wAzWrJZpY2tu19fKpbpGmN0h7k56AVxnjXxLd+GdCvr7S4kF8Hz0yqDgBhXl+gahq980kt3ffab+fM0kTv9xSOOK4KXtKt0unV9X2S7L+u5xTd5xg27vXv/AMBLorf8E9mvbrR3ErQMUVTgyEZJP9RXPxSW03iN4tOmWRoJlYYOCOh/Wub0W9P2+TTZhhCm4KP4fUV1XhrwPY6X4l1TUI9W855IwSBjEBBDDcAfUY/GtoxcZ3nLpdeex0Ot9XS5bu+j8vM6DxxbrPqRukkzHIPu1kaRZ2l+jwOGEg5UhSwx/te3vV5ZpNUv40OMu2Cvb6iumsLW2gdfsqKqAFXZRy5z3oUFbUmVV4ekqb3RzMfgHQ5oXi1C2jhhZfnkU8jvnPSoI4NL0sx2PhayEduvyyThR5k575brius8RXllBabbxtuw7goYZb2Irmn1WyFoyWdrPE8ikLMpwif7x/wq/bSaactO3+Zz0Ye1aqzjdrbsvMp3UqW0k4CoJX7KM7KYbSe50/zcnzzxGHHzN9Kk0m/tNL3SSINQnPQbMID9Tyfyqzd+KNSuR/qbSIdtqYYVOp6P7265I/N6fhucFDp2q6dPdTx7/NcEGLHB9jXP3niDxZD5itpUwkB67SQB2r1dtSFyoMlm8cyjHmI5bP1BqN7KHU4U8+d4sHqpz+eKpwg/iX42CrKo1vy/cyXwxf8AizQ/h7Bqa29pqOoXTbxDIRGIF/2jnmpdF+K2oSSvaeI9JgsrngL5TmRXrYXUtKsrO3tp7pFhTCRknGSPUnp9Kq+IZrG2ljS902OZMhh0BZPYik1Sd2l919Ple34Hk08NGU/3qcvuV/P1+dixqPiq3mgMjaVBeAA/KyAn6V5hqPibwF4mufses6XLpsq5HmA5KH2/wr0m/wDDG6GPUfD85lt5V3rEW2yDHUD1x+dcP4j8MWWq7m1XTiJT1nRfLfPruAwfxq4RktYya9P8jpVGnUhbD6902/y2v8jutA8N2sHhCC30e9SSy2l4HXlHU+45z7HpWRNpupk+R9oWZu0YumHHqQa5jwRph8J6m01lfXjWTfetmbcjZ65GcfkK7WeHw9fTC4e9lttwzJAFDEH1U9cUPf3n89S6EatDSa06aXt9xd0/Q5baQXKzW9xLCP30K/MxXHII7n39q4z4jxA6bNaCFvsksTMjdVDdccdCPQ10ulrHpusm/wBLeSWOLKYlPDr61LPr1xa3Msv2WKa3JO+FxuVcj0qYxbd3r6CSqym2ve066fKx5J8Ibp7h720uiDG0WzLcBSehzVzxX4UXULWe2Mji5juVmSMD73y4bB6V3Wn6nps2sWsE62FsLqQ+VDbRKheT/aA7VPrFhPYXkCXSLvBY/wC8o7VrzpSbgXGmpL2Nbe39f8E810bTbm58ValA0JWwiskjfI+XkDA/nXcaNpNpo3h23gsiW3SO53HJwKmliW1sWSyjL7vmklbqCew9qfF/qIlZtsj52qTgkD2qZT0stjZQ+0+7+7scp428NS65bJLAn75cxgkDlM5I/D+tb/hK1tPB3hF2slxfRALITnbJI5+9nuB0x7Vs2sMktvGrxsJgoBOOG9x71xvxDgvUtILWMGIFsghun/1+1PmcoqBnKlCpJt7/AKE/hOfUDqeoXU0sk8M7cFznLDrj6DtXWalJLfaHFHENiwOzybhyzNwMfQVi/DKKex8wzI728ERY5PSRs4+tbJEhsJt0i72YELkZfrzj2zmptrcfMnNWW1v6+4wvDWlx6Pb6jKf3stwwCuAcAZrVjkCyNnDkDJBHWr9xah9Rto7h9kBQIY0GTuz/AIetSalpy2EshUr5UqYjP93gcH3od5O7BVIXt1Z5rqmqm68SyxhP3RcFMDgADpXWaH4bGkR6lqUIKwXS+Y0StkE57elZsOk2tndGREka6c4/eEkKD3HYV3OiRv8AYrVdyxusDxSo33TycN9eaG0tFtoPEPkgn2f4GBc7Lxo1tym8KDjvjv8AiMU3dL9kOxSXhk+dupwR/KqFrDcPe2sVsGd95B2nHAPJrqYUjcSGO3MFxHEXZSCRIB2/GlGPM+U0qNU7R3KJIiuFvpjmK+TY5GcDjBH1pNPiXzpLaRVLMHMTY5GwZ/WlV4H0m/tY2WS03CaEk/6tu4/EHFQ2t00Uml+a22aKYruboY24OfpSTe/YizcXb+tLr/Jle6Vm88A7GXG0dj61e1DUTf21izNi5ih8hlBPC56/pUerW0kFvcxhd2JDsfsR0rMYu8aSKDtZQgdemaqS1ujWMY1LS7f5GrY3jWV35hUsm3BA6e1IbyO31AXBi3QBizIecA/4daoi5EnlLKuGUFCw7gdM1YtHja0kaVgwibZNER1U9GzS5SZU0tWt9B2sRvC0dwuJEcEqeuR2qms5OCo2t0Oe9dJpAj/smQWQM1ntbCO3zcdeP8K58SRSyqJiPLcABieUHqKG01dipT5rxa2/rY0Fmlu4zdWLGSWBA1xbNnp0LCpYxb3sQkgYxPIuWX+HcPWsyeK40jUIykjJIV3RTIeGU9vf6U9LzAZjIolk5fCAKOOmKNY7/wBITp6Xht0/r+uw6RS1gDjDq449eM9KryTGQL5oBwMAY6ADrVhvMk09nk4YD5R6LkYqkYwdn3h0wKLaXRpBLW5JaYNouPmLMFAPb3xV4MHLW6uTlwBn9DWXBMbKYZjIQNvwT19RXRSG2F2btUJt7gZOOCp9R/hSSd7Mmt7r232NjRWSWxleZ2aTBEnHPHGKoPEGKK7q0smSeenov6VUuLsQTebZ3EyBiPNiwAT7jtVcXio5V1E0LN82Mhsevsapq2hxxoyu5LqF55bOFlXG3+AcZ9zUng3UDaeKMyCNYrmMxnAwAR0qkZ4BOohg3EnaASST6c1K9lsxd2qgbG+6R9046EelTKPOmjplCMoOnLqrGp4qt47PWVCZWOZcMVxjJ9PWqn2WH/n+H5GmLqyajdWf2wKFiyJCRnqO1Wvs2m/8/MNaq0t3b5XMo81OMYTvdLtcxrrS4p72LSNTjDpIVi2sNysAcg59Dwc/WvHNA0XWbD4vfYr+xnh3zskw2kKITxuB6Yxzmu/1/WJYrS31OyEsUyRfZ5VHGGUYzjsfeo7L4kQ6TokMur2v9oyKRGpc5O088n19ulc9B8j55K/T5vT/AC+RyYuEq0YtOzVn9wmo+Hf7M8VpeWUzy2ajhXPzcjHUDkVgaZbaxpXxfvLiOKZ7C7dt7A/KY25/Q11fjfXYdL0Wz1XS/wB/pmoIGhIXaYhnlc+oNeaR+LtbGogQSm6RTlMrllHpWlNTnUS5b2TX9ehrU9jKEZOT3T/TU9olQ2t5JICFiU8MTV+11CW2hEl3dQ28M+JI/MYBs57A44rn7LSdX8RiN7O2ZY5FHmSygqF+lZXxj+H97qmoaVFYapameOARSW8rlNpzwR279/SodOo5KOie2ppia8EuWPvStsjsmt9JuZXmvo5Jpj85leYqh/AHn6VkXt7b3EyI2IbWPiKFOgH+PvXF+E/DuoeHpL2w1O4N2Bt8lY5DhT36jIrqpNKAnUs20/3Se9U4OPu3OjCpSjzu6b6Pp6f0i/8Aa4JD5dlaFEwAWLZc/j0FWntbSJFYCcXDDJRxgD8e9RW8sVltMaiSRegx8qn196ntoJr7fcXMuyHPzzSdB7e/0FUlY1l7uq0X5lWSb5cKobHoeKpyMyyBsOjdQUODXW6ddeG4GMUglmlYEGeSI7U+i0240zTZ5JTYXwuOOUC42fietS5R2TMY4uEZWcWvl/X4ni/xa1WXULSwjjhIa3OA4GC/tx3rvPiXq914V+H2hJJCt3c7BH5knVXxyM+laWkeE459YFxciCe2iffGjdCc9WFXfiz4fPirS4rOBlT7OwlUbeh6dPSnyxcVC+71OLEu2JvSelvueovgTxIfEHgGzudNAS7tWPnRK2GSTufp6VeHiWKZgL+O4jlHHnRAZ/4Eo4Nc74L0Z/B+l3HlSxma4IL7OcEcY9q2Vv7DVMjULUx3Y4E9v8pb/eHTPvVNRTsh0qKs3ON/Nb/1/VjScRXdv51sLG/jH3t0GHH1wARWVJa6PdbjJHPYyL/y0j/eIPqp5H51XIWK5H9nX0ccqn7sx8p/pn7p/OtU29xdx/bI02XMY+coyt+YHUGqV3ubJey2lb8PvW34GYuj3to32nSLyG7jHJNu/wAw+qHmtC38Rm0Ee+2WGRW/eE/dk9QwI4rOntJEzd6eSu0/OicNGfb2qJ9Sku0NvqLGSNhy+3LD696Ukayp+2Xv2l+D+fc8s+NmpwzfEXS1skFgkbxsXj4KEkfMMfnXvOsMNV0XTtb8nmKJhKrkdjjJz15ry3xB8OJfE2saZeRSwzR2zRrOucebbhuoPqM4r03UHOnQa3pUdsy20FsqxMCXwp5HB7ZPJoUb21uzzYxaxDS3VuvSyT/NGLpeowT7pLiJSBnKEYAJbgn1xXK+JZJRrU9xHKyxsPk44AJzWpBbvBJGxjxEQrFT6nkZrVFkmoeVPLEnkxtveIdXXvj26Uk7PU9WpGNOXMthbO532sJjLJKxx5juQBgev+Fc/qur2txqL6bdW7yxKP8Aj4QcA9yR6e9SR3E8/i6/Eu+KWJCqoyYVFycAdsYPX2rnr661jSNaD3Rgv9MlfYssS5257EetJQlf+v6ZMXFe93/A9J0ueC201bJIhFFESTKv/LY/X2qpczwJNL9kG0qG2yBfvE9RV4xPbaZ5F6u0OC4G3gDGRzVAXFnFBvtys8u4ZycKD6e5qbtIyha7a6/cMk+1fY4Lx18h9/EjHgsD1+uKnvdQnvrJJpysahztKcq56Zx25qqBLqN4sTRiaaZsIrthV9celW5rIQO0N6UKjpGrdMDkf1qbsp8qkubf9CGzleJoZZlXBcruJ3Bj0AP+NMjSWUytdkLKrNudGwCM9B+PNZ8kqHbG24DOfLU+lWNNvNNvbi4kVftAiRlCK2ewGCPWndJWZrOPKnKwy3njRfLIIRnKl8fMvODXTSSfZdW04Q3G/TfKKF2Y4Jxz1681z0FhH5EewxLC+ZAMkfMTyPrnrV/w9dwXWnz2cc8dw8Lna3BbBP3TnoRU6Xs3uY10pK/3/PqZ1itqmszwy7Gt5wcEEgdePxp0jxXNyIpVfMa4fYOmOMj6cU6bTzaSC6YqrQvv3dcheSCKsxxWGsu+r+G7jzIpkbfblvmRj/npV3S67msqkFK9+m/n/wAEuaXbC+0Cd1cM1qW8xe4XBwR71zrWsn2ZJIWJjWYo23pnGf8AGtLS5rzTboLYSKJJkw6OMgkA/I3vn+dXdB1exna6tNQiFq98gVQq/Ksi5/LtQnbSWxPNOk5Sirrf/PT72YgmjLcpmXhceg7/AI0x4mBLN8quuM54+laGm2Vze6pNBbxq0wjdlboBj1+tZkMzSq5k4K5JBq0zpjJNtLpYuabqUukTOGQN2K54OR1/Kqk6RtI4jXbExLICe1SWoS4ZY2wpchUZunPY0+4s5rOSRZArjO3gd/ap9BLljJvZs2dG1OC/sV0nXflVOILgD7vpmqUul/ZbuWN0EvlnG9OQQehFVmBVgssTABQx9qcJpYSrKzMoGMdiPQ0L3VYxUHFtwdk+nn5Fm+ExjwkQCLyccnA9apGFnh3IVEifOM9xV5bxJFSSRSGcbTIGJ/8A1UkkrGQSSKjbPlAAxuWhO4Qco6WKK+XNDGxBEinpnvn0rRtgGiESBhzyeig1HLp2TDNandHIfkB9fT61A85hldo3Ik+449+9Fuo3afwlmWKBonUsEkBwT1H51RhG2X9+5Ef3Q/UEVp3bGOZGSJSrYPI6j0qjc7DI7rH+7HJQnp7VW+gU22rdyNXWCVJIvmmQ+mRitO9aONUkVzG0o2vGW/n61iFSi/L8qHnbnOKmAeZkL5YhcHd2qJMqcLtO46aJIJGCPkjBU9vzqx/aL/8APM/mKngSO5kgtIYnWJeWIOdp75rS/sS3/wCfg/8AfSf40KPNuYzqwVlU3OR8dXUUNrJEwEdsz4BCDJc981zviT4WyahpwNnqqyTvCt1FC0W3eSPu5FbPjSyn1fS7m1+V1RgUVRkgg+tatvdSQQ2ETykCOJIw5Yjb0547etY0NKbtvf8ARETw7mlFbWOR+Dt1Zav4f1PwX4mtwZI5Glt/M4KvjlfbkV3uk2uieH4I0tNJtom2gmQxhiT71m6lo1rca4NVMAt9RT5HcHhz0w/9GrYvrMXFx9htriF75Iw5tgfnx7DvXVKu5fC9915o5KOFhB2qf8N8x954w1JlENpMscYGCyxgH6CuWuGke4EsrF3Ztzl+S1XUgljkZJQwKnBBHQ0xYkN185Y46hRkn2FZcvLqevRp0qP8NI5nxj4xh0q/iSSMSTMmRIGwwA7Z712ulSRa74UtdYslwkqElj/eGcj9K5fxz4J03W5I1m1BdPuVX5JJIi3XsQK7fw5/ZvhnwTZaHYAajLFEyPOflXcxO4gdeppQ5VTbb1v/AJ/8A86tXrKtGNON49zj9b8V6N4cQtfW8t/eY3R2sRwv/AjWYv8AwkniSaK71q7FnAMSRWcI2R26+4HUkevNdLJpOg3Gqedc2Usl2qgBV4QMOhYnr9KvW9tJdukShUjyQAzBcnqeT1Nax5UlJ6vz2Xov1N3Bzqc89Ir+v6/4BSjglunEMG7hQDtHJ9zWlFousxozWq3LDGSvUH86zNf8ZWfhnS7m20q1mvNYkBSIImUDDqSep/rXP+Gf+FlLMuq3N/HarIfNNrcA5C+6AfKPTODUxhKWsY6d3p93cyrY5xl7OK17Wv8AN9jvtMubixlX7ZbvFkd12sa2v7NvbuBZ8ogbOElOxivtWc3iG9vUMcixGUd8da568W6uJSs8mVByFkBwPcen4Uop2vEfsZ1HzaRf3lzVNPaJpZLe5jnVfvJnDKfp3/Cs2xulLoknQtyabomn6np9810JEktuc7epX6Gt8XGm6tcMLq4NtcHCgvAih8dsih6aNm/tHCPLLVd/+AijqMCNPlSXUjg4zn61URns7hZYCUkU9RxkeldZu0K1lEchF1ID9wLtDdgMjtSSR6b5rLBA0kjDPlICwQ+5q1NPczjirLlcXb0KySh4RqFtEHaM4mhbo6/z/Gs+7s4L6zlvtOQxtDzNblstGPUeo9627WwaLJsIZhnO5JANvvgj+tZd4kmlXsV8kOFH7uWM9CrDke4I6H1qyKU1ze49en+T/RmTpt89hOk0RbZnDqOOD/jXqEJg1KwW6t9kdxLH5auSM5AOM+vWvLriCOOZ41bdEw+VvUHkfzrc08JLbzxOWCtEOnHPQ/41Dg73QY+hGqlOLs/0FNvJfG5srl86vbIFcAAK+DkYx6dPxqhp9ylsZU1KKRVJwu04LAfexVzT/Mj1RZbmSMX8Q2Ozn/Wx9AfrWlrTWV/bPHy8zsREQuPn6daUrP1JlNxfJbR9unp5dvIRkt9QQPbosUECBUbIZmB6Amud8WT2lgYjeQs6E4E6JkqQOhx1/Ksm60vXfDs8V8bJJ7dW2SJkYcEjJPPXHT6VrLdx6rq/m32YNP8A+WcSj7+PWizS1LowablB3iv6+bKMPiZ72wktoriKRGG1UK/Muev04p2hadMt3HaXGxfOPygD7vpn2966zUvCOnXMtpf2KfZbiL+KIbQ2f7w71lQwvbak7vuTy28vfu5I45x6daTVlpqOniIVIv2as/1FIOkX8d3L5eyF9olGTk46Cq2qSxTajcuryTFmJ3hvvE1qatYw32VdN0hbzNi9SBxmqt1pTzEOg2LwPm4z9KTjfVBTnBtTk9bWM26HmmOa4t2jVYXG5D/GB/nNeX/Byc3Pi7WoZCPLmt3coeAAG6gV64tnJbQzx3BbbJHgAkjkHqB3OK57w14b03RtRudVtkdJZkZZFds4UsMhRV6ODT8hVYym4yhsrmvaRPa2sxkZNsKgiMNgEnsvqeleOeBfD/iu/wDFdw+iS/ZWWVpZfPfYuCcnrXr2ozhrzEdqjsVJEqknfgdcdBWppbxWGkahLKW+0XI8teOoxz+GTSi42cWr3DEUnO1RNqXT5/oYXjXw/wCJ9VsLCXQ7v7NKZvIuHjkG1kxyx9R7U/wJ4YuPh/pWrXWq3RlnnmEUKjpwc7sD1rS0m8nt5Wj+1MmzaEXbuXGOcDpnpWhpsiXk95puoSH7LdgSW0kxA2SDkD2+lTzR5eVoxnQlCblJ3Xz202/ruYGsG6n8LXl5pEghuftSJ50mfl53MPqemayLLxFDpOs38fiOz8q0kgW5tZlQ/M+AWXcO3+Irs9Ahkj1C/wBD1GAm3u1Y5ODtkTvmpdKvY5NZGiXkMVxpuoRMrR7MnLcdfQgULlWkunbfp/wxdZyXP7PW2u+jVv6+7zOV+H3iSbXBrNxpmkNYsLWWO2u3zsZznbktx1p3g2w1K18KmLxa8Q1S6ZxBFkb1jX+IkcdegruPH2kQaf4YtLXS4hBBCQmxemwdK8+lhaeF78MWW2ZUK55TPf6Zpu1rpdb/APAHg4PEpV+e19LemxMEKRyKMhoxkfWtu+k84QTN9yRB84746/jWNHuSYeZn5lDZ67lPfNXyjSWcFrnmKV0+oIz/AEprXU76iTaZaumIk2bNsyqQSB1BHB/KnTQq1ksm3naCGTkn1BFEKMLZZ4MyXEI+5jO5RV240yR7dL2ykRrdlBMRHzLTRyuai0r2/r+rGCkciQEqvy5yQetWlmaa0JMfGSFYj9KkW3iNwI5coccspyC1EiS2ttLbu+UEgdPb6e1CjqauSk/Mu+GrgWdmz3BYx7iRhc7GII4rNeKOaclCCVC855PuatwzJbWiQyKxS5jLls9OoHFV9FjxcXMTAONvmHJz8o5zmpStoZpWc6hPqqu0MQLbRgjn07VVMAFpEzjqeccFgOtWtVbfIGDAhzuU+lL5cws22hWOd3T7vqap7ocZWiihPHAkwaA4U53LkkY9OaiLkEYPI5AolCuoAf8Ai546n0FS3C4LhiuAmVyMcVD1ZsuzHxXNxcrsghQKo4VRgknrk96n/svUv70P/fwVSikh8uNLnULfT1lOA8vVjjoK0v7Gsv8AoNJ/36NHOo6XsZTmoOydvk2cB8QdZ1HQb+y1HTQo03IEjAlt57hs8g/WvQItKTX/AA3He6NsYsgZYZGwT6gGub1iyhureSGYLJBKME9j9RW3bRzaR4Q0+TT5DGIXCB0bOPSsqaiqdra3/q5FWFWM4ypy3017mHrutHSIDBqcdxDccJ5jL8uB0D/0aqeqWw1iNL3TruSy1SFQYZ1+8B6E9xXfxS2njnw5f2muQIt3axbxPjHGDz+lctZJp8cVna6Xf6fdSwxBDbrOHlwOuQOlW0l6/oCqczdOpGz6/wDAfZr7iy/iA6f4ft5NZdJrtSFe4C9fciremxLLfxXKstwhXeTyqgEcH6Vj+IrAa9p9zaWEQVym1U9SB1Ppmovhzp+q6V4GuLfWYZRcxyOsG8nKQNgYz0IzkiiMXLmlLp+vYzm1R5acU/e09PU1Xd9XnKRKpRT8i/d49fas7wlr6ar4hu9Bl09YfspJkm6E4OOtefeP/EF/oWq6cmmTOs/3wq9wDgDFet6TpQtzqGuS25s73UrVA1vIMMkhAz+pqoJOPPLbVfMMRXhGboQeqsWLq0ke9aTawR349h2riPF/jrTtL1aPTbTTY77UhIEknLZW1DHG1MfxY6mvSdctzBoP2SN9180ahVz0XPU/U/yrwrwn4QvG8T/atRWRFjnMjIfXOQSe4rSnFTn73wrf/Iycp1Kfuf1bqe23USrZabAHNvKkYkkZVG4E9s/SmzWF3eR+XD5rRA7tuCSR/ePekt9atrZiZbe3kmVSUnkfOG6AFf0rz/xZ8Vm0a/mtJbe6upYz8sq4ijB9EOPm/lWV0+lxSlKkuaWnm/Psdu9o4DW0ZtxcoNxiD/Pj1xVOTUJw+xgVK9Aeamgu7LxTpdhrNrLHeCLBSeFTFcwHuGHf+VX9dtbGPTJdbuWQ6akfmTSbirR+/Gfyq7xitdDanXho6nX8zJS7ZiG8sFh/ErEGqmoRQ3KKsm6Jw28EcEH+VN0bUfD2uxs2ia9HK6jJilAWRR9DjNXbuBLe0Nxe3tpHa7crMzYDfSnePc6I1KUtYss6Gscj4uIxNAOS6cunvjqP5Vq3+mTrB5loxmZwfLmj/j78474rjbKdMpcWNwOuUlibg/T0rrdI1yScKjOsF/EwYMgws475Xpux6daSSWxliKdSL9pDVf1/T/I52LULuKXP2mZJFPUPW5FqK6tp0iXwZbkNtWRPuvkEjPp0rQ1bVoI5d1xpmmzBhlZNnzfjWLLqxcFxawAA7sqO/bFPzSBN1kpKnZ97ohsbZry2aKP5pYVLKMclfSp9EuGExgY8SAqvru9PrVS01FFv0ktCEvEJdV7Fe/4djWrq9tbXaRajaboROPm44Djqp9CDVxaaLnLXkls/wZnaxJPp2owOQjRyKJAWAIdfY9qvQXQ+ww6ojoZo5MRW5AC56Ak9xU+k38MwWx1qW0MKtmM3SA9euG7VkeLtYtY5xb2QjNpbrtBQDaTnk5/rUys3dkxTqSVJx1W76NC69fXE23UfEdzDAsYI8sE4YeyjqK8/XxPqOo+JrMBF+whlULEmCoLdD+ldbNpEes2EEtzKczYMCA9QDyTntVTSNIs9KuJHNwfOMxbakfGB6H1FL3LNs05UrRh07HtNvEWsYyUKOIx8rVx+uST2t0iabDEW3fv/ADVOGHsfWt7R9UTWdKEMV4jzg7cqcOMYOCPwNY/ie7gtp2luCA5UJIi54H5VCeh4uGhJVXCS17GlolvHNuZOpwG2jOe1a2qW22KFZgpg3ZKgeg4FeTal8QrHRx+5juZ54uWgRtoVcdx0x6d61PBvxb03xFqaaVqEP2cXR2RtvLbW6gZP86eq1a0CvQqKfOtl95Y1Gd7bXpbdQfKk+WNhyADg1Np1oZtRMs0MjQxoWnYDIGe3PXiotd0m+e8kl2FkRiRNGflI9cfhWlqcc8uiWuxm2BC7AfLubuxpvVnoynHkiota6M5jUtRt9Ggjf7XbwvLIVVmk2MBnkAe/emT6iLxYJUkjkRcEOpyGOeTkfhWL448Nf29pjCI/6bboXQEZDYxlfyrF8BafdWmj3UNwrx5f5EJJHA7fn+lDhZc6Z00mnU5WvmehacrPqcNq6jc5AkGO2AfzqOaUQ3UxVEMVtL8q5z0//VTtDnB8U6axOfMVVyD321W1BHW/uoiDv8x1wRzxnn9KOVP8CuX95Z9l/wAE1tUtJbPVLbVYWjaMokxV5vmGRyQPTFU9O/0fxVp0qtuj80KH64U9P502ysV1zT4Y4Xjj1O2/dp5r4EsfJAHuOaoaouqaM8TXcPk3UYyhIyrD6/Wpa90mEU06TfvWat5dD1nxZpz6nok0MK7pl+dFPcjtXkFtcpa3D740eOZDDPC/APofqDXs+g6mmraZDdRqyMyjejDBVu4rA8UeGLWWWfUkiU4TfJGBw+OT+lTSlzx5ep4+XYtYdyw9Zf8ADnmskE9i8cVxlYsZjPYqa0on2rFeOflWRFb39/51Iusi/t7rT7i3jFo5L23y/MrA9M9siotLxLaX1l1LQGaMn1Q5x+Vaqzdj3ZSk176s/wBH1/zJbdZgzNbsQUZgPcev5Vu+DtRjSWSwulwJULK2eDjtjvWJpbs1gZVAzDlT7g9jUpRUuIWYYKEMp9u36UnG/vdTnr01UUoSJL+MwTlpAvkStsYew7017R5LMTo+9VIQqDkr9ahubiS5MqbsF2yg9+wqe1m+z4XcfNYbJY24wabeuoWlGK7kbRiaICPmaNcbSfWmR3UVrZM7AmR0EBHpg5P9KbdXEkNzHNBtEwbG5hwRnuKS4Md9HNKkSo6MfNReh9xSZajtzbCWrvd3ETyH92CFx6A+lamqTnTLiaGeBRyFIA/gI4/OofBE8JuXkmjMgXaAi9AMmpNQsZ9S1W/u42aTL5IIzgdAPwqIu9zKbXtnCeiS/wAjL1RoLK3t73T4rm6MzYIiXJjPoR2FUTrkM6m1vZpxctJ+7DwHG3HTdWisl1pV3KsUrW82AGA6H39KgexvJG8x1Dbn3Z3DLe9Np/M1imneT06Pqcl43hvb+3tBptpHM9rN5jFx8wGMfLUP9veJ/wDoEp+ldixTY4m82KcewH4VBvX/AKafpTnShWjFVI/D5teZpTpJOTj116dku3kZMM7xsyZOe4cd66zw3fJLp9zYXqfuHU42jJU+vuKd4q0aOW8e+tYtnmfNJCOqnuR6irXhm1MFtc3xgWSO3gdnjJIMmBn5fwrGn7kHzE18RTq0Oe2v6lPTYnOgeIIbNgbia0KoB1PXpXjPwu8N6raasdYmtWRQHiRWUhmZhjIH417J4avbFNUsb2zvo5rSZ9vktxLGCDww6cVv+GIks9K1G/WMEWLuIxjsBkn610RtByl1at+aODFRjKaqvVJprze1vwRh6XNr2kJvXSdqkZZzbMSfqafdaneanDHaqjqgYfuY1OM59cZ/CqX/AAleq+e1yLyRWbnZn5cfSuq8SXl1thAnkC3EStjjuMnnHFSrPU6KilCpFzgrvrd9PkeW/EmSLwxNBrVrbwT6ja4iSaRd3luTu+UdMjPWuo+Hd8194Vj17dPcTXly2/zTudXBxgn0yP1qr4r0az1/wtc6Vd3Athu3R3JQsI3zlWbHO04wfTOak+EWnSeGbR9Du7y2uYZ5fOEkJLKH4xtz1/8Ar1ULJS5n6fr/AJnHX5/aXjHS2vnb/gdDopprmUvJbPEry5LtOpLcdTnoMdqxnvS7G1sx5MIBMkjffkPdmPYe1dB4pVrO4khtzsmf5toXcxXOcfjSWdnDoNgJtSgSW/umDujDIjXqFx+ppx1XkdFKrBQUrXvsv67GVo1iLmOd0gYRMjJFPIuN74yMZ+n61mX+kQX1u9rqNqVjlx8rrlSexIPH4irXxL8S6gnhC/1DTG239o6vEqZJjQEbj+X6VN4E1IeM/Atpqd/ujvX3GT+4HViCw9AwA9gaIyvfTYh4xxny1Fa/z/4craPo1loNg9raLIgJyFU9Pxp1vfJZLNa3CG70y4UxzW0q8Mh6it6GzaIb5rVrqM/K5RvmX6j/AOvVHXjollayT38hs0AO0yty2B2GcmiVndtmkZ0n7kldPseT33wZW81T7V4W1q3WyZ8+Rc7kliGegYDDfpXpM3gKW90pLG+sYXt4zlHWT7vrgisDwXC+sxzX1jd3MUHJG+M8/T1q/e6zpmj3iJP4klikB/eeTGzrH67l/wDrUSbsk9H87mUcNToOToz0fdN/kVLbwJdaLqaJZyt5Dn54XPB+h71r3mlvDGZomEiRthtpO5D9PSusazk1PTlmjurbUbdgGiubVirRnsSM8j1FeceOfHOoeB9Sg+zaNDd28qDzZZHOCcnKexxyKLu+1yoY1xje+39eq+46mG7sr+yEOpb4JY/uTwgMrezA9DVmC3sFiwhFxvX5SzbSPpj8azfCOseEPHVt59pLc6XeADzrYnIVj2yRj8q6yTQdL0xoSsN1cySvsjk3Z2PjPzLx8oxyablZWTIli6VrRclfp/wf8mcfCI7K7knCKJYuU3L1z/Qjg0LqVxZtLJZW6zW1x/rrSTo2Ou0+o7Guk1bSgoDXS24YDkRSE5Ht/hWVGrRadsazVgzmSMKd23AxgnPGR/Kpv3OmNaFWPNa9/wCv+CR6lpP2qKCSwxciRA4iDDzF9sH734Vh6hoV1jN9EbSL+5Kw3v8ARf61p+GbldZurqOyF3ZTQOBMqvkBjnoOueK1b2yltbWRrS8S8duWS6twXPqA5q2rrzLhiZQfIpL8fz2OasEmgsZb5g0lrZxMqtIdqg9duaZ4Fv08VT36NAF2EneTgIP9nHSrWrnUNa0s6Y88FnZj5csNi4yOAByScVGnh59M0hlsgVR+WJOGkb6VnZfMcr6ptJvb+u5zfiyTUPCcbalptxHO28co3GOuGHXOPSuw8O+K/COv6fa32qSTLcOeE3NgHHIPrg5rC1zwxc6t4PMN3JHFdRtvZQctGhPyMwHvke2a8n8N6XrFj4st/DxgFxFPcDBQEjH95TVON1zL5nNXl78bt2el10f/AAT27Xbbw/p92b+4sRereqUi81d2VHU8dMcc1g6DY+H7LWkvo9LWOUsTH8obbzgMB612PjTw1amxsrS4s7nZbJtNxHJtD55IIBzj6Vj6FpMelSiaxuYpbV1JFvJztYdASefpRzS5d2VR5Jw5mr32f9bEHxq8eNpVhb6TpEji9vAGLIOUTpjPqfSuo0trzTfBelx/aXE5jDO5wc7vr35ry7xVo8mr+MrG5khxDkiZl6RgHOa9Uv8AVbbTtPs7rVpRHZ26+VGg5MhPt06DNKdvdSOd0HRsnqr/AKf8EpXNpP8AZRceYZHRyWIJDc8YHb16VFd2CWsl0uPlRjlfTIzgn1qbVNQSO2tZrRw9pOizw8/Kw3dfwqxfXsU9vb3LDZIP9ZHLxux39wRUxWqOuEpqz6O5ztvBLBrdsEOfJw4x7L0rpb2wmtr6AyDIePc4bgn5cZ/PmsSyikvb+5EDnzBG7hlGenJrflvBqmtJIJPLWPa2e4UDnn09vem3Ztl4mcudeS1OQNvPHLKGLiRPu7Twau6PrTahHJo2qgPE6nypJOdjD+lS+IFEGpM8EyNA/wA0RTrg1TsJUiuHu4onbUIzuGMAsDwSAaUt7rc6JNVafM1ruvJnQ+G9V1GPUYrGOQFYz1H3Xx/Cfwr0ixu4r233pgn7rp1we4NecaZbwajCLi1nkTUFy2dwUOO4x6iqematqGialKkm0wyfKxC/MAO/vWLh9qJ5GKwaxLbhpJdCTxloa6dry/ZIf9HlUyooPAPcfh/WsTTLjyLiGdeBFJ8yn+6ww1d54lUXVhp2tWV19pgtnBlTOQUbAauQ1rTjY3DzR4FtMcoueQD0P0NdHxe93/p/15ndg6/tKShUeu3zW/zsP0uVbPV5oJDutJ8x9eOnH+fepZx9mu40lOASEBx1FZyeXNaIgUrPGx3gn7ynoR9Kttcm6gNrcf61SAkhPUjpn+VVfm+ZtKN5c33/AOZHq8RguTF2YjD+3rWhr6f6NZXqqAWPlTLnJX0P4jmqbsBMhm+eOBdw3e3GKLa6g1K5FpOvlvcMCshJweeh5rKTSdyGn7su2/8AX4hMpIMcpKuuNrKM/pUmmRpIj2kkzRM7As3QMP8AGlvoJYLlkXllYJ17dqSHMkZ8xWyq5XaM4NHkDd4aD7Uf2VDJPGoDliFi7uDxnPpV3wVcf8VD+/Kqrq27J+XB7Vjx7ZSxdnLk9SentU1hM9nMZVIC5Ct7DPX60pRutCatPnhKPVml4ntZo7mSK2YPaNyQvzBck4GayVkWSPyZl8uWMbQ2T17cVrtYXLaXc3K8BZC6kuN2z6Vj28cl1KzWxeSVfmOfb3qpu+oqLXJa97dfPzNuzitLizdZsOy87mwACPc1Htsf+fqD/vkVRtrmb7HNBPGrCQH2x78VS8tff8z/AIVdK9rBCk7u7NSTVjZt5asbiNesTqTj3U9RVC219l1FDDdGGMnlJFyCvccVt66lnJbRuLeZjkBcYwD+PaqGnaJaX5Zn8tJwPoR6cHrWECacqPI5TiZlzbW66tJfWqRxQBy0aAYycV3XhGSJPD16L07YbhvOPfakgwP1BrJk8PxW0LNd3cLqAMKgOcdyc1qWUgSzH2FA4FgGUdeVZuCPrVvSDObFVIVaXLDy19DzrxFd6P4N02TULx/7YSBgiRRZjDEngseeKueFPHx8a6ROl5ZRWl2kL3MaxnIAVhg889Bivn/xHqmv6vqc+n6ldTs3nHMcjcZJ7V6L8L9K1TTdQ1WW7T9wNOe3Rgc4JK/0BqqUJNc8/l936sznVqVqykk2o2Xzvv5L5HpkpE0RkjAw43YPYNwR+YqymgMdQt2hl2TQsskTdg3UA+x6VT0ZRNbFMcEMu7PTgY/WtX+0/s18s7/ckVGb2YYyf61Vr6nbV503CBd8QXyPeQXZBt7lWILH5tntXP6it0d1xNO97Ex5mUhsHtkdj7Guu8d6bFc6YLuNApxuLL3ribaWS2VHtnzkYPcN7Ed6mm9bMywDjOkpQ3Wn9MTS54jd7Z9rLIhQ7h8rZGOfrVvw+1x4fjkTT4okiXKeSQAuPpVKVUuVaeJPLkTmRR0x/eq7NdbtNhdxvK8Z6kD2rVJdTrqwjPdb6Mml1i1uJHM1m0MpUriFiVX6Cuel8LW174oj1rVLhrqFECxW8yZVT64PWryDCiZl37jiMdMnufwq6ZHMSrMS8j8kDsPapVoy03InRglyx2INZ1MaPpdzdaedsx2xBAPlEeecehrz8+BofE2rSX89zcWchKsdi7vOBGenrXY38ImuVjfeinjDeldT4S0p1W4jvVgazjUPEyPlgfp6YpJtS5iMTCnCleX/AASloGmHT4Cul3BttiqqpnDNgdx3Fat/o1p4ltJCJrU3QXEkLgZ+jKex9xVO809ZC7adcJdxxkllZtsij6Hk1kPcSNcRyxT+bcRjKOVy6+2e49jRpvEy9m6vvQlZ+n4MNG02DSZ0sodMt7JRIpdIYgquQeNzVwXirxV440XX3MsKzac8hAi2tjGenHIr1ptWt9RWOO6329ztGJANu5unXp+dWorbzZ5vN80qoB3ugwD65+lK13eepnK0Y2ceW3b9PI4+0u2mtYJfsHktIqyGI5ypIzjNa7CfdG8kKxROo4HX2P1qTU9Z8N2cvkz6nYW8y8YL7unc4GV+tW7O9h1a383T5odQjjO0vbyjhsfxA4P4URiu5p9YTtp94yBYACZ4/s7RjmXBHmfXFTpJbhEE4luFK7fLAY+Z/vcnH41T16fV9EjWXRtPXUbmOLdIrKzhc9Cqj+dYWkeMvEepoIm0OZpg2zcIGxn+lO2nMkYuXM9NvUsvqKW+ostnpka4JIjZzlGx1GfStPRniv4obXVJo8yEndn5kJ/2qn0jwxq+qT/2j4hVLZv7kj7mPoTjgVneI5bi8lbTtGs0Dx8NdJ/EfQE9PrUNO9zoVSnWfJT3W7vt82UdSZ9E1qRJH2Ruu0SoPMSVff1FV9Mi8nW7GawMc7SyhlkQkBR3GOo/GqulanrGi6gmnappIu7Q5LI4Egzjqprs9JHhn7NNrFvH5EEbFAHcqrPjJCjk1XL0N6lX2cWrN3VrrZ9vP8zChbWJ/EN1f3V9ts/NIfc2UA9APTFTQ3PhzUbuVbK8BlGcqhAGc+hqGW6mv5jcFIzFEeIgMRovb6/jzzXO+IPDnku+p20QjuUb50j6Ic8ZHeq0TsmNwu0r8r2sv61NjxJYyWD70YtlSMj+Ie1cdrt1d6ra2tlKZHijccnPyE4AOO/Ga6W2a8m0tLeXlS3yFh0yP0q+nl6fpqxmJJrsdZtpyMYwOe45qVNJp9S5Jygoy1Y2XTRZadp9tExNuiN5RY56nOPao7TVrLUILqzSaOWSFwV2jBDAYIq1YSC8t8RCRsNgKBypzmsjSPDFvpGrXl5G7me6YsUYcJ64paNX6kttNQfS5r6M8ltqlu6nawJVx2II/qKgW4+z3svkFlIO5S3Ue1T2sZa6ji5DOCF5+6QePwqHxFEY9RuHZ8lyHG08HI5/rT0aZquWVSz6r9RbWJNS1D/TpBBBJx5gHC+nHpk1SniuNH1Iq+BNbtgdw6/4GrUUau8U0WZAnOY/XHPFS3/l3NrAyylmU4ORyo9/TmpTT0Y4ytKz+F6WKQjuPtJvrJngCv5rAHhT6fSutJ/tLSLa/iQC5RhvZMENk4PFcbaSvBLJFv2xsfmBOQD612lraDTtKkkl3XFmT+/RTt2A/wAQx3oXxGGM91x79PNdh9ppcJgeSxfyJZlxLBnKSfh2P0rF1uzljhijZ90aE8FvujPI/CrOmaoNJ1dmmTzbR2ym5smPHT9K3rywbWgJLVdxlbdnGQAefwqlJXszl9pKhUTn8Pf+uxxKJE8kUMOScZDtxnmopYXBBbITP3iMA/Sta90ifS7u4+12ksyqAVZG+UZ+lVr61YWyzpEy78ZXdkIfXHai+p3RrRk04u6Y23nhW1kSQbzLhgvoQef0qLSZVW7UPHkK24c9BUX+q2kbfNGSau2rLa2IvpAvmyHCbl6/hUvXQc0kml1LVxNFeayyQEZlk2oCeM02WWW3nZMhmKlH29FPQ1Q0y+Ju1uZEVZFfftA4PtV3Z9ovJTMGBkXzcJ0XJpLcycOR8r2SKULEtI2wDkAnritKGDz0lKgZUDcD9etQw2wclI+ZWYkZbHbmka5KOUX/AFshC53Yx9aq2twm+Z+6XbbW5bexNo8EMoG7y5SxBUHjBAqlZ3cmmXeHB8t1KlUPXPqO9QsyxyIGHAcbhnII7irE9rHiaLa6S253HPO5D0/Kp5b+6hKnBXVtyvPhSzQSZGflBHQe9H2+6/vf+OCorKNp1n2bRGSAQWxU32Z/U0as0ajezOq1mSGCeDyUUqD88jHIz6Y6V5Z8ZoNYbSkXTn/1rbn2cOV7ZIr0A3E9/YX8M8IiuYIxcovcrWB/ahVfNnJkjwQ8bLuyD6Vly3ST6anJQoScXH5feujJPg1cz3PgWeO8upptSUFAtyxf37898fhWvpl5Lo12L64BAj4lReAAWwaZoN/b6VEl3o9isCXNwDJby5JC4xle/Wm+MrmG5W4toG2W12NxVhyjjquffgitp1E5OX9eZjQotN0krxffy0ZD8RfDemW2qWut29jBIl0cmQr91+oI+tP8O/v9L1LzlUFI/kKjHB4I+nStvTpIb/wvHpWrpK8JUCGeMZOR0PsRWeLZbCzeC3fdHICjOR2+nbpTStdGlKdqXsZ/Env3V/z6EPhkG2SAzDCzuVGfYjH5kGqV5lrK5gb/AFtq7L/wEH/CtKJGkksraBc73Vcn13cmsbWbpZdY1d4seXJO+MdwMjNVJ9Dpp3nVb+f4/wCX5Hf+Drsax4Va2mw7wgxHPOQPu1yv2ezsb5rS+nWMMQqyDAO49hnirXwnuSupXttzteMPj3Bx/WvJv2hxe638RrLw/o0Ms1wEDGNDjczcg/QDvUvWatu/6Z5laf1OvVitnr83Y9UNjZabfrLDqbpKh5imgIDDoRnoQa5/xZ4o8M+Frb7VcRXM0xbNvpq/Krv3OT0SjwVYXnhXQlste1ZdSuGIDwM4mWAegyM5984rkvHXg698ZfECwsNKVlZYdlw7rlLdQx5J+mMeprRxk5KMWazq1PYuq7p28v0/rzOy8CavP4usZdevoSmxWijhX7it2Ax2xW/atb2hdmCST/ecseB7f/WqW30y08O6Rb6PpEUj2UCEO0RzIX7s31rC1CSKDErzJbxscKJ2AJHeh2TfLsXhr1Y+9oaGoMmoRhwsaNE21ig4APQkdh71WBlspVkmWTywdsiqfyPHWq0W+1mV4h+9Xoc/eHofXiuotbu3Nv8Avg21skbeDj6dPzoujoqP2SSSujnrgxNM08UjBwQUkQhjj05q3I2jzwq8kl1BdkfNJ5YKsfcA8VZvrHTHPmWzhzjcYmG1wPUY6isnWzp2jae11ci/dUG5jbwh8D8+lRdLVIlVINJ3aJjA0lrtiK3G3+KNs8fTqKl0jV7mxbMZZ4w3zRtyGHdTXPeHNZ0jxJG8+iXTCWI/vIphsdR2P0+ldBeo9tbR3cgQA8b+oPsfWrunuXzU6seXdM5TXfhxZ6/NPdafdNbIzlnhwd2M5IBPHt+FXvC3g86VctJZ3M7ecQ0kkpAJVQccD09a1LTxXpT3htZysF0ThMcK3Yjnua6dGhREdWkQHgK64P0NDbas3ocsr029NSnHc7IzJLeC23jylkE+0vt/iC9SM+lVrDxFrumXIt71zcWq8rIqKwx/vD+vNcf8TfBx8RXMdxBIxKDasbfd/D0rh7Lwr4hiIjl1KS0iQ4AEpZmHsKLGkKSmmpQUk/v/AOAe2+KPiro2jaYZL0FizeXsUZOcV5hb+PND8Uapct5GoxQRoXVIwvY/pmotT0RdQtBaXUcs6p/FIc5/2j71o+A/huLC71CW7lFtpcoUxNjJYjnv25qN0T9XeCqKVPSL+bNXQ9Wsbe0l1WwLxzxj5EvXGw+2eMGrulfEHw7rkI0nV0trKbzCyyQMPLZj1OB0NZfjLwlb3vhxtM0vUYpG3CXITAb1X8K5fwR8Kra21aC71q4DQROD5cZySfenytK6ZVZudpKN/O7TXov8z2HULKO30dbPQCzxNmRrnjLufunGOQOD+FcbpUWp6XDLaatOL+Sb5TIzDOSep9a9Ct9Ttrjw/OmkKLZowEiBbLsvTgdjXH6tpd1YwBrzekpIIVh39SalPmXmGDfNJqe9+u763JoLgTRW1jJb7rmMFCyjng8A+/vUupWMgt0jn+6CesgY47jjofrTIblNYt1kJRNTtj+8bA2zKP4iPUVNpwS4aR5rz7PbBtqsqZZz3wP61V+xvJuLutLbrfXyOe8Lz3ki6tMY0tUs5AsasuGYevNadjq4vr5ommQTsRGVA4APGDn863B4e03UbaZNPvluLr758xvnHrxjmvKpNLv/AAt4xSGVGltL9vkkPOG9CaOR2cl0Jp1KdRtPfzVn/VzubiGWK72EMoQZJPQGs5zuUh32kdc9vSr+oM1xBG0hZpVJwSePTOPrWXIszxnzQAB056jNZs66W12SWEqLfQJLmGJ2Ct83r3FdLqugGS8KadPEjwxCWP5gA/8A9f2rkhbK/l7WJduMHvXS3t8ltBHHaSSQTQgfMBg+/WlHczrqXOnTf+Rzd6rPJI0jgyqSCcYwR2rqPB/iC3RxZ38SqsqeS7MfkcdBn0Pasa3KXF1snXzEm/1gTAYHswqjNaiC4ntmJ3J39R2qpJPVGlWnCvB0pmxq+ky6bqclvGN9nu3RnOSFPQH6Vq6Pql1BdR29o7GJ0JVP72O1J4Rgg1W31CG4IkkFvuQnOd2DzWJaJLJcWe/cqmUoZMfdPSj4k2crtVUqdTVx/wAtzcn13VQ8U9idpI2tGRuwB2GeoqKbUpNaupEhhl2HAKBBtz7/AI1mXUN9p99cQzLJshzucdAOxz71svJbw+Fft+nozy7Qs5PDIxPWm17yRMqdOHK4RV3on69/0Ma9snjMrKokOcsqA8e1Lch54rcNHi2iIjVV7tzTtNvbp4Wk3BoUGTkAc56VpDZcadcQyz4uUIuYwo4LZ4FK9zWU5QaUuhz1rsW8CyZVN2AQOnNdDpVobjUbqBHQyhBsZWBUisSSJ0lLMBhmwfr3/nUlnaXDeIbOGwBLhzyDjI/wpS0uy6y5otp20NSSwmEN2oUGW0+8ueSvc1iuyylH3lCPxwa1fEU80WqzRNIyMAN4U/ez2zWWrozAYwDzwKp9iaPNy8z6k6Recm0ncT3xnNSTxzrfyxQs7Mg8vjuuKZFM1t+8dCVAI2r1Ge4rb1ewjvdJg1axkyzRhZYycdO+e1Zp68v3EzqckkpbPT5mXb26wWiyxy+VKpIcP/IDuan/ALUi/uyfkKq6fI0guFkVRvQAE8kGo/sq/wB9K0hGMkPkjJvnOvu4mk+IsWFzbC18hgOmCDgH8a8/KmzvpYT1id4sEdxkCvR/AEjXkuo6g5OXZYdp7bRn+tcNriA+Lb9F6NdZ/MjNc8VtDy/r8zDBTaqyov7MUv6+88BGvaovj1JZLyVmjuNgVm425xjH0r3mO8bxFp5vbW5juCk6wzQsu11J+Xd7155b+DYrbxZc6nNIk25iYIQed/cn2Fbnwxgnstd1LfvEaSJIc8DG8GummozhGHVK/wCK0M6VKrRqTqS6y09P+Cdvo0QisL5/na3hfLHJwDnH4dKf4j1JrDS4p7MI8Tne/wAv3geh/nWja2ktlp3ilLlCsMoZYy3RuWII/OqENmbjQLe0v0yDCmD3IIwp/mPrUtdI+Ro5xlUct1f9EQeG/EKarpOo3z5XULGTOBwArrgflzWRHEfsVxNjhAqfUsf8AaboOkR6PpniARySMs8sKAMMYwTx+Aq+F/4paVh/HeqPwCH/ABq3ytXXZfodGHvBSf8AeS+Wn/BN34Tx51q9f+7ABj6sP8KTx6ttZ+K/tUEKLqUsAQXAHKrnnmnfCqQJrl5Ef+WlsGH4N/8AXqbx9am98RpDHtWXyQyux2jIPQntS2tY4p2/tJ8+3KcyqLPKoVQCzgHHY9SfpXXRyJoOhTXCYOo6j+9ZhwVU/dA+g/nWPBpZ0uSMajLELmQgLCjhyiH7zsRx06VHqeqR31/i6Z/sf3Bs6qOgIHt6VejOiqliGlHWK1fn5ef/AABmiyI94UlleKVgTHJuP3uuG9Qa8w+PlrrK+IrIwwziyeFYo5I+UY85BI6HJ716JqOnXmm3wjlR2iyDHNsO11PcGtqK+87SGmnYEEbDuQMjY9R6+9LS6bM8VSdRKVOWjMO3tLmx0fTLe/kDXkduiyY9cZHP0qzBfG2COG5UqvIzgZ5/nVrWX+0+TfxYMMqBWA/hdeP5VnIV3cAEHIwfpVSV/U6KUU6SUjh/B2s6tP8AEfVrDVZ3uHBlfJ9AwOB+Br1y4a3tyYpJwjrjd5q5VgedpA7VhW2kaXCsmt6ZbK+qoh8xnJ3AZHQ+nHNdFqVjHqaLLZXCG/gXa6MpxMB1/wAKzSWzOH4Zcs3pd/L1OHtfA9vovin/AISDTWdbOTcJoIlBiYN1wQcr64IrfvbiOHT5Ibhz5QOQRzx1yR9Kjieax/e2Hmw8lZYS25R+FQeIddg0iyjea2zHKm47V3Et7k9BVzhdHQqXJt/X9ficdrfhGbX5DNpU9kbeT5TKSTtPrgDr7V3w/c2UEDzG48uNY3c8FyBjP1471xXg7X0WeW7trdrRZmYmNH3KwHf2NejiC9vbZLrSZ4rxCuHiaMBvp6UJv4ewp+7JTk9H30/Qy0ksZI2DX32cjqssTMR+XBrNmSyeQi3ne4cdWKeWo/DrVPxJ4p0fR5/styj/AG9B+8jjUjZ9aZ4T8RaVrN4Laz8j7XIRxNwR+BpSlpsbxmopu79NP+HOp0jTnuYpCZVZ0QsiKOo6nNZuo3lxqKhIWxFEMNCpAPHoO4rXuG17SHeG1jRCG3l1VWU5/XFZFxpcxT7dDcWu1zyIWOQ/93AGRSWhFKScueTWu3UNFspJrlYg6xhlwQnzArnrjtXSXWnrCWTSoIpbiZdu+Y/d4xn0HrWfocuoWBuru9bKrHgmbAYeg+leWfEfx/rGnzmx0+4aHzIvMknU4Ygk8L6Dikk27I58TKbk5X0X4novhTS4dIv59R8S39tdSWoCRxWrF0i55Y+p6fSun1rxJpOsWTxLORGpG8GLdgnoc56V4t8NNY1e7uSmrRtJpcyCEyyYDEnv6ke/tXYHR0MrxRXf2S4jBGyZtqzL2Kn19jSs73Qlhozkqsm7rb/hiKazmt9V/wBGf5mGWZDwUI61dsYlSFhOzJEX5Ock/nVazuzaXMJlZbhOY5cN2/wq1q7RrIrW4DhlIjiJ4jz3NXF6tnpNybUX16lVr63stYhuNOuiXRx82R+R9q7zxnoA1/RVurYhJAofYPX1HvXlGq6X9mjEtwYkZl3fK45/CvV/BUd3b+BY5J5zISuVB5wvas1JuRx5klTVOtTlqnb1OUhgVIooXKsXfexB7hen50hslluVj80Qs4IY+x7YrcsdMjmWd5riJCMttLDOfp1rLvYbCS7EUF0TNn5euM+9NroONZSk0mcedWttN8RtpOrtLHIh3xkkKrDPBH1rp797fUiHtgyFmCkMOnHXPesz4leB5fEi6bf2ar9tsyElVOpXrn8K6nyf7O8OQGe3YSNGI9wwRj1xRNJNcuzX3EQxMpu8t72X/DGHBeS28GxlWTygGVVUBhz1yR0rK1DUFupFlOQ/3CSMEc1pypaLdsizqWMe3DsEcZ5OQTmolsYY7R7hSHQt5anIJY9ajd7ndTlTT5raljRpxYxLe2zT5D7JAg6KR/I0kMr3GnXUNvnc0pmyDjaFHb3qLTp7eONopjKpY43ocED6dxUMkUlnNuhk/eHmJ+mV7mmkkJwTk77nVaTq8r6FdR6mYZlZNmZCAxx/OszWIVtvCto0DKTcSHeFJ+ZB9049qy4LaIu8d3K0UjRlyduc/wD6xUL3ckmnw27tugts7Oem7miOln/WxlDDqM+aG17vttp+JoaLH5tpKcjbGrHb6+xotDlhhsMzBm9QKu2YkhtY5XgMVkYxArdN5PVjVZBtmjGCHjyp9x2NVFJxDm5nInu0Wcb0k2ssvRj8o96n0uCVfEX9oySCCJDv+uR0AqlOxJ8tdo2SByD0OK6iKKG7tLmS5PzQ4ZNncEZ/z9KKjv7rMK03Tjbo9PvMK8tH8Qa00ob7M8u51LDghe1UbrTZrCDzJV3JLyjg5yKaNQKyEq7BozuX69Ofr3q1qepfaNLiiijiiCffCtzn1rP7WprFVIOMV8P9f8ApFWa3ifnKqd4atfwhCb3TbiC3yLlGYNGx4PGRWfbvFe21qoba+Crnpuq/YWzaTM00Mh81T5gQn72Kl6pW3Jru8HDaXQxLMPHdTRy5SSM4YY5Wru9f+eg/Kt7U7Oz1jGoW0clrfEcgEYLDqTWR/ZV7/wA9YfzrWNn7y6hGvCprLR9jo/BiNpOsXdk8ivb3Y86Bx0LDqPr/AIVxl+fM8S3TEZJuPzO6u41T/R/DNvfxA7rFxJn/AGc/N+h/SuDIaXWgy8tJNn0GTz/Wpgk5emhlgffnOt3Vn6r/AIFiRLW4t7wXd1DbJavgpJIQSw6nA/GoLtbe21CS6ygikXCyA/ePbNY/jPxktt4ssfDMEMc9vEgE/wDstiuq0rVdPhgJisleDO2SGZA6yZ/unqKdrWmtuhrCs5XaV2tP1XzL51GTXGtbZ38tJQVZc8En+IVbnkWGNIUlR2tECowOWI7gjup9exxTL2CxvtPi1Hw/Ey/ZWJkhX+D1GPSq22B0iu/tARUARkI6rjp+XFaQS3MIqMkrKyXTs/8AgozNRO3TpQM4e8OMnP3VP/xQpbqMxeFrIH+O5dh/3yBS64uG0+BP4ka4x/tSMTj9AKm8UgW9rp1iP9ZEplf2LYo2jY64O/JHu2/uv/wCLwFOLfxbaZPEgaI/iOP1AroviDGU1iCfcQhhKtjvj1ritCkMOuWcw/5Zyoc/iK7H4l3AW7t4z0wSSO1J7J+pjiIP69CS6pr+vvOe0hLVtRtIJA0rTSKkj5wBnsB3xWhPoqPKSs8cJYkIsnG7B7DqR70um+RbW/2zTY1a+lj/AHcjHIiJ6lR61etNInCS3uqOSSMCTJwvqzE+nYVsttQqVrS5r26er9ClHqWtaXBJpxFvNB/CsnPB/unv3p0DRf8ACG3QaECSO424H8IbnNaTTaMWjMt3dqigbVBCrgemRn8a1NPt9Euo3S2y3mDDMzEhh6GpdlqjmqV4wXM4NaptpW2PPtKvDasYzzC/DL2q3cW8YKPGfkYcEeoqbxToJ0WdZoGPklsYPO30qpDLsjIXBDDOD0zSWp6KlGqlVpvRlnw8UXxDDA5/dXWYj+IOD+eKkvLG5i1Oe50+drZopTGQykgkdQPaqtjLEmv6a7AoFuI+fqwro/EryW8srYwZZpACRwBuA6frRyqRz1m/bJL7SC3e5uUM2qGyeZRgBEw7cev+NYmoeRqBksJIwz7CVjchif8APpS6/qlhpNhqV25nNpZMkSIgzvbGMfick+1Y/hC8OsLceIdSmhgtVcxJJvVRuUDgj0AIH50NOxjC0Nfw/wCAc7ofg2fR9QlnaSaODOY4GBPPr+tdLpGoNpV+rxyFMN8yE8H/AAqTX/HGhW8Dbr/7UrDBWJ8n8gOKxtO8UaRrW+PTNIe3WIjLSMZHkB6nI4X6UpxvqdVOcZLklHc7HXPD/gvxlOl9qtuUv8ZMkMhQvgdGx1rNT4X+EZLmG88PXU9tqEADBTLuTJHRs8j8DVdraRcPEGjQHIATOf1q55dyFWYArg7vMDbc1PO0rHK8FGDvCbXY3E0/WNLWMXcXnQY27hIGI/HrVKLRorxmlWdrYbd2Wj3hm7jORj1qTS7oNljcb3H3svuI/Crd9qICG3upH2MfldFJ8s9ie1TGzJvUTst+6/y1KMfh2S/1ZdP+3b7Qr5kpRSp46KfQ1H49+H2hzahaahcxRJBDEE8skkuwzzjv+NW4HlitpfKuJopmYObmP58/7ynn8qreKb64vTZvIyXARSiuhGMnBJ4+g64qo+69NgUKtStH3vd/r5f5GMsNvLAVWGRbdRx5IAJPuT2rmdD8X6Xc6k+j6kJ4gsnloLxdskf+0pB5HtXSaf5QaT7SP3cWWweQT9P0rlvFFno/ixntoxCtzFkJMmN8be/tVq27PRmql7Q/r0fc6LWtNGnSGYujoBkNkYYVw8/iy6Gposab2PyJbxLySe+af4U1HV9OLaN4gsFuYQD5V0VJwAfXpj68iugbSrGxtDdWcebq6JBdsZVR1xUtqN00VTnKqorZ7HM/FSxMuh2N7p8khuoxi5UMTyf8K9g+FniK61f4c28L2ri5tkFtINuM8cHPSvNkEhQ+SAwwdyHkGvX/AIdXttB4Y+0yYhiXhwQB8w9BWXO5W02OHNcKqS9qryu1p5nO6lpz6W8cNy+b64+Z8NnYmeBn1NV7qSO1jKxwoNvUkAE/j1FWVW78T+IZZ4eFZs5PSNB0qHxJFaxMsEFykpHDtjv9a22bsdFNvmjTnrK135f10I7bXr5YEhsp9jyPsIHXJ6Hn6kVv+IzqNva2X2u3WSDaAyhcgd+PevOLyKZrmEwblZXUB07HPGa9c1rVbd/DwXUonaUAJiM9Xx39BWKTbsY4yHsqsHCN7vXueS+NvBUXiK9fUvDhuUlc7riO4yAG9Vb09qz7jwp4h8O20Tsn2m1A3F4nPy+5BrrW1W+dGSzEggj4/dj9eK0PDvik7xaaxi5tWBXLDla1lUdkpa2KeHq0lzU9bdOpHFpkk+m2k8e2WSaLeq55BHUU/T32wyQXCpIrfc3DmJu4PoKmuLi7t9TMFrem3iYZiDp8pB9DU+oxWt3Hjc8F392QoucMO9ZR0Vg529JbPX0MO7kaG+WMs23HlleMgdhz2qa2sDPLb2lsgMryBlAO4Rj1bHf2pBok9ywlubtJrdMBinU46Dnoa6Lwtp1/BKs9pbQpEsoGGflVPfHelOVkXXrxp07xeq/MXx0YtO0xLEOzSsinjoCD19jXLW96rwW7cecuVLHuPSu88YwF9wYLgsDu2gnPOK8zmUxSuAflb5uf6U4uyTIy21Sgk99/vNhmWa6UKeSgY/Xv+ldFp7xSaXLIHzcBCGTeFO0dOO9cpphZrT7Sf4CUJ9Sa1kYLY3geOKTyyocbSWUfWi3M0ysRTv7vZlaW2RMyMcozFCR/dPrVS/tVgV/Kk3BTjaw5x65ro77T5m0GK7iKyIq7XKnP51gQKl1DHbxnFyxYKx7nrirVrJvqVRq8y5r7PUsaVJBJpZikyJIiRG23nJ5610FuhvvDb3ACmeH5JSByR61z/hy1S9jurJnFvKD5m4jnHcc9AKfoly9tcXq20u+FlIb0daz1WvZmdeHM5cr1TT/r1HOrFMFmOMgqpI4FVvJh9G/76qwZFMyFRllf8wetT/2cP7sv5ULljuylJR3djqvEwNv4CvVPBMWPzIrzOJnKJ5TbZcAK3vXrPjO2Nz4XvoEHzeUWA/3ef6CvJNOBea1XuZFHWoovnv5mOUSUqE35v8jhp/C48MyS694huo5bu7LFEQlti56nPc103hTU0u7SJIiHhky6nPfpWN8crzfcRW0QZViUNnHBJ7Vyvww1Ei8WD94GQs4PYj0rop/vItPpt6IqlUjTmqVviu/mz3Hw5qq6HrKSTuUs5x5cwP3Rnv8Agav+JrV7KSVVAMc5bYR/c4Kg/T1rnr2EX1kGVcA8MCf1rpJnkufCVqLgZMMKokp5J2tt/P2pU3cqpHlrRqrro/0HrZiTxlbQMN0cMUeePRAf51zGr3bX2oTybtw3sin/AGQTj9K7CaURa/q8w4ZIiVP0QVxVpHiMyNyFHNVvYvCa+++kV+Oo7TIc6xZxZxl1z+dbfjWRry8vpc4ig/dBj64/+vWHZS+Tr5k/55OCP6V00xHl6nHMmfMxnJ4OTzSa5opGmIuqsZ+X5tXMj4eIkt1bwAkpnLH09ePyrW8WPcT601tLKVhiYBEZvlUY9PWsuOA6FY3lxbBybYLN8vUrkFh+XNWL/UNO1ySHULa9gHmYLhm5BHrirT11OdtfWObpb8Sm80cqSCYk+W21DjB4ptnevbzjyJNg9M1du9KjuJxcWOqWMiyjJK5wCOOtJH4fuvMUxzebnlnKYAH1NDZ0KrRcdXv/AF2OnmvbPVdGktb0/MV+Rs964aFhBPLDKeny89q6+PQ3uraKNkVTGCSyHPFYB0sLdlnYs8bgOGHbtikvI5sJKlDmjF/Ik0nSX1LUohuEcUbiVnb0HNdX4uiN+I0tQGYNk844IqsHSyspmVAxSP5UPRmxkA1wltPr/iCS5/tiSSKJpMRkDy8gdQoHOKq9ndGLc61VVL2Udi14l8O6pqMf2e9hjtdMLNIXa4XDueNxC8kiuO8beFL+8uNI0vRYgmg2EYy5kCCRmOWYqe+a9Ej04wBmjH+rGMuQAv51Wl3RszmdS5/iGGz+lON3qzeNNVPid/6+Z5xafDKSWU/2h4g0iyi3ZAjR5WH6AfrXcaFoWi+H7fybLUxdseXk+zspb8zipGlmY8O7gekY4/So7YT3k5htUaWQdQozj64py7G0cPy3lzP8P8i/LcQJGY4XuHB4yQF/Sordo0DbbRmJ6sZv6VmavcNorGO9jkjcjIJjIX86ydO1+HUpXhijlMq9WCnaPyqNLbGsYQasnudfPcT+X+7a1VRwAyqzgfUc1UW9WLdDOG2N0AOAfxqva28ylTJHIA/AOwirmoWLQQLIAZY+rK45qNGJRpxfL3HaXe/Yp2KlpIychXPzAexrUlME0Ul7YwF7iSMxu2QFQkYJK+uOh4rMstMtr2HzNPudsoG7yZuo+h71VdJ9PuGWeOeB+hGDhhVLTVEShCcvdfvditqaMttMqkgnC5/M1yV54Tu2u4r/AEafZcwnfICMBk75rtrjbcphchB8zOwxk4/kBW78PriNmn06+UGK+UrG2P4h2/Kk2ky8RNRoubV7HPaPfiVZY8o29cuj/dY46j0NY8hee7Krgu3yKqDIUelbn2GOwuL22u0dZomZAycfjg+tMsLuy0yA/ZVaW6Y4eRwQyjvj0pOLehvGaTcqavexk/Z4IRKGLIV4Z89T3wKu3Or3A0yyg0Wwn1VzuWa3hbac/wAJ6Hj3qDWbW4M6/uZI4ZF3BmUgD6VNoeoNownuLfBlUYjkUDKn1/8ArVKtGVugV4OrTvB69DrdQvptG8PGCa2gsr64QM0MT7jGCOjH1rm0g822A8oKRGZA2eTVVrybVLS+u7pmku3dcE9+cGtS0hVp5rWJ3NwLUEZ7sFyQKd07JMwhS+rws373X8Pw1Oa024e3MdwS7Bm3HnnFd9rrtfaBB9ldpBMyjd3Irk7SxV1iT70Z4IHUD1rqDd21npMdtAsklzGCIwRhV9yamnFqQYtqVSMorVMw4naK8dbYJ5Vv8vzHqf61jalIHuGuFIDE/Oo4wa0Ggc2zRod0nLH3/wAaxrrfIvzqfMX5cnqfY0p6HXRiua563oVtb+IPCNv9o2rPEDtc9jXOL5qS+eGLbWMbOntU/wAJNciiSXSLs7XZt0RPRvUUnjXTZdM1FzF5iWMx3qy9FYn5lpU7SVmeLCLpYqeHls9V6PsOeBb6x86yZzOx2SAAA/Q1Vh1S/wDDxZGtmk28lgTuX6g9qzrAsJp4Y7nYpJxIGxkdRmh4L3U1eZL2SaRR83mOcqPx7VTipbnV7GN3GbTj5nWaF4kt9evxBerGrMvyMOMn0Nc34t0ZtMmV2BUSOwRT/drnJQ8L4kUhg2cocGunbUU1PSkjLPJLGwYGUkn3AJqY3T5WCwzw1RTpfC90UY4/JsrKIEKso84t/T9KjtpWebUJU3mWaMhlHQDOavIbi4t4bZArNCSYlbAJzyVAPWqG+VL6WTy3gLHy3Cjbg/SrtbX+tzeLve+//BO505jb/DZtwIZwRgjHVq5fQSlrqNtcsMmHMhHrWxoNzcXfh+50m+kAdB+6bYSSOorJi2xS+XNC7FMowZtmR700k6dvNnDSjy+1g922/kyXWby3vb6S7tLG4iNwhV2LDBJ69KhZbe3t7NrQqdzHO3qBgZD++c1sLFBc2M8FjmKQDdtJG7jn73pXMNM8LSM42rIPmXBxn1FRLuzWjaS5VpboXZMJNu+8hPY/mK0PNT/n9m/OslLhFiCxuHhGMt6N68077ZF/z1X8qUbNasqVNyPUtIvYNc0tbqH/AFUylSp6qehB/GvLNSsW0zWGjQHMbh1A9M8VqfDzVzpmrS6ddNi3uGyrHor9j9CP6Vu+ONNzqVjdICd8gR8f5/zmppRVN6bM4KMfqWKlS+zJaf1+B5X8RtMa8019Yt2iHkblmVx7ZBFeR+A0nm1bcDwATlR07jntmvbvFEkY8E6zAf4jyPYdq8g8K6hbaZZRpCFWRZGdyepGAAK3orlnK3T9ToqU71YX2V/0Pc9PUPppL4WQEN8pycdCK6Hw2Yp9GvbCXlll8xQeynr+oriPBmo/a4lZ1wX+Ug10+i3H2XxDaDjZMTbyKfQ9P1xUaxlYvEwbjJL1XyLOpKbbUrxZOfPt8q3qCAKw44gtiy92IAwPeuk8QQfZ7sBz8ikgHuoI5H4Yz+FY0kE25oEjLTI2QF/iHXI/pW0HoGGmnBP0/AwZYzHqMwPDKeo7iuhjnWeJS4P91yO59/0rJvB5s/nJ8rnKuuMEGr+lBZ4+BhyNjj3HQ04q2h1VfeipPobVkqvBcrnDbFdW/Hbj8a5J/D2gXdxLO9p56h9rIrGMM3cHHNdRYo7QypGcyRo5x/eBIOPr1ri/BGoSf8Jxqlkil4ktzcKGU43BgOfcg/pRJOUrLTQ4JSUFJvyO4sGt9L0xbdLOx06ALkW8K72/z9aG1llt0CRuwf7pZckH6Diq+sFobktKH/fcqTjkduO30q+sYEERj3KrqEXc2B78VPLpcz9nCMVJrcsR60bXT3uHfdGgwSwxvc9BWNZS3OtXKRQBUaRssxHb1NWNStGutHmig5e3JkYY61my3TaXaLaWETS3s3LsvVR6f41SilqaUaULN017zf3ebOpe80zRW8tJhd3+PlAHEfufeqOo6jq9uFuWW2kWVfvhTmuClUCQvNdK9xnJRAWx9W6V2nhzU0uNJezuwW8sZRs9B707jq4NUIqp8fe/6Ff7f9sibdbx7zg9Tg/h2rQ0/wC0ynMLwQxqB80igqvHbNVrW1gluirfu7MI00pU5YooyQPrWKk82tpcQyxiKKUYRAcKi9l96l9xumppqOiXc6VfEuiLfLYHVtF1K4Jx5Skb8+xGRWnPr8aW7JptvFDJ/sOgFeRaJ4EuLDXvt1zCoghB8tFx94/xHOK7S9mktY4xFbNLI/zeY0ZKJ7D1NK3M7I5o4OMmk3d/h9xq3PiKdoFXVbTTZQO0g8zj6Co7XxNo9ooaOwsQ7HB8iLYR9RjpXPR6dNcOXujKScsIxgMfc+gqvNZxMCqyOzjruA2/pUS5UdSweGfu/lsdpP4gWeWNIrSOMHB837+0euKnvLvTpURJ45WWTIBZMEgd68+jjltJlMIcZ/iRq0Lqcrp6iO9lneRssp4K+o+n0qdVsRLAQi48jDWbOPTr2OSyYtG2V2HIPPoafN/bsAEc1vcSwNwhki8z8jimL4quoCLcw2k8WQFV4/m/Ait3Rtau1DoFuLVUJdkYbiSTgDGOAT3FVzW1NqjrU4pzin6nPtaajeFVniS1tUb52K7enc+tNujHFeeXFOCigrGF4IB5JHvW1f61dXIklnVHkVvLUMcqq9yB3NczqciTarFLMFRnX5dowC3OePWle5dOU5fGkvQ1Ly8sb2CGDWrh47vbiO8HUqO0nr9am0/T9E0+dWTUItTmIzGqevvXn/i2xvL26WWEO1vtCiNT932zWp4M8KiC+iupFdZFIZUL5O0HJz6CrdlHV6kzjKKcU2o9V/S/JnQazetfzujP5YwVKrzyPb/Cs7+wryNPMa0mjibjLDBP4V1nltYarO2m+VKu8OjbQxIYdR+ZFZepalcSyM2o3UzeiA8L+FKUXuXSqyVlSWn4/cZ9pbpaQNEyAPJ2k6fgKuXmbSXT9SgVCVPzlDjI6cU37PuiE8hJUkqzKp9OD7U9hi2jgDxsjAABucYPX2rJXvccnzO7+ZauNGvFkEtjGZbaU745I2GQD2x1qgLYG5eO7uo4ihwys3OfQAU2B5NJ1iO4WeNbZRuYHOGX0Ga3LzUNGvZZc2sH7xl/fOOuRngr1/GrU77mftKkXZ6q26Wo3R0spLtlhV2MQ+cugH4fjXGXcImu7tjlf3pXJPHtXrNhp1tcaW09lH8zxkbt25m9vpXmmmuBNdWkysyyZU4HOQeDT5k4hgq/O6ko9LbmbYRPp14ZBIyTJyCOP1rZW/1a8ikFyZprVuGLcgehHemarZNaxw/aEPkNwk6cj6GqiBfO2qHCjo2ev0NZxVtUdrcaq57JvuVjEwudiP77qt3jySGNLGdiYxl/MO3d7Ljmm+dbm4CXkTblP+sVuT9RTNct4IpUOl+YIsB2dm/SquU5XklJf5ENzPNblHmU+W33c9j9e1XLBrWeQKwEcpP3t+Rn8OldT4Usk1uyltrkCVI0Esb+XtOe4PvXK6lpedbltbQsGGQDJ8uWHbNZp3V0YRrwqSlTejRfu7K5tJfJuEhAkHyEtnPvntS6XIpuGttS3bnG3cxyfbnvS6fJJsXT9WSZEPyRynLeUf8AClii+0tcLNbq9xbceZGfv+hx61XMQ5OzjL71+ZrWrnSXkE4k3Md1vMvOB6H2qxqs0WqQSXsY8q/tQPtMfTep4DgVhx6tPJBxJGACPlZMkYGD+YqhYzeTfuV8xlZWQ5OOGGK1ulqZLDtvnfxL+rf111OitrpIo7a6ZAZEYxykdDxx+Yqe60WDUWP2WQiP7y7eQARnFYdlKsdlNFLuMj4DexU8H8qu+HtYGnanb+c3+izDynDHjHrWcnaN0RUpTjeVLdfj/WtjOeyn0u5E0Uat5Zyu8ZV/qDU3/CRyf8+en/8AgIn+Fa/iazuYpZhBH5toSD5gPoP51zP2M/5zQ1Hc2punXip1NSvcsxSC5GQ6ny2I/Mf1r2SzePV9AsryU4PlCQn0YDn9RXks8f7m8jx8rjzYj9Dn+Wa6Xw1qMt34ffSIWIOSvHXax6fqaIe9G3UwzGi61OMo6cr38nuczdWZ1PR5xKSguGcjjqOuR+teKaloN1pNzIZ4maHGVkC5BH+NfUHjKxj0+DRobdFyGMYHr0rx74u6Pc3sULW4BWAbiEHr7Uc/LPmWz0KVVYmnzxXdr8jN8DeILOO6htFkm8yRvlLDAJ9BXpc8w+2RXEP3gQ4+oOa8W8OaBc2rWurXM8X2YP8Au0DZkYj1H8I+tes+Eb63u/tD3JASFBhT3JOAK0qrVNbrcqnOUoc816eZ3/iCJdUsYr6DjeM8/wB70rzfxZqxto7Is8kT+YVRlOCBjgZ9jXoWmuJvCV0hLRiOQmMn07fjkVx3izSR4g0+4s5IFgnwssDD/noB0/H+dQpWfkc+Fbp80P5W7Eemao+t2omuAv2qJfnkAx5o9T7+9XtGIXUyoOFY54rj/BYuYbORJ0aM+YUIbrx2NdNZvtmDg8hf6V0PRneo3ptI6XT0mumvpLR9l1bRCRMfxc9D7VxvxG199It/t+nERC72lYugDEfMPzzXefDhvM1S+zzmBOPxNeYfFfw7eX261sxukt7gsoJxhCeMVnJrmV9tPzOFP99Ugt0lb7v8ySH4h3upeRbahpMPmKq4eMHLj1xXdwQNqVoFjldJFTzArEkAelYtvZw6bpljuiVrtol3nGDjFOimuY7hJopDCq8iTt9Md60vda6G8aV6a5NLHXQSvb2NwZwI5JIwkkgYYyO+O1chf3BmP2ezSRYnO07OZJz6Vty30N8gSGOZnkABBAG71I9qtvJZeHbEXEZimvipVXHKxDvt9T71Kku5hSfsX8N5Pp/X9djN/sqewtlFy9vZjH+qRQW+hJySaoSagmlQ+ZcDzUkbcIk4aT646Cp9MgfU4p9Z1qZo9OgOVjXlpG7AVdtVsZBZ3E6ZtlLP5TY+bHTJ9Bim22tDWUmrqer62XXe1+5b8OaVd6/YG4uJRZl87VUZZI2/hx05FbVvZaF4Qt5J5rjdNjrM4Zz7KvaptwudMea7+z6bbzc5387fXjvXF3cWkRGSfRne8nQ8ySD7h9cEYIqVC+558IzxMnGTaj2S0+ctitdai2vPJ/at7dyRglkigcQog7ZxyfzrMgtXtLKRbO7vMGQMN0pIUHjHJ59a0TrF1dFY7u4inHTy5I1YD2GBXGeIW8RaprS2elxTQkPiGCJAF+rZ6/jSaTdk7Hoypqivht6f8Mj0bT7iPT/D+6IRXFzI+JpXTOPYUxvE6CIxS6VZzQ9gGKvn1JFWNL8PXWl6TL/bElpGZEG2BX5Dd/8AIqmdM0+CJ5yZpCuCEwOPfjqKUbW1MKbw87t6676/oRjWNMlc/wCgtFnGEeXgfQ96t2dr4f1UGOZ5rOYn5T5gYH6VkvpM87+Y8UsadeVHT6ZzWaqWszgRTllJyHCFCKT0Or2VOS/dyafk7mzeW1xobmC1t7aRuSLnydzkexzxVa0XU5bzEolaWQH5pAVP58GoINbv7O8ktbOeYxJj55VBI9x1rM1JtZbxPYXNkZ5o5XCybWJDH3qd9LianFXkl6m/MWMyq8TI23GxvXuR7VGLMXFzF5yrmOQIp9Dnr/OtS7ttixMHEoicqZOvzk9/pWXJeqkaskYVgcc85OeDjtU2sOEnNe6XdaEF1e3bWqBCiAFk4GcjGfejz00/SHjVzJe3LhSsZxtXuCffI4qBLaRIbeKaTAmPmsgHAA7t6/So9RXd5j44DeZg9QB/kVpdJiUU0oX0X6Cm4v8AQ762aJQssbeZsLfeTP3c+h5q744/sqKKHXY7gw2d2pZ4wMsz4zhR6nv2qnI0l4ouJlACj7xPOPpXF+JdZ0nVEh0i7vnsVjyALqFljz03A+uPoKun70vIzqvkcaidpbPs/wCuhfTxymqazbWelW7RaQ8Xkp5ihZC4GSxwfXjFbV7I0Cw7QQrR5BI9aytA8IWmj6bbX1jfRao7Pg3CY8tOPu98HFXrouVVQWAHAHt2BqKj966WhthUnBNO5Su3M9q0bsW5ySDxVVbmPTLGdp5iYo1MkhxkDA6A0/VbyDS7PzZo3z5gBI6VPNbQX9jKjQiSCcbXQnsaUejlsdUmrPk3/qx0fwc8YWOsq7Wk0gjiDJIkvy7eNw4z9eazY7ea/nv9QtQ3yTF3AIBTJJH6VjaFpdh4athDokToJmLOXfcx4/8A116DdwJpfhHOGjurkiQ4HUYx/WpjLW3dnnQUqElKXxzsv8zlpLy5ZH/0iUxscbXGQaryo3knKAk8gqMEAd6vR3PkszTIZIowGIH8bH7q/SujktrGSRLSZ1a7YAyzL03dkHsM1pc651lRa937jzyeRwwwQcj72OaguZzKN2ORxnOK1PE1idN1FoX6L83HfNUnhiMIkiG85+4T29aykmpWO+MoSipdzo/h74tbT75LW/ObZzjf02fX1FdFrOkDV9Wu0hkUTHDgKcCRDzkH1rzoQyt5XkhQgPORx/8AXrudOSbVLa3lsJEjv7RAHiUnJHYD2qU7XPKxVGNKp7am7N6Pt5E/hmWyt7hob8PFdRD94spzvGeoFaGpWulaleLDZEwXUg3xupwr+x9KptqMOqWUr39uIp0+WQxjlcd/zrnw1zb38azMfJLZSVT0FNK2xzRoyqTc7uMl56f8H0LetaK0SnNvJbXEYwzEfJJ7g+tYaMI7vEgLMcGu9bVP7Q09rC/x533oZQerCuR1SBZYEuLaNhPCMSL1z7g1oleJ1YWtOS5Ku5Deur7nTdkc4xyCO1NjMU1uY5Qu5WLBW47f1FV45Gk3Pv8AlK8/4H0puwWksckhcwSjlh2qG7o6uWyt1O28G3UN2sukXW4JInmQCXB49AfUVrf8IuP+eR/SuTawMdnaSWhIliXzRtY/MD1Kmrf/AAk9/wD89Lz8v/rUU+ZK8VdM8mrRqyk54d6Pdef/AATLt4GufCz3ABLwMRn2IqT4Y3CL4mVGPyvGdv1rb8BW8V94e1G2ByA2CT6la5HwzaainiOJtKUNPA+XU9NmeaKck6jj/Wp2OUaka9GTtb9V/mdz8W45l0qwu4Mj7PcAlh2yOD+f865tEt9ctpRIipPPhGIONsmOD9DXf6/cW0t7FpmoqrWl0hRgem7t9D0Neda3pM3he8jdJDPaM37uTGDwfut7jrmqgtOWWzOPLZqVGNF6S1a81/w/9bnG3fhH7B58URkDl9zLtOM1N4et2gmNu3CFleVmHJGcAfrXpMdzLqKrBaywyT53qk2AzcfdrO077FHdPNJZCC8SYcv8yKRnLFfbrih80fiZ1xrNRacdV2LWvXJhRNOjhMUIUyHPBAAyWx+g+tJqakQafdoChkhUNk8ggZBrzJ/iHaXetXySB5UDSRxuVwXwepHbOK6fwNq9zrfgOyvLpzPO2oXETE8lR1UfkcCrhBpOTXZnEqsKcqcE921+F2a+rJElhDLHGoa5upJdwHoMEfnz+NZlueHx2UHj6VXtr159O+zybyYbudwT0AIUAfXvVqFQJig/igU/+OjNUj1aSag0/P8AM6n4YyZ1m6XHW3/kw/xpvxDtpbbWrW6tiq+c4Vi3QD1rO8A3X2bxLbhjgTBoT+WR+oFdp48s2uNNEiLlo+cHpSktjysRL2OYJvaSt+hwJjunlYXisqx8KD6e3tU09pJE0T3EZOV4Qtyoz6VXttbkKrEjqXAwAeSo9q4KTxTqug+OsT3BmtGcI8cpyChP+eavl52o3O6rzwV2tj0tJIljRXiVQQMhjgD39RUOr2rtasZgFLkKgxyF/wDr0utk2mpW6YyWAkRvY8j61Y8QRtHY2l07sYXOGc8nd1xUJNEwdpQa6kr4fwjbWsaHJkO7ik0u1WFo0uNohhjaefPQLxgfUnA/Ci01KKTSUiB4jkwSe4PcfhV25td+qeSwDW0xRi4xtZFYnFVpfUxk3HmhLS7b/r5GVqi3muwCY/JGMiNOigelQafb2unKJroNMfumJW2q3scVuamdOO3dcXRkDYCI2FX8KrzPplxbK91FcbYjtARwox34/rTfcuFV8ijZqPkTad4mtzIkMOi2cKE/eDDt74yDVHWr+0mup3t7SdJwPvpNjn24yKpwa9oV3qsekaPqWm2kjA5iuctK5HJOcYH0zmtxLqGwmMa22n3MhKhi0qsV+g6gd6hwvujmUqEZ80Fr25vzu/wucqgdLgShpJH4+aUlvwya6DS9cNku+S1hnQkDIyCB3GDwasahrF3cSGOLToZLdcARmP5R7nFZ+p6pcwSYhcb1HKKo24PpxU8jWrOhp1kozivv/wAiTxTZXGtalbXumW4k0+cbJDFIFeJhwGK9/wAKgsrK20118+eIXIJ2tNGRG/1680y9afT7V76885YHXeIYuJXwOjY6CuQ0T4jfaNYit9RtXitp2CKpfeG4wAc8g+4otKSv2JTlGCpp3j0/yuduLS3lU3zCy2RtgIhJZifUAjP40sEuDIVWSK2U7WljxvZieijoKqXKw6hfb4kaOGIYVQMkADmjUxNdJAPlbIIEanAGMZP1qUy1G9lJ/wDAG+ZCJfLt/uRyL+737iwHOT2Jqpd2ircmWTGGc8Z5Udce1S2MKaNoOo6zOmDariPvlj2x3xXkeq+NL7VJWhlwlrI5bKDaxHPXFawpufvdClWUJ2R6trWqm00aS+t9jzFVij8zJA7/AFpuhapHrHhVpZwIL4yMCOw2nJ2+xyKzPCdodU8ITJdr8sYEqMp5UA8Y/CtS1ittPdBpjO8KEHDDJ5HzHPvUNpK1upSh7zt0JrJvt9s6+YyyHKnsoIHBPtXNa94UsdT0+OPUGnW6XCllXDd8HJ4I/CtuIsJZPsqtJvyORwRzU91IJJYlk+bcoBYnl2qU3HY1lBN2ezMrwPoWmeFre+sIL2e5hvlG4SrgK46EVJqMFylndpHnz1U7cdT9K0JEiJuYwAQhxG54I/LrUdm218SqWI52McZ59aqMmtRU6cYQahojNisJda8Hz2+or/pC27EEjGH7c/pXEeEl1qO6uCftJsbWM+eJFyqAdOfXPSvUru6do9ihdzNkheh9qxPFmsy6ba21pFceRbvKXmhVQWnYjgE+nSiDck4W3uzKSlBqZR0O9aaKS4ngmQH5U398+hFdzHqT63Y3Vq8J+0W6I0OzoQB0/KsQHZ4atrmJVBWbbJGxDFQRkDj8fyq54ZZF8RxTRv5b4AO0cHNZ9eb+ty6q5o8/WP6f5laylia4ZJMGPfG4H0bH9a0DF9k1y4jnJKSkkHOOCRyKxtWOL64KgK3mMwIGOMmuql8u50/RLu4AZJVKyH6YH/161krScSq/u2fSWn4X/QofEKxi2Ws8DNIQu193Jz6VxMYlchII2cjrg4wK7rxKPJu/syvvlAzk8q3bn8KwrTRbg38bRJtRyNwznaP8KzmrWZphKqhQSk/Qx7Uyn/R5Mg9RjvXQeH9RfS9YguY2dkT5ZlXHIqB9M+zzuWyNhOBjGQKi/s8rcW7LIIknfo361Erao0qOnVi4vZo6yGSwjj1i7vbqODSuZDLM2NgPB/px61zMmpJNZW7W8r3dmw2x3Kodp9OSKy/GlveXWjz6Zp8azmS7jaRCcb0VuRXtcOh2cnhmHToreO3hEY2Ig4Q9ePxqnJR5V1d7+W1vmeLPEPCVb1FeLtb7tWeYLdyXET+VlZIAHwp5AHcUyS8aJ2mhYoki7ihGcN3puu6RdaLqckTBh8u5GznIPv3FZ8jliGbARhVarRnsQhCaUo6pmrdASQJPbrm2bgngkNUCvL9kjtnClEc7WI7dxUNq4imRUZgJPug/dDdjXSajpGLFJVfNwxwVB+XPtUpu/KZTmqbUZddihpV9/Z0kcT4e0GQEY52Z6ge1bXn6J/em/OsG2tFklEd4DHKfk8xm4Hvirv8Awjp/6CUX604S5dEYVVS5ruTT8up0eo3+ieD4JLC0SQXVypbamWI4xuYnpUXhW1vtO1/e6R/YLmFG3llB+7x79a4R5pdY1GaeQFpZdzHdzjAJAFbeqXzx6rpFwrt5P2O3kC5444NKjHTXqZPBOMPZ3vKS95vX0t+g3xVLqEGq3NveNhvOM0T46jtj8OPwrcv5ofEvhKXy0P2uBQ7L138ckfqKufES1W/8PRahEAZLVg7Y/uHg/wBD+Fc54QvLa2mh+0O8ZZigIGQQ3BBqk24uL3RNOSrYaNWKtKD6d1/mc4jyR2dpeRsyyRvgP6EHg/yrqvEa/ajZalbBFTUYgJc8ASDg5+vSse1WJNOvbS4AMUN+FYZ/gbIz/KtvV9Pu7TwbPbSISbaQyQuvWRSMjFOS93X+v60OvEVEpxezvb5P/J2Z4Lq/h+XT/GEUb27fZL24VkkzjGTgivR/F8Y8B2Gk+GfC5lLCbzriYnLM7c4H4fpWt4Vkt9SEH9oxFXeRXVpQCY27nmtvVTa6jDqbywhpYJEliYj5sZ2k59hVQm48sWtn9+1vuOOVKLrKTTt+V3/wX/VjGvhHJBC6Lje8ruAMfNtXNRWfN/bA87o1T81x/StLUrYQosfG5ZX/ABBAwaxlcxSW0n9wgfk3/wBeqWh6VJ80LL+twR2tbqGZDh43DA+6n/8AVXs8xj1TRRIP9XNFu49xXjmoqEvJQOivkfj/AJFeo+BpftXhS3Vv4d0f5E0SXus8vOI3pwrLdP8AP/hjwCzstV0/xvJay20vkI5TzHBC7eeQe/arfjTw2ut24aBAbuE7kYHGR3Br0XxLMkWqMXXejDaQfY/55FZV6Ymu4TbyM1uy5IYYZD6E9/rUuTdl1R20pe0guZaSQunSXsvhXSodY8lr+1wDKMFgnbJ78dq1LW+txNNYaom3T7pAolH8BHRvzrO0+MTfui22VidpPT8atplM2l5DuT7q8d+xq29W2ZunCK9n2+/1Xoyk+mzafLNbPhkPAk6K47EVv2J81NGtgmH2uzKvOEzx+dZV5d2tlG32p5HWLapBHyjP3Rn6Vq+GZ4/sOpanCoeWGDzImxwAAePpxUN21MsRUbp80t1+b0/Ux9R3WO13s7m5MnzkxplVz/D61DLr+mtYPZvp14sjZDnOOvoDXilhF4q1fxTc39r/AGm9+xDCSBTt5Pc9NteyxJ4qWW2XUJNPaMACSOeRX577cnNXLXZ3FGbnpNbedjB8B+FvDWl+IRqVjDd3WpRsWiW9dfKiJ7gDGT9Sap+IPA0Gta1ezXGtGLUZGaTfHEfLDE5AI7DHGQeMV6FaapZ2Nwv2nTbco2d5hYZX6Via/wCD5L2TVbvwfq8K3RjEkdnK+1vU+wz2NTDmve9iJRp02+aNkybwpo15aaJBp+qaql3cqzCN42LMV7A+o+tbYsbW02zSqt0RgEO2OQc4wK8jl1LxlpDpFr9pexQM4CFlygz/ALS8V2nhGbW7+2ZZbO4PQ5eNiQeo5+neqna29y4O8bJ2X9dTobiTzluHvFjY3ByIjkAj09u1ZOleFdJGordyRWRYNkF5eYjW20aQ7kvpgrPjdEqncOe+eRVHV7eyNtvtLcJOCAzqd2awbu7lRd/dWly5d3cBudkJle3UEKyycE+3HFUYpYoAxeISqOTDkqetLHsiHkyFtoCtuUd/f8R0p0scVtdbkcuT/HjoD9aroaRjGK5SbVrqO60SG1SONY59zvAV3Y54BriF+Huh39xtaX7JIBuZCDkfh2rt7KKYXKNBsWQ/M0jjIAHJwP6+9UPE+oaPpl/JLqF3Ik05DOQhIQY4Bx39vSiKk9Imd4w9xevcsNY2+nWiaVpuWAiUNJ/Ae2c+lUoYnjSZJoykMK8TucbmHJ2+2M1MJExC1pLJPZNh0YN8r5GflqtriK8E6PvZzHl/m4GTyP5flUrfU2he1k9yGx1rTL1VhtmkhmydjGEKhH90981a1GWCS3WNVTzxIMvg5KgcYI6fT2qlpGii0lgdts8rDfFH/CPdvStBbm1FysT38kc4yzeXDmPPpTdnqh2S31/ryJrxoryE+UgUlFUDHQ+tcF428QXmjaq9lZHY0cYkZigYsSOcV2ct3Zx8XjSo4Y4K8A5HFYtza2Wo3sVzNEhEZC+Yf4vrTp2h7zVyowb91aIq+BtXu/FdpIkqRRSWy7jcMNisPp61Q8WWTtqgvrWOSSEKkbNkYXAzvIP49K7TSIkSdxBCsVvMrKMr2x1+mamksrSWCBNzqcBZUbB555B7jilGbTbSE7J8snseV6Rf33hvxHNp11IUsb8BlLH5SeoYfjxXoOgWF095A6M7RvcBQ2MDn/8AVWX410S21yyTy44op4SoQseM9CPpW34Mje31e2jvLhM2UCysu/OGHT69KKrclzdeoJyp05Jf15D/ABX5M+vRQWsbRy4PnI38Ld66fwJBBrHhhbK5JDW8kij1GCOa881O8ibXbiWO4LymQyHnnk52mu1+Gtyk+tbYcoDGWeM+p9KU7qV+xONg1hFyv4Unfz/pnPX19K2vOxk85o88EcH0FdRqOn3Vtpsd5athI4wGI6jP/wCuuU8W6XPpviefKMsDSmRWHdT6V65YWf2nwyltIgjMsOMemRxTk/3nl+hlj68KMKVSGqf5HkrX814qLPlfLBQt0LH1qzD5bxB7hJCNhzt4xVC2Dw62IJVO15Qjrjpz+ldGtla293KWuWzG2wjORk9B71nKPvNHXWcafur8CjNGbqyhuhIYLlAADjh8d8+tdB8N/EN9danf6ZqbGVR+9gl2447rXP3ImxGgbauQdp4yKR7r7BbGWAzrcxuPLcY+XHr603F2sjmr0FXpuD67eR3njzTTe2CTRgebFkdOo9P0rym1ijKvBN8pzlW9a9k8Pakut6QrT7VmZcSIO3vXlXjDT5NO1VkYbdr7lwOCp6Gqi+eOvQxympKPNhZ6NGXt8qWSMlgB91jyK6Tw9q8mm3tra6gfNtT82xgDtB4BB9KwEzM+1HQB+m49CO1ETLHNGuoeYqKwOQOVGaiVmj1a1ONWLjL/AIPyO01uyia7nsISPOCNNEc53jrtPvXH5m/un/vmuk12U23irTZYG3QsseG/vBhg1c+xReorqounb3+y/E46FVUYR5tbpP8AzOd8O25upXFqFF0E3xr0DleSM9iRmnajDIdOiO1s2mVweoiY5Gf91sipLe5nttZhMluivE+woiY4P0+tauj2zSas1g6MY2ZkQuc7omHKkdcD19axitNDSpUcJe0e2/8An+H5nRaBKus+ELiFsF3haJh/tYxXA6ILSWKJLy4a2YD5ZNu5fow9Peuh8K3n/CPa9c6fcP5lnMcJIpyD/dYfhwaxtetrKzvbm2jeUckxnjHPIz7dqbV5X6M58PDkq1Ka2laSa/Ey9QgNpq80TzJLDOuRJGcqT2NdtoOuGTwljVZVEbyfZYpCMcn7v8q43WY420+3cfJJGgDL+NWPGWk3ep+EbHStDlUln85uOBx1qU7e7La6LxtqlKMXvf8AL/PQ5208XxN4uHhtNJlW4TKm5boMc5x6e+a7XQ5pJdYtbdLfcGbMsueFXvxS6PpktjpEl1ePbfakIUXEkfzkAdcgevrV7Sp3TSzMFRZ5LlYXfG0oGX5SfQcmmraK2q/Hz8jDmlyzu73enlf8yLVo3mn1HA4hYzJ/u9/0rl7r7j46Bzj+YruNLksbvUZ7aIySM8bwSSyDG4njI9sjj2rhnybTDDDh9h+o4NapnXg5bxa2t/X4FrUfn1Ap/ejDfmAa9F8AboPDTu/3PMdlz6V5m0wbUfM6hY1XH0AFerLbNYeE44lIXEW5uO55ob0OXNX+5hSfVo4jxZIs07ImCC+9Sf4RjmsHzMM7sCM8CretPuXcGxjIPuM1mNMTEqp0HIJNJ7no4eny00jf8FgXuqTWso3MYHZAe544/Krc1x9ms5GuYQ8lqGZ1z97A4qj8Oo2m8ZRMMgRRu7Y+mP61c8WgL4pvIhwkqgjHrj+opbo5KqTxTp/3U/0/I4C11K58b6Pq0lii2ht7iNMSsSCMdsd/au90eaXw2lnHbus6tCgJk+7Nk4OD6ZB+lcV4EmisfEHijSHjbY7LdxxJwxA4JA74zXXTmOXT7MQtJNHDOzKnl7WjyQSDz04/Oq39Hb8kZwXPeE9dWvkdBJc2eoaels9zBp6pIzbIpQFP5VnXvhmW1KN59uIn+7Mx+Q/j2rz/AFzTLt9QU2yNL57blCj8/oa6Gy1rS/D6xQatq1wZSAv2eJPNCn6U4O6SiS4yw69yWna1zZk0vTbeJ5n1aGaJAAyW8ZdifQGvCNffxbrnj6WWw029gcP5dukQKCNBwMt06dSa+hE1yC0t4WsbfzzIxdBcIEAHrtH9amstee/mZJbRYpkAZfs5P7w9ApB9/ShSqLWJjWhWqxvK9l5pfhY5DSJ9b01kti000sRBnAUyR7x19qxPiZ4v8Q6XqtpLpM7Q6dMu5ogSodu+4j+lehX0OrxR7RexxW5/5ZfaBHnP15Nct4h0mDW7X7HqBKEHKyrKDtPvmiN4vm3OlwjXV9L+QzQdS/tKwtb6NmRrmMYVzxuPXJ7itW4WWzu/InVI50I3BenrmmWVvp3hnTbWGzYXd1EmyNz9yIevuat6TpFxfM+oajL5FsvzPLJ/ET0A9az5Las150o889F+Lfkh41A7WFzEs0fXIyh/Sp7bU7VkaKVRHF/BGqbgPz71Bcm3t55DGyNbICTN1DkdsevtWRZCDWr8BZCg27iIxjn09BVtpLYjkpyV2rf12Nhpp1KLblbi2bl9pKnGehHXtXAePdAvNSvJLuxLTSEDzbZ5NpUjowJ9hg129xa29jas1xvcJkq/mDczY+VeO2f5VQhvorGyD6grzrKxHH8Z9M+nrUqTv7o+SMo3RT8G6JJpHhi3iu5RLNuaQxBjhOc4VvT6VpvaxvZwyxERJKxLB+AAvYevNTag03+jxOEDSPuG0Y4P+cVffyp5AJBHtsQQyL91ccBc9znrUa+olJwSsFofsum3Op6gh+xW6BUgzjzpAPlT6Z5ryPS/Geq634wmsprG3RRuPlwqVEQz09/xr0rxHqlvttopkubqFMlYxwm7uT+PYU61MaedO1hbWjOql3EYXOeQuep4rVJqNluxRpzuquz/AAt29e7+RQK3FjEs7CK4gLYMTLuAPpn1+hqtLPaTThbGIxCcgNbnJUY7j0rTtp7m93GKPz1TO3jAxn0FZ1rK39uW8iQJ5pk2bBxz3OaiS7HdFXu2tV/X9MqeML59NikjiuSCAsQ2sflA5wO9bfh0JqXhtbjOZBwpzyK5T4jxFp7oMoZhPjn2ziqXhnxRH4dNhb3ETi2lUl2HZieM1Uoe6uXc5al0rp9EdTeIv2VBLhmckt3wOxqXWoTYafaXSri6kT925H3l9OO+Kt6skEWjadOrLJJch5AV7r0yajaUvZRTOGnkSIBEJzjjjFRbVM25uZKS2uzxm7uNRtvGkU+0+VfPwD0JHBB9K7U+IL7wfdHUYAruGCBD0x3/AErRl0eK6nglaENKDuUYzyepFZ3i3Qn1exECOBJGdyM3TPQirclOopT2EqHs6c4Rd79PX+mdlpfim48d2kAkhiBLgLg7TnPTmvZ4xsjVcAYAGK+efDejW+g6LC1y/l28QLGZj8u7qa7n4X+O7fXpbnToTITAPlZ+uOxx1rntKSdS2h42ZYdcsYwt7vT8zgPjZfXui6pdX+mMyBps+Yo+6RjP60eDdTutZ063v78hPOUh5AOGx3IrsvEGn2WurfaFfOEaZm8mbp8xrhNG0i+8OadNpd64/wBHYqpHQjNa1rOMUu+v6Hp4Xnc+WT05V/w51ds+LFrkFpo422OhOcr6qfUVfim+028iI6lEAIyP4fX39x2rmbW88pIWiYsh4kRuje3/ANerUTtaTh4sm2lU4+h4/wDrGiLsdc6G/wCBp2l/daDqKSxJtjDBjCc8r0IHtXc+IbW08VaB51tsadQWtpQ38WPun0+hrnLKNfEOgvaEAanbIWhz/GB2rN8GahJBNNb7mUuP9X2fB5GPUUmuV86PNr0vafvoaVIPXzX+X/BOXKyJvEp2nHPeti80yaKwtLuZtymEsqj+Jc96L23R9RuDGgEPmbjx/DmtGST7fegyuBE+I7eM5+6P0qJqz02PRq1W3GS26/5GJcXUskdpMSS0bBCOwxyK1/7T/wCmg/WsbVXhtNQEEJ32+4jcDkfQ1Z+z2/8Az8H/AL6FErK3MDUJxTOjmjaykFwbOe9nIysysBEmP14HrXHaR4+07Rtajj1GZZI5JG/0lycZOQRnsOetddq8VhGlzYyn7Etzt/dm42lD+P61wviX4HX15ZIml30AYZkBmfg554I7U4zUGnNXj5fj32PKrVUqLjdXe1/+Ht+R22paOY9JtpdJma6FsxbIIZhG3zAgj7wHrWNrN7FqOqrOQU3Iikf7Q4NN8C/2v4N006Xc31pPPAeFj+cIMep7fSrnjPVray09r+8itpZXA8qSE/xDsQDgVpUtGVou6OjCVaq5XWWr8++r/wAzm/E2pxW5+zF928BBt68mvRtKtLbw7oTG6kkkuGRMKOvP8Irxv4YaJf8Ajrxl/aV7uXSrRvMdsYVmHRRXrHiC7XVL+5FsQyxJgMOgIpuCSS67sxlV+s1PZr4Vv/XmNvdV+2FbQ/6hcMIRyScdz3NWLpFh06QRABbuHBH+0pyrH361k+H7WS+1+xd1AiZiG9gox+tdD4ljWC4hVFG1IwxXHAz0FZLV3KnywqqlH1/r5nI/C+eafW7iWSQsC8qBc/dCjP8ASotTOHVgMCW4kkH0JP8AjSeFWttN12/htz+/EUsrsOwZeB/n1qXWk3XVnAgGdgA+pOK26JnXQVqzf9df+AR+HYftmsJEBncwz9Nwr1bxbc+XYmJcAk5P4dq878CRBvEUo6MsLMp9DkYrq/iDLtlgRD8yoZHA9OAKLaJHFj17XGU4dlc4e8H2hZo0GfJjMjkegI/xrJfjaR07Vu+Fmil8RRQzN+7u0eBh/vDH88VSe0aEyWku3z4WZee4HGaTV9UetCahJwfk/vudZ8IrcG41W6I+YBIgfY5J/pWH4rmEuvXWNweM4Bz0rf8AhpdRWIlgk4a7m2oT0JHasfxJps7eLb2MRnDPujwOobn+eaErfcedTdsfUlLsrfKyM3UNLji8VWPia24uDZltoHBYpg/qDVefxNqGj6jbLalJICFMsEkYYEnGeetbd0225tkZceRF5YIPQg5z/Oq99o0VzNNcZP3hIoA5APeh3W39f1c1jGla01v/AMMvwNqV0+3YtIfsdzMNzqkhMa/KCcg/Ws6Dw5ZS3730EK3V6Dkyx2ZYKfbPFY3jXxbbeDtMttQuLMXt1qEjGGFjhBt4OfYYH1pdJ8e6xqltaXcl5DYicfuoYwFH0APWqUXy3ZyRlKUnTp7pa3/4Zs6LUbQ21s0jJceYGw0tyuwsfRVq7ocUltaPLeIVibkOEPPtx1FQp47cWnkapYJeP0Lg7Q31GP5VDbXg1i8ggtra6tInO6RmnZo0weoB44Hajn01Kkq3I41Y2Xe62/P8DQn8NperLdX1xMGkO4sSqjHYBTyKxtQ0T7Jb+dbXMU8CttkXPKg9CapanDd3F/MY7e7aEyEKSGbcM9Sf1qa00ueOSCM+Ys90SvlgYVUOc7j69PpTv1ZvTU6aUpVPlYs2drDbzBrhDcXCYMaKp2j3OeKzJ/FNvf6o2mi/tJL+AEG25Bx94kDoT/hXMeOfHeoaNJHYaTIgkEIRmeIN0bJwT69K1tF0vRvEMqeNLaAQ+IFti1zZsrKjPjBdce1VJ8sb9/6+4wqVJqotPm9f+GNLW44dR0S6jtXa3u7ggjb90HHUDuPbtUHgDRRpxaPy/Mu5Cp+8SM5x+XJqbSdl7dxtPGYUI4CKSBxwK2fDFjcvre7DRpGGLTEYQD61jzXVrm9ZQhCT626/kU2h0i1Vku5WkdjuaBQw4z0DVTe1PiHXrWNIVt7WMqscS8hFB5rm/GHiq1XXrtNLCywK+xnIwCR2H+NdB4d1QiG2vrYDAQykntgcfz6U5xlBeo46w5ou8rdeh0muWovtfilgiZ4IlOGTgJszgfXNZlrBItiFf5E275GbqWZuuO9bsGrwaT4fW5+zj7Nd7mfJPMufmIHcEc1zMmuW98/7iaCdGbJx94YGAMdu9KKv73Q58O5v3LaL9BJmXVfENlZwkRQl1gTPp3P1NXb5hrHiOWGzR4bGB1glJ6BV4z7ZwazftdnZ3kN+YQJEkUxIDxxVjV76fykso4d15qTiSVVGOD0Xj2qt9jslGXMlBdLa9O7/AK6lifxbosd2dJ0W5jkvIRtkZejey+tN0jT5U117i6X5oEafbkZOBXkXjSO50jxNpl7YJFFJ5wgYBcr1/wD116XaX8hvJt/yyKpUgdChGCKUnFNJGdKlKKnTW/V97/PzK+qRR6tdSx3IwJSJCB2Oaxtc8PQaoslrG/lOg2RvjoRXS+FB9p1i5OPuQs49sdPyqFpovJknicMS6uxPUqc5x+NSm23JM6na7pW6IWCJofDenWc+1ri1tGtyV6Mxk6j8DVy2BaINHH80Vl8pXsw4Jx64rmrfXbmXx7caFLHGLdIvMR89OAefzrVvdcjsQ1tBHHNIVPmksflz2X3q1Fp8n9a6nLCqpQtHu/z1L1jp8lzfwIv7tGILNn7oxk1Q1ULGyxWqb1jUrvHdic596vx3TfZ5zM+wEIfl7+uTWfb3KzwSyGHyyx+RUJwnPSs18NzePM5anFeJdJ17U447GGSV4i3I3YArp/AXhpvCpEkMzT6pMuG2DKxrnpz1NbltNDZxvMBvcL8p7bvXFFhYTTWj3yT4uVbcIg3Jxycev0oqTlNJN6LoZSpwTc2vLX+tjsPGmm2v/CPNqtvmK4QK+7GQfqK4zUbISW32gXCNLIAdp6tnuPavRvF6CbwNehenkBx+GDXkrXB+z2bSEghgF57YpR1jF+v6HPlXNUpXvs2vlbYhkjPCKgAUYJx1rQsVLabcxyLnyT5qe6nhh/I/hWvrNnEstvNBjZL1XGR07U/QbPfdbOfIlBUn07EfkaUXa1zuliU6fMZOmX80AQ274uIHDg+q961fEFni4XUbT5I7n94hTjZKOTg+/WubvYZLDVru1Jw0L4U/y/Sul8P3X2nTZtJugDvUy2jf7QHKfXFX1sxV48jVaG3X0f8Alv8AeVWuo5bDzWk23UhKtuHtz+tYOtpONOEMTSJITtUofujOc10N5HDFprKnlhfMDHfweRg49qrvZOZlt9Qj4A/dvjcCp6NkVMW4avdEx5GrPYx9PhNteQW+oSl4ZVAZnXG1vb1rr/8AhFdP/wCgmP8AvyP8aqPobXV3DaN5SzRjOcEAehHrWn/wjMX/AD+Sf99Csry6HPVrqNuWdvlc8q+JUOq+IorWS3Xe4UCSYKV3t9av/DWTVrCzu7TxNq0xt2AWCF8vt/HqPp0rvfEt3JbW8OmNJ5txtBZiAAvsPT61jR6XamJp5FmmKjO2L5Uz9auhOcIOCfuvoONCjVUatSLTW1mWby0smhaygnlXzVJEpwTn6D+VY+teD7TUIrG1v7+ez0q0XMshXDyk8nA7VoFf3azQpHC0LAhBLnP9a6G0/s2Z0udZDtFAu/7MfmUn1Y9x7U+Wzuh1lyLq1r6/1+BV0y7in0iPQ/Bli9lpSDa9zKMbvUk1RnngtLgWdm4lWMbXmHSRz1x7UeJ/Fd1qmbW3As9PHCxR8Fh7kfyFO0LRW+0QyXPybAHaP+4P9r0PfFac3YdOkqFPmqLlXbd+rfV/gjo/CdkIp/PuOI1Y4x1Gev4U3xZMbTTbu+lUszEkYP5VnPqC3F7aw27eVaqrtI/fg9qs6uJb3wbfLADJtLBGc5O3rUyXLHmOKVOSqqpPrb8zyjwVrFvf+I9XKeYLhgMoR/BkAnP4CuxvJN2vQMBkRrH/ACB/rXmvwljLeM9bBTaI7Rsj0AYZNd+JSl+khOSCAfpXRO1o27I7sDN1efm3TaOg8EAQ+J0D4/eKR19Of5iqWmeJl8WeI/FMJg2/YItqNnIYZPUdjwalEg0/XbS4Q4jMoOf9kkVH4f8ADE3hmbxDqUrpI+rSvIsSD7sKnC/j8xJ9jUJ62fb8br9DmxSbqwqR3dl+d/0M6xBj1OxkU4ZZ0YH/AIEKd4nnYa3qGWxiVsY9M0NhGEkR5Rgw+oNWPEFkb+1s9Wtx+6upDFKPRxUu9tD1E0qsZS9P1/Rne6DZ2tz4V0q5vFWKaMCUMnB3DPX3xWVqWrvcs88YVZ1+ZCerIOtbLsdP8LWrjk7MFT0Ht9K4K6nQT+ZBIfLznb3XPUfSmurPGwlL205zequ7ffsF7Lvl3AloyA6t32n1+h4NWX1G2stMa/nkl8iJlVth+ZM8ZHtntWa84t7hSV3op+ZT0KnqPxFRX9tBJFd6ddE/YbuPYX7gHlHHuDiqutz1J0+aNkZ3jrRbbxP4a+yCdnaJjPZT4+YE9UI9D6iuV+GPg3UbrXYdT1wO1npiEW0L/wDLSQcKAP7oPJ+lbHgbVb/w9ri+DvGFoZtOly1rqCAlojg7XVh1U+navUNPRInNvOykrIVeVOdy4+X6ZB/OlK6d4S0f9f8ADnlPkrXlKDUl+PW/mZEX2iAgtJbWsTD5WlIJb3VRyTWD4xfV5tMl0rw3Hd3N9NIEmvmRkVI+6oDyMnvXZSS3PnuumXVvJsAUbVUSKB25GarfbtWBLS3FxgHBb0/KhXTumdUk6qadtfk/yucv4O8AXOi7ZdW8QGCZuPLjkYqo91J5P1rtVu9G0H98slzdXDMBGHXgDvz05rIvNSn2uZp1kbBJ4G4/U4rD0fxPYT6lJpccsjOQd0ZOUbuRn1puMpO8m5CWGUY2m9Oy0v8Ahc1rnw7pepa+THF9pCxmbYRjavofzqvoer6e072tt5SRgNHgsVAX0zXSaKbHw/Dey3c0k1/dxhGiQf6pT0H61yUfhrR9F0e61STVWezQgk7CG56L9c9qzcYt6J36CdVXam/dWieupv3djcXNhFJps0QeJlDowICxHIyPXnvVfx/4jGh6VFY2Cut9cp5ZMh5jBH3j7+lL4K1tNT05JIUIW3mMSoT/AA5zgmqvirSF1bX9Q1BjI1q0e4oyjKtgZA96qPuSu+hmo+0nyz2R5Xo3hjUNXuWaIhLYE+ZO5+VQPT1NdPeX11o1rBYQxJJGzbWJPO0jt/OrvhrXrOKRLd5fIt42CgMQFGTjnNdxrGh22p3kM8BiWNv3nyfdJX2/z0olKfNea0N3UjB8ozx/YtdeDNOgQeRLGoAAPUMACRXjeleH9YTU47Z4pYo1fLXB6MvtXsniHUIb+2dLd932ZRtJ/iA64rNspZbq02g+XsXGCM4XOcfnSjUnGPKmLD0uWClLe/56mS9ss17bIu0IGX5e5APJNdNojRQG+8QXhLzLuitlH94jGR9BWVptulrN9quVyI42YhupPQAUjzM3hJMk77e7wyeoaqil8jsqpVPdWzsn891+X3mbbATXLPLEjhBwHXIDdjU2pwPZSBkwY2GN45yT2p2lSLLdy4TJPIX1Pp+Wa6K3gs4Zds6SyC3PnSNJwgbsAO9Z7u/UqtW9nPVfIr6VaHSdBupnG28nUhvVY2wCPxrzzTtSXTr4WWooTChLKx/iXORXZpqLalouq6owZRNeLbwL6IFOTTdb0KwuvD2kSXURFxd3DbXU4IVeBVpcq5X5/gc0G377+KT/AEv+BkaNocMuv3Wp28kj3V5EwRgMlTtJAH4ioU0K6tLzbfRIssiKzxnqo6/nmt6S/i8I+ENd1e3Ba8hcW9sG58vcOG9+Ofwrz34c+LdY1LWf7M1W7+0WoUzIHG51OeQp68+lDjJUnUb3fze39f1rzrEJYj2cY6L/AILPR4T5kD7o1EX8T44APSqOqX+l+H7IXmp3AgtnkKxqoyZD3IHtxUsTSTmO2j5MjMAB0z3J/CuY+KPhG+8Ra1pSWTrFpUEOwqTyOcscepqaXs026myTNcVKrBKNFat/h3Opsr62vYxewvHNaqC0JXo59/p1ryrxbr+paV4tsZVldLeN1dArHaQTzmvU1s4bPTtH021Hl2p/dlfxwc/WuX+LeiLq9zeG0hVGtHARVH8I4Ap0Ze6+l191y61N1Kdo7rX7nb8T2ma5XUfCeoojZVrPfGPUFcjH48V5kbVrzSEZAVkgTLL3xn7wrb8E6vJc+FbGYwvst4/s8yk4LcYH5Va0i18qGeRxiMy+X8/8IPWsabfIk9/6v+Rlhf8AZVO3df5GJNfs2jQAE+YDlWz9w9x9O9aPgvVYm1L7M7BpGHzI3Xd2asPWLX7DeXECOGtmPyEdCp6H+lZAc6br9hdSNsGAjHoCM5B/nWkluux3VaMZ0rR2Z6N8U9EKSQ6vCpEewRzkdiPut/T8q5zwzMskMyyOQS6spHUMOjD3H6jIr1q0aDXPD0kBdJY5ojExByOR1rxjw3p80cmr2k29ZrHIbA54bqPcdaW8FLrdL/I87L8R7ShKhU3hb7rlu+EV1dzySMVK/wACnjPfH863vDVkl7B5Z1OAOOlsxyWT+h+lVriZ5LcpOEhuZIsmZEBWZex9j6isrSbdotTjupIlmTaVDA4ZTioqqy5jqqKU6bSdrfM79b6zsLmOx1CTJiIMM5XPyns1Xf7Ptf8Anvb/APfdcF4g1CK6jtJYWeaOH927Ec7T2J/Oqvkwf8/R/OqTcdnY41gW4qXM03vp/Vu55XBrHjHxZ42SPyHHmS7mCIQir7k9q+jk8PodOjkkkeSVV6ROoDH054rJbxno1rcxCx0pigQbZEARwfQ+o/GsW78Q3vmyXtvYldMPARwSFGeo96lTlKEYySVv61Mo4XEXbV4rza+5Gy2i6dOgWZry2mc5wiiQ/Q4GPyrA1OKa3E+nSOpjlX5GYlQcHgnPQ1qeIINUkmspNNV5LN7dGWVMY3Y5y1TXF4k9qBdnzD5KozHGfM5HU1V01dHXSnJKM78yfTsRWukxRx2VzLLbzahFHtjgibzAH7O5HYDnHrTvEsx02zj0y3Y/aJMPPITyAfX3Na2nI+jeHWvb4+ZKHVVI6MOxH8q4i5u5Z7ue7uB5k0rb+fU9vwFCfYMOpV6jk3dRf4/5Ir6lrUOkSWxlDtvLJGqDOeOSa6rwhfRSQ4icvZ3SYweCrY6H8sVxupaZ/a8KR7d06D5MdR61h61eXvhvSbSIyCG5aTYxHUDk/n0q4tSXJ1f5G2Ip3i03pYXwnBJonx8t7N0P2XUUlhYdnUocfqBXTXkDWd/LbyHmNmTJ9jisT4e6udR1qwu7hUkvLaXMTkZKgnBx6cE11nisJORfwkMks7AH1G0HP55pyTgowl9lW+V7r8zLCQ9niJSvpPX5/wDBIr3/AEjRoJRyUO011lp52r+GdLvLVVe5tHaOVWbGRjDfmMVyWlt5ul6lDjOFDr+BrY+HlzFctf6TOQPOTzY+cfMO49xwady8XBqm5L7Dv8nv+f4GHrVrJZ3TRsDsZQykjGVPT8e34V0fg6SObwq0M+GWK7MnPbgn+dZ2qvJf6ZOlwiJeWDYOz+JN2D+IP86j8JybtF1qNSQ8aiYe4IIP9Km+pVa9TD67pr/h/wATvtRzd+CEkjwx8lXyPpzXmNiA2S+DuPf1ruvhrqqXemHSbg5eFTgH+JSf/r/pXNa9pv8AZeoTIDiEsePTng0tnY5MF+4qVMNLe916FPal5C1vJtS8iJ8ljx5i94yfXuPypsQW7shayfLPCT5LEY4PVD/SoLsbJN2flPOeopwkE0gZcCQ/eHr71ommenbS6/4Y1PDl1bSyJpesKoTcRbTsPmt39M/3T6Vbu45tPmkW5XbIpCtLH046Nj0Nc/eESsS4+fvx1/8Ar1uWmpHULKKC5P8ApCDbvz94Dv8AXoaVluc1am0/aLZ7r9V+v39zntflnTU4Wtbjy53wRKp+VuepIrqo5L03u6fU4XtNu0gMFOfXheawJnF1eLZ/ZfPm3cIowwf1+h71eHinwjo0wsvEEunRXkeFYQyvIUPo23ODShGc/dgm/Q5sXVp0opz/AE/C4y5hS8f98YkuBlVdThZOeB7eleet4W1Cz1ue4aPcpctE8bAd+vWvXIU8Ka+6SaVrVvK2d3lpdZ49MHpRqPgrMjTW29oydw2tuyKmTnTburMmnjaFRK7sjkLG2u40t1uZGBuJPvZ3dOM57muc+Ni6veahpPh7S4WXRYFEm9TgSSN1dz3wM/nXoWpxpa2+n25UoYC4O7gkMe3rim3JhsNLEs87ShgSIlX5mx2wRxz1ojKUXeO7LrQjXUebbsvXT8DnfBKR6BZw2A2zxyRFZlDfMc87h712bTq8aPG0aGNtyo4xu9c/yrlE1CzudzWlr9lmxjO7IHpUNhrGp3MM0c0ocwNtZWUdKV7J3ZtOjzNNK39fM5DxJ4O1KXWpAyBLSaUuGPQZOeK9B8O3FxAGt5mCwIRtY8exFFhqUeqsYBCN8Z5VThSfWti2+y2sa7lSeV2y0eSSuD1BonOTdpPYTcYxacdWc/43vLfw74blmTf58u7yxjknHX6D+tcv8F5b67hvHmd3E74HmH2rT+Jljea0RME+eLMflDkbT2x+FWvCGmz6L4bgSTajXDNn+8mDx+lW5xVNRi/UiNOTfNJ9CPxtrkej27XFzukSI+XkcZPtS/DG8Hi+WNwuy1kLxyqeTkjg1g/FTTJ9R0iCztJEM0cpeVMjIGOprq/gHZWum6DcC3cTOF3PKucE9+tFSaUEkte/YivVqx5uX4UtPW+5zlvq50/xxPosuI7iFvkb+8y81a1HWby11jXpJnMxazaaJGGFLDg8e2a5Txbp2p6h8SjdWsEpme9WRWCnBTdnOfpXWeMtFludSu5rdwgiifI67gwwV/OqlKKnZbaG3POsrzWonwv1tvFuharp0ipDc2RW6V1GBICejD1967K3RL7RtNtnbbLYSSOc9Sh5/PNc14E8NR+AvCd5qV/KBeXpTzCxxsjHIAHvxWFoPiG88R+OIoLGJ/sK5zMq8LxwT681MXzRlV2itv8Agepz06skuWb1v620s/wZ1eq614TsbD+z/Fks8y3yDfbwqf3K/wAJYjoeaXQ/B3hbQGfXfDV79tE0DG3Er7vLyOT+A7GuH8aWMs2pXsskCb5H3OW7t0OKsfB6aaLSPFMUrD7LFsUB+djMcfL6Zp1Iw5Elfddd/kEqMoVVKUr3/q39bnXaSfsV5b3N7MIUAYxkEAlj6j0rT1Ixy20U0HmIjjhXPrXiPj7S9YbWzelJnslwg2HPH0r1Pww1y3gnShdo4mlZ12vyzID8v9amfJG3LK7f+VzeM5zqtzjazt6rUva1Ed+nzRZ8pY1y39x+pzUWuyI+qSXSqAkqrLt69v8AP51pwj/imdeYnmWZPLJ7BcHArE1LLCN2xtaJQAOMYGMflQmrX/roddB3dn0uvyf9ehJPJPaeGrhbHMUV4xdD2D47e2RTPh3q9zrXwmvrm+kJuLecpuPVjuFXtP36lokenhGUW0LYb+8x5AFc74StrjQfCOtWcqMLe6vlkhPoP4hS5koxj/e/Cz/4ByToyliI22T1/wDAlZ/dctyXDTaexlIcoSBn0Pb86r6jbQX2mLayS+bOgJK4+6PTPr6Uy3uhBNGtwAU4Z+f4c8/pVHwfrT65rWsaekAWKNSUueuSPbtSV0nU6K34ndWqxpTUH1v/AME1/g1r1xoOvPo18S0ExwGbjnPBH4V6f4k0iCwXVdWSN2ln27wh9B1xXnXhu3tX162e5QLsJcN3GOa7vVtf+12VwklxBFa5zu8wbiM8Cpu5VPLT7zyMXRdPEKVPbS/pc5C6laawhuIU+RUKswPfP6/Sq2o28sWkWrROWbbu3L3U1v8AiiW31PTI101VjjQjzUQfeOPvZH86ydK1NpbJIIY1bywYiR82D0x9O9Ny0UmehTqOUFJK2u3keaeJrnVLHWIXt5CtpOmQitgE9wR61B/wmTf3Hr1DWra0+1pFcRpLA4CyAr/qz04NZn/CuNB/vSf991rGrSlb22mi2MXVq0daWz11NmxsLi5T7aQLYA/KAMID7j0rZkm0a8mRfEFg6XUY2Ce2J8p/fCnGfqKi8f6ncW+swWEJVLZXQbAOvIFa+u6Za2vhHWngTYy7WBB6H5c/zrlVKfXr/nYxlV9pyOWnNtbdXdtyi97pn2a1trbUolXcRGk+QjsB0J7fjVe701jpcdyjuhhmZbhCoYqxHXPf/wCvVHQ9HsprdfOiEn+jGb5ufmDYzXZeGYwt9fWWSYGjMh3HJLbsZ/KtORvbdE12sPdwbdt7mTrOoJP4Qiy8eFlBZSeg7AfjXGSRSiQgIcgcr6Vs+LbOK21YQwgrEVzszxmtLTbWNzHIwJZLUsMnqcnFNUpfEmdFFxoUueOz1MrQoZLQSzHI3pskk252DOcD8hzWJ410iPV7ee3mK+evzK6jPuMe9d3uJ063QHargBsDrk8n61JdWcEcMZVBudiC2OewpujJ3V9iFiPfcpLfQ8b8KyaZ4csZ7F1MupXx2Cdv4QAcBR9etdq6eb4GtHx8yT8+2R/iK5m80y2ub2KaRCJIpBsKnG35jxXeWECP4Ek3A8vn8pCBV8jqJtb7P5Fr93yyWza/ExvDg3Ndxn/lpbt+lVfD9x9i8Q2UjcJ5mxj0wDxW14WgT+2Ihg4aNgfyrEuIUW4JGcqQRT9lJW1O1WnOcH1S/VHa3umSw6zqgneNVu4pEgjA5k+TO72Ax1Nc14Cb/idy2rj5bu3eL8eCP5V6Ld2EM2s6PdtuEzLtYg9RsPFeb2q/ZNWt5YCVeOUbT+NJUJO2vl+aPPwk3Woyg+sV9+q/QteERJZ+M7OPdsBdoW9+vH5it7x0UOv21szLH52FDN0yfWq+p20dv4/tzDld9xDIcHoWxnFVPjLMbeJ50VTIssYBI6fLmlGjKTWu5jWqXrQrd4f1+ZkX1vc2968MyBZAdoB6N/jUJtS3zRAgj9K19xvJreO4+cMgck9c4z1q/p0KLfrxkZBwfpVxoya3O/20owu97HL3EjMB5o2zLwf9oev1qNCUYSRnkc49a7nxbplrFY6ndwxiOW2b5NvToOorj9PRZwfMHVc8etCpSety8PXVanzpFnxZZ3WoWi2ehubG7vokPnocFx3UHt74rnLD4dWWhaJDPdW6XtwzHz535UHPAA/rXdRxCXT7EMWBCFlIOCpUDBFbsJDWdq7qr+fGwkVhw3PcVE6El7jenboefKSoyU7JvbzPO9NsLSJm+z2VujhTtKLgj2/GtPTbhbeePzJ7q3QEYkhlIC/UHjFbH2S3tNYRIoUMcisSjDIGOeKs6loNkEguEV0M6lmRW+UH2z0pxoNaI6ZVoTfJJaNFHU/G1mlzLpuuQpDLGwC3Lw/KT1DcdM+vSmXdrc64WdNTtpbmNQyLjarIecr6/hSeMdCsrjRJknV5GgiDxyMfmXHbPp7Vyfwdi+0Q63ZSySGGxXzrc7uYzuOQD6e1N0LxdtGjhivZNOGn9fkHiC7h0V4TchghXl+oc+vSpfCuoWOoX8727pMsqhZE6Nj+8PcV1OrW8OuaQLXUoo5kXOH2gMPxrx3TLcaT41t/skkv7u5WNdzZ+UnoaSoKzi9zrlUm1qes2vh/ytSEdkzszsS7AD7pHFaqxWNrKI2bbIigY3Y+b8a154I41SaEeXKiAbk4yD2NU7K3jOpmRlDMQoO7nrnP8qzVB2uzl9s6keZvRIx7qN4J/NjUXDA7gg6c+4rNm1CaR1t1XiRydp5ySP0xzV7W764s9Ueyt5Ctuq7dp53Z7nPerb2cR1O3skzGgwvmJjec+5rRUJ9GddJ6JyV77Hz38Q5pdPvrtoZGeTUHPKknAHGBXtfwR0+6sPAVtcXsJSaR2TYePk6gmuysvBGiwX9s7QGc5Zh5wVsEenFUdQ1a4lvbm0CxR28JZFREwCPepXtK6XZf8MedO06zVPqvuS/4PoZl40VhqDXdtuVCSFUnjPrRFatNdPJKFBZBujb35/P/ABqea3RbtjyfmyM84+lXoII5JdjrnzeGPfoec+tV9XdrnbKXJFd7GN4jvYb8LbTwRm3wAYpDkNj3qjDEtu8VnYxpEuAWS0iKlf8AHjvXTNpdrNvjdSQpXB78mpI4lsPt722Vfkbu+Kl0JSdtNAjUjCPLFHOa7YXU8iQXGn+a7IpyqHDdsk+tZlvZWtno91ZW0JhEsgklAPO5T3Hfmuj0vUrya8W3lnd4SDLtP94dD61nXsKJ5ci5DsSSfxpyoSSvfY6IcyfJNLS239eRQhkkkefdHG2xSzFhnOB+VL4XM99q9hvlYEuB14VevFdVpdpCbSfdGCDBvx74Nc98OznVLJm5IfjP1xWfspcrZMqycKllsv0N3x9BFp0sUK4g09lM8nYZ7/p/OsLVYYdR8L6fqlgW8hco6sPmAPT/AD71D+1FqNzZaBZw20mxJiQ+Bz1FanwcjTUPhxaz3SK7GFEK/wAPBODj1repRlTp05X+K/3bHlYTMGkv7lvne9/wsT6VbppXhi4uriRUlup9yE9AAOPx7Vykl6J4oQfuZZwvbJrofGh8+1WyYBbeJSFVeOuT/QVy5fbqGmW+B5ckZLcc8VkqUkrddWexhdnUl1f+a/I5zxTFcCZp4ELQSRMj4P3SK0Phrp0Ph+1nvZZUSG6YIZWbADHpg1uTQpGjADIdV3A8g9a4P4jQDT9Xs9HtXdLBdsyx56M4BP8AKtVQdb3JOyWv3E42SpWaV29Ffp3PSLTVLK01Bo5VfPKlxjCsRgfzrzi91iVZ7mzugZbeJiMnuPb1r1jwrodjc+Ary4miLTuoy+eRtYYIrjb7QrG51iJJEbb5hBAPXJ71FCSjFyt/SX/BM7c9SST2dhPAl1cpYSrC7G0dWCKRkAf0rN8NXd/onia7hZWQFNwUHKv1wa9C+xW+kGKCyjCxBc7TzVeXS7N9Vg2wrGZwocp7jnHpURcpQkntKz/E1tGUlZdPvIbbUI5bQG8jKTTnhcE8fWrv2W3/AOeTf9/KxPGsh0rTrqWzAV4cohIzj3+teN/8Jr4g/wCgjJ/3yv8AhXXhMrq4uHPCSX3nn4zM6eFnyWeup//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This necrobiotic granuloma demonstrates a center of necrobiosis to the right, a rim of lymphocytes and histiocytes at the center, and a multinucleated giant cell at the left of the specimen (H&amp;E 400x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pathology of granuloma annulare - necrobiosis (H&amp;E 400x)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 313px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power view at the edge of the focus of necrobiosis in the upper portion of this photomicrograph. The upper necrobiotic area shows faint basophilia representing mucinous degeneration between bundles of acellular fibrillary eosinophilic material. The rim shows numerous histiocytes and a few lymphocytes with complete mucinous degeneration of normal collagen (H&amp;E 400x).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41690=[""].join("\n");
var outline_f40_45_41690=null;
var title_f40_45_41691="Pubertal problems cancer surviv";
var content_f40_45_41691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77692&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pubertal problems in survivors of childhood cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Problem",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Precocious puberty",
"       </td>",
"       <td>",
"        Brain tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapid tempo puberty",
"       </td>",
"       <td>",
"        Cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Normally timed puberty with slow linear growth",
"       </td>",
"       <td>",
"        Chemotherapy&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Delayed puberty",
"       </td>",
"       <td>",
"        Chemotherapy, leukemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Interruption of puberty",
"       </td>",
"       <td>",
"        Hodgkin's lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High dose cytoxan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior fossa syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft versus host reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticosteroid therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Absent puberty",
"       </td>",
"       <td>",
"        High dose cranial irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gonadal radiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy (alkylating agents, MOPP, COPP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Infertility",
"       </td>",
"       <td>",
"        Gonadal irradiation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chemotherapy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41691=[""].join("\n");
var outline_f40_45_41691=null;
var title_f40_45_41692="Medicare resources PI";
var content_f40_45_41692=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F60545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F60545&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Help with understanding and choosing a Medicare Part D plan",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        These Web sites are only for people on Medicare",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Medicare:",
"        </strong>",
"        This is the official government Web site that lists the different drug plans Medicare offers. Here you can compare the plans offered in your state and view each plan's formulary (list of covered drugs).",
"        <ul>",
"         <li>",
"          General site:",
"          <a href=\"file://www.medicare.gov\" target=\"_blank\">",
"           www.medicare.gov",
"          </a>",
"         </li>",
"         <li>",
"          Site with information on state help with drug payment (how to contact each program, who is eligible, and other details you should know):",
"          <a href=\"https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx\" target=\"_blank\">",
"           https://www.medicare.gov/pharmaceutical-assistance-program/state-programs.aspx",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-800-MEDICARE (1-800-633-4227)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Medicare Rights Center:",
"        </strong>",
"        This is an independent non-profit consumer advocacy group that helps people navigate the Medicare system. The group offers a hotline with counselors who can answer questions and help you make the most out of your Medicare coverage.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.medicarerights.org\" target=\"_blank\">",
"           www.medicarerights.org",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-800-333-4114",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Medicare Saver:",
"        </strong>",
"        This interactive Web site makes specific suggestions about ways you can cut costs based on where you live and which medicines you take. For instance, if a drug you're taking has a less expensive version, the site alerts you and offers to write a letter for your doctor with the name of the cheaper medicine. Then it saves a version of the letter on your computer. You enter your information anonymously, but if you allow the site to write a letter, it does put information on your own computer.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.medicaresaver.com\" target=\"_blank\">",
"           www.medicaresaver.com",
"          </a>",
"         </li>",
"         <li>",
"          Phone: 1-800-480-4165",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Social Security Extra Help Program:",
"        </strong>",
"        Only for people with Medicare, this official government site has information about the Extra Help program. The Extra Help program helps people pay for the costs: monthly premiums, annual deductibles, and prescription co-payments: related to a Medicare prescription drug plan.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.ssa.gov/prescriptionhelp\" target=\"_blank\">",
"           www.ssa.gov/prescriptionhelp",
"          </a>",
"         </li>",
"         <li>",
"          Site with information about applying to the Extra Help program:",
"          <a href=\"file://www.ssa.gov/pubs/10525.html\" target=\"_blank\">",
"           file://www.ssa.gov/pubs/10525.html",
"          </a>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         SHIP: State Health Insurance Assistance Program:",
"        </strong>",
"        SHIP is a national program that offers counseling and help to people with Medicare and their families. This site can help you find a counselor in your area who will meet with you one on one and talk to you about your Medicare options.",
"        <ul>",
"         <li>",
"          Web site:",
"          <a href=\"file://www.shiptalk.org\" target=\"_blank\">",
"           www.shiptalk.org",
"          </a>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41692=[""].join("\n");
var outline_f40_45_41692=null;
var title_f40_45_41693="Fluvastatin event free survival";
var content_f40_45_41693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76372&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fluvastatin improves outcome in patients with a low HDL cholesterol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 429px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier curves show that in patients with a low HDL cholesterol (HDL-C &lt;35 mg/dL) fluvastatin therapy prolongs the time to first clinical event (revascularization, myocardial infarction, hospitalization for unstable angina, or all-cause mortality) and improves event-free survival compared to placebo (p = 0.002) (upper panel). Fluvastatin had no effect on event-free survival in patients with HDL-C &ge;35 mg/dL (lower panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Ballantyne, CM, Herd, JA, Ferlic, LL, et al. Circulation 1999; 99:736.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41693=[""].join("\n");
var outline_f40_45_41693=null;
var title_f40_45_41694="Lateral tibial plateau fracture";
var content_f40_45_41694=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F70950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F70950&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lateral tibial plateau fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 307px; height: 426px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This anteroposterior radiograph shows a nondisplaced lateral tibial plateau fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41694=[""].join("\n");
var outline_f40_45_41694=null;
var title_f40_45_41695="Lymphadenopathy in syphilis";
var content_f40_45_41695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical lymph node in secondary syphilis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Such nodes (arrow) may be found in various locations and are usually firm, non-tender, and \"rubbery\" in consistency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Hicks, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_45_41695=[""].join("\n");
var outline_f40_45_41695=null;
